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Allergenic peanut proteins are highly resistant to digestion and are detectable by
immunoassays after gastrointestinal digestion. The application of liquid
chromatography-tandem mass spectrometry (LC-MS/MS) methods for in vivo detection
of peptides originating from allergenic food proteins has not been thoroughly studied.
The aim of this work was to develop an in vivo detection method for peanut proteins in
serum using LC-MS/MS. The method(s) were validated by analyzing subject serum
collected after peanut consumption.
Three de-complexation strategies were evaluated including (1) MS acquisition
settings (i.e. inclusion, exclusion lists), (2) commercial depletion kits, and (3) organic
solvent fractionation by discovery LC-MS/MS. Overall, none of these approaches were
successful. No improvements occurred to peanut peptide detection using inclusion and
exclusion lists. The commercial depletion kits removed abundant serum proteins,
however, they simultaneously depleted peanut proteins. The fractionation method was
efficient in reducing sample complexity, but demonstrated variable peanut protein
fractionation.

Due to unsuitable de-complexing strategies, we evaluated non-depleted serum by
targeted MS, including parallel reaction monitoring (PRM), multiple reaction monitoring
(MRM), and MRM cubed (MRM3). We identified 10 peanut peptides, representing the
major peanut allergens. The limit of detection (LOD) of the sera-peanut model matrix
(10:1 (w/w)) was similar for PRM and MRM, with detection at 1.0 ppm peanut protein
(4.0 ppm peanut). The MRM3 method did not provide improvements to LOD.
Following development of typical targeted methods, we re-investigated PRM with
increased protein loading (600 µg). Peanut peptides were detected in two subject sera
(sera 1, 2) at two different time points (60, 120 minutes, respectively). However, robust
method development was unsuccessful, requiring further investigations in methodology.
Lastly, the intermolecular arrangements of peanut seed storage proteins were
evaluated by offline size-exclusion chromatography (SEC) with discovery LC-MS/MS.
Gaussian modeling was used to determine the native MW of proteins, isoforms, and
complexes. The combination of Gaussian modeling and discovery LC-MS/MS of SEC
fractions was a highly effective separation and identification tool.
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CHAPTER 1: LITERATURE REVIEW
INTRODUCTION
Proteomics is the study of proteins, their interactions within a biological system
(e.g. structure, function), and their relative abundances (Cravatt et al., 2007). The field of
proteomics research is vast and expanded significantly due to advancements in protein
biochemical techniques, and in mass spectrometry (MS) instruments and methods
(Gillette and Carr, 2013). Proteins, composed of amino acids, are important
macromolecules required for many routine and critical body functions including
molecular transport (e.g. oxygen), immune responses, cell growth and repair, and reaction
catalysts (e.g. enzymes) (Berg et al., 2002). Foods are an essential source of proteins, as
well as other macromolecules (e.g. carbohydrates, lipids, minerals), and the sole source
for essential amino acids, which must be consumed through an individual’s diet (Shewry,
2007; Tessari et al., 2016). Unfortunately, for individuals diagnosed with a food allergy
or sensitivity, consumption of certain food proteins can be detrimental to an individual’s
health as some allergenic food proteins are highly thermostable and resistant towards
digestion, characteristics contributing to their allergenic behavior (Bannon, 2004).
Food allergens have been studied using a suite of molecular biology and protein
biochemistry techniques including enzyme-linked immunosorbent assays (ELISA),
immunoblotting, polymerase chain reaction (PCR), and digestibility assays (Koppelman
and Hefle, 2006). ELISAs have been the primary method used in routine testing of
allergenic food proteins, however recently, mass spectrometry methods have been
developed for detection of allergenic food proteins (Croote and Quake, 2016; Koppelman
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and Hefle, 2006; Monaci et al., 2015). The adoption of mass spectrometry in food
allergen detection provides numerous benefits compared to ELISA methods, including
multiplexing, identification of specific peptide and protein sequences, elucidation of
protein modifications, and individual protein quantification (Croote and Quake, 2016;
Monaci et al., 2015). MS offers numerous advantages however, these methods have not
yet been routinely established and still require significant time for method development
(Croote and Quake, 2016; Johnson et al., 2011).
Food allergies are individualistic reactions to food proteins affecting previously
sensitized individuals, and have demonstrated an increasing prevalence over time
(Sicherer et al., 2010; Turner et al., 2015). To better understand mechanisms of
sensitization and allergic reactions, it is important to understand the uptake and transport
of allergenic food proteins across the gut barrier and their subsequent interactions with
the immune system (Reitsma et al., 2014). Previous studies have established in vivo
detection of allergenic food proteins at very low concentrations, primarily by
immunoassays (Baumert et al., 2009; Husby et al., 1985, 1986; JanssenDuijghuijsen et
al., 2017; Schocker et al., 2016). However, in vivo detection has yet to be established
using MS methods due to low analyte concentration, analyte conformation after gastric
digestion and uptake, complexity of sera proteome, and sensitivity of mass spectrometers
(JanssenDuijghuijsen et al., 2017; Reitsma et al., 2014).
Our aim within this section is to establish an understanding of the current
literature and knowledge of in vivo uptake of allergenic food proteins, particularly peanut
proteins, and the application of mass spectrometry in the study of food allergens. Peanut
proteins are considered one of the most potent allergenic foods, and several studies have
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focused on the in vivo detection using a multitude of protein chemistry techniques
(Baumert et al., 2009; JanssenDuijghuijsen et al., 2017; Schocker et al., 2016). The
advancements achieved in mass spectrometry have expanded the available proteomic
tools for allergenic protein studies, and as such, are the primary focus of this work.

FOOD SENSITIVITIES
Food sensitivities, including both food allergies and food intolerances, are
collectively referred to as individualistic reactions to foods (Taylor and Baumert, 2012).
These sensitivities only affect a small subset of the population, but can have severe
impacts on an individual’s quality of life (Stensgaard et al., 2017; Warren et al., 2016).
Individuals commonly misidentify food intolerances as food allergies, whose mechanism
is distinctly different and involves an immunologically-mediated response (Sloan and
Powers, 1986; Taylor and Baumert, 2012). When properly diagnosed, the symptoms
associated with various food sensitivities are easily distinguishable (Sloan and Powers,
1986; Taylor and Baumert, 2012). Recognition of the characteristic symptoms associated
with each sensitivity, immune or non-immune mediated mechanisms, is critical for
accurate diagnosis and dietary management since many individuals adopt modified
dietary practices to avoid consumption of offending food(s) (Mazzocchi et al., 2017;
Taylor and Baumert, 2012).
Food intolerances are non-immunologically mediated reactions and the
predominant food sensitivity individuals experience (Guandalini and Newland, 2011;
Sampson and Eigenmann, 1999). Individuals with food intolerances are generally able to
tolerate larger doses of a causative food before exhibiting severe symptoms (Taylor and
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Baumert, 2012). In contrast, low doses of allergenic food proteins can elicit
immunologically mediated reactions in previously sensitized individuals (Hefle et al.,
2001; Taylor and Baumert, 2012). Generally, individuals experiencing allergic reactions
exhibit more severe symptoms, including anaphylaxis, a distinguishing feature of
immunologically mediated reactions (Chinthrajah et al., 2015; Taylor and Baumert,
2012). However, for a majority of individuals, these causative foods, classified as
allergens, do not cause adverse reactions (i.e. allergy, intolerance) and pose no imminent
health threat (Taylor et al., 1992).

Food Intolerances
Food intolerances are non-immunologically mediated reactions caused by toxins,
metabolic or pharmacological agents, or other unknown agents originating within foods
or food additives (Boyce et al., 2010). These types of reactions may include
gastrointestinal or absorption disorders, and, are commonly present in pediatric patients
due to their under-developed immunological systems, however, these intolerances are
most often outgrown (Sampson and Eigenmann, 1999). Food intolerances can be
classified into three categories including, (1) anaphylactoid reactions, (2) metabolic food
disorders, and (3) food idiosyncrasies (Lemke and Taylor, 1994; Taylor and Baumert,
2012).
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Anaphylactoid Reactions
Anaphylactoid reactions are clinically identical to true food allergies presenting
many of the same symptoms and mediators, but, are non-immunologically (i.e. IgE)
mediated responses (Sampson, 2009). In these reactions, eliciting food substances
initiate the release of mediators from mast cells and basophils, identical to mediators of
an allergic reaction (Lemke and Taylor, 1994; Taylor and Baumert, 2012).

Metabolic Food Disorders
Metabolic food disorders are metabolic deficiencies of a particular food substance
or food derived chemical, and are genetically inherited sensitivities (Taylor and Hefle,
2002). Lactose intolerance and favism are two well-characterized disorders, with distinct
mediating mechanisms which are discussed in detail in subsequent paragraphs (Taylor
and Hefle, 2002).
Lactose intolerance is the inability to digest lactose, the primary cow’s milk sugar,
due to a deficiency in the hydrolytic enzyme β-galactosidase (i.e. lactase) (Suarez and
Savaiano, 1997). The disaccharide, lactose, is hydrolyzed by β-galactosidase, to its
constituent monosaccharides, glucose and galactose, and transported across the small
intestine for metabolic energy (Suarez and Savaiano, 1997). A deficiency in βgalactosidase results in the passage of non-digested lactose to the large intestine where
bacteria metabolize the disaccharide substrate into carbon dioxide, water, and dihydrogen
(H2) (Kocian, 1988; Taylor and Hefle, 2002). Individuals suffering from lactose
intolerance exhibit mild localized gastrointestinal (GI) symptoms including gastric and
abdominal cramping, flatulence, and diarrhea (Bayless et al., 1975; Suarez and Savaiano,
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1997). Many lactose intolerant individuals can safely consume small amounts of dairy
products without experiencing significant symptoms (Lemke and Taylor, 1994; Taylor
and Hefle, 2002).
Favism, another example of a metabolic food disorder, is caused by a lack of
erythrocytic glucose-6-phosphate dehydrogenase (G6PDH), the most prevalent
worldwide enzymatic deficiency (Taylor, 2014). The consumption of fava beans or
inhalation of Vicia faba pollen, which contain the oxidants vicine and convicine, results
in damage to erythrocytic membranes in individuals lacking G6PDH (Mager et al., 1980;
Marquardt et al., 1997). G6PDH maintains the concentrations of glutathione (GSH) and
nicotinamide dinucleotide phosphate (NADPH) in erythrocytes, preventing erythrocyte
membrane oxidation (Taylor, 2014; Taylor and Hefle, 2002). Symptoms occur within 5 –
24 hours of ingestion causing fatigue, abdominal pain, nausea, fever, chills, hemolytic
anemia, or more severe symptoms including hemoglobinuria, jaundice, and renal failure
(Taylor, 2014; Taylor and Hefle, 2002).

Idiosyncratic Reactions to Foods
Food idiosyncrasies are adverse reactions to food additives involving unknown
mechanisms and capable of causing mild to severe, and potentially life threatening
symptoms (Guandalini and Newland, 2011; Taylor and Hefle, 2002; Taylor et al., 1989).
Sulfite induced asthma is a principal example of an idiosyncratic reaction and has been
elucidated by double blind placebo controlled food challenge (DBPCFC) (Taylor et al.,
2014).

7
Sulfites, the causative agent in sulfite induced asthma, are naturally present in
foods due to fermentation or as a food additive to inhibit browning (enzymatic and nonenzymatic), prevent microbial growth, inhibit oxidation, or as an aid in bleaching and
dough conditioning (Bush and Montalbano, 2014; Taylor and Hefle, 2002; Taylor et al.,
2014). Individuals diagnosed with asthma are more likely to develop sensitivities to
sulfites, however not all asthmatics suffer from this sensitivity (Taylor et al., 2014). An
estimated 5% of adult asthmatics have sulfite sensitivities, and individuals with severe
asthma are more likely to develop sulfite sensitivities (Bush and Montalbano, 2014). As
a result, sulfites must be labeled in order to protect those sulfite sensitive individuals
(Taylor et al., 2014).

Food Hypersensitivities
Food hypersensitivity reactions are abnormal immunological responses to food or
environmental proteins (e.g. pollen, dust, mold, animal dander) and categorized into four
classes (I, II, III, and IV) based on their immunological mechanisms (Gell and Coombs,
1975; Sampson, 1991; Taylor and Hefle, 2002). Food hypersensitivities encompass two
different types of immunologically mediated mechanisms, immediate hypersensitivity
(type I) and delayed hypersensitivity (type IV) (Taylor and Baumert, 2012). Other
hypersensitivity (allergic) reactions include type(s) II: antibody-dependent cytotoxic
reactions and III: antigen-antibody complex mediated (Sampson, 1991). The primary
focus of this section will be on delayed- and immediate-type hypersensitivity reactions.
Allergic reactions, including food and environmental reactions, are classified as
type I, IgE-mediated, immediate hypersensitivity reactions (Gell and Coombs, 1975;
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Sampson, 1991; Taylor and Hefle, 2002). Food allergies are caused by naturally
occurring proteins in foods, generally present in high abundances (Bush and Hefle,
1996). Only a handful of foods are known to cause over 90% of reported reactions, and,
are commonly known in the US as ‘the Big 8.’ (Bush and Hefle, 1996). ‘The Big 8’
includes peanuts, tree nuts, fish, shellfish, milk, egg, soy, and wheat (Hefle et al., 1996).
Allergy to other fruits and vegetables have been reported, however, these reactions are
often milder in elicited symptoms and localized to the oral cavity (Hefle et al., 1996).
These food proteins are labile towards heat, processing, and gastric enzymes resulting in
their rapid degradation (Amat Par et al., 1990; Hefle et al., 1996). Any protein is capable
of eliciting an allergic reaction however, these reactions are rare in occurrence (Hefle et
al., 1996).
Factors influencing the development of IgE mediated reactions include genetic
pre-disposition, increase in GI tract permeability, premature birth, viral gastroenteritis
(Taylor and Hefle, 2006). A study of monozygotic and dizygotic twins revealed the
identical twins (i.e. monozygotic) are likely to develop allergy to the same food,
illustrating the role of genetic heredity (Lack et al., 1999; Sicherer et al., 2000). Other
studies have demonstrated the importance of gastrointestinal barrier permeability in
relation to food allergy and other atopic disorders (Chambers et al., 2004; Nunes et al.,
2016; Samadi et al., 2018). Several studies have demonstrated an increase in
permeability of the gastrointestinal barrier in allergic individuals, allowing an increased
molecular transport of intact allergenic food proteins into circulation (Li et al., 2006;
Samadi et al., 2018; Yu et al., 2001).

9
Cell-mediated reactions are classified as type IV, and are delayed hypersensitivity
reactions (Gell and Coombs, 1975; Sampson, 1991; Taylor and Hefle, 2002). These
reactions generally cause localized inflammation to eliciting foods (Taylor and Hefle,
2002).

Delayed-Type Hypersensitivity
Delayed hypersensitivity reactions are non-IgE, cell-mediated immune responses
whose mechanism(s) is not well understood (Taylor and Baumert, 2012; Taylor and
Hefle, 2006). Cell-mediated reactions are caused by the interaction of food antigens with
sensitized, tissue bound T-cells, causing the release of inflammatory mediators
(Sampson, 1991; Taylor and Hefle, 2002). Affected individuals may experience
symptoms 6 – 24 hour after ingestion which generally involve tissue inflammation
localized to the gastrointestinal tract (Jones and Burks, 2008; Lemke and Taylor, 1994).
Other resulting symptoms may include weight loss, anemia, bloating, diarrhea, or chronic
fatigue (Taylor and Hefle, 2002).
Celiac disease (celiac sprue, non-tropical sprue, or gluten-sensitive enteropathy) is
the most commonly well-known cell-mediated immune response (Taylor and Hefle,
2006). The consumption of gluten containing grains (e.g. wheat, barley, rye, spelt,
triticale) causes an inflammatory response in the intestine leading to development of a
malabsorption syndrome (Rubio-Tapia and Murray, 2008; Taylor and Hefle, 2001).
Nutrient malabsorption results from the gluten-initiated damage to the mucosal lining of
the small intestine (Rubio-Tapia and Murray, 2008; Taylor and Hefle, 2001). A
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multitude of symptoms including inflammation, bloating, diarrhea, anemia, fatigue, and
weight loss ensue (Rubio-Tapia and Murray, 2008).

Immediate-Type Hypersensitivity and Food Allergies
Food allergies are classified as immediate-type hypersensitivity reactions, and are
IgE-mediated responses to proteins naturally present in foods (Taylor and Baumert, 2012;
Taylor and Hefle, 2002; Yu et al., 2017). These abnormal immunological responses to
foods can cause a multitude of symptoms affecting the cutaneous, gastrointestinal,
respiratory, or even systemic reactions (Taylor and Hefle, 2002; Yu et al., 2017). For a
majority of individuals, no adverse health effects occur during the regular consumption of
allergenic foods however, for individuals diagnosed with a food allergy, consumption of
allergenic foods may cause detrimental and potentially life-threatening health
consequences (Taylor and Hefle, 2002). The immune system contains five antibody
isotypes (IgA, IgD, IgE, IgG, IgM), each with their own specific functions (Murphy,
2012). IgE antibodies are responsible for elicitation of allergic reactions, in both food
and environmental (e.g. pollen, dust, animal dander, mold) allergies (Taylor and Hefle,
2002). In non-atopic individuals, interactions with allergenic food proteins are mitigated
by IgG and IgA antibodies, and do not elicit an immune response (Valenta et al., 2015).
However, for pre-disposed individuals, interactions with allergenic proteins cause
antigen-presenting cells (dendritic cells, B-cells), to induce T-helper 2 cells (Th2) which
then produce cytokines (IL4, IL13) and initiate class switching to IgE for a particular
allergen (Romagnani, 1997; Vercelli and Geha, 1992).
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IgG4, a subtype of IgG, may have important roles in tolerance in certain
individuals (Chinthrajah et al., 2016). In subjects participating in oral immunotherapy
(OIT) or epicutaneous immunotherapy (EPIT), investigators reported an increase in IgG4
binding after completing the OIT in peanut allergic individuals (Koppelman et al., 2019;
Vickery et al., 2013).

Allergenic Protein Sensitization
IgE mediated immune responses involve two phases, a sensitization phase and an
elicitation phase, illustrated in Figure 1-1 (Taylor and Hefle, 2002). The sensitization
phase, an asymptomatic process, initiates the production of allergen-specific IgE
antibodies by B-cells after initial exposure to an allergenic protein (Mekori, 1996; Taylor
and Hefle, 2006). These allergen specific IgE antibodies bind to the surfaces of tissue
mast cells and circulating basophils (Mekori, 1996; Taylor and Baumert, 2012). Upon
subsequent exposure to an allergenic protein, the allergenic epitopes crosslink surface
bound IgE receptors (FcεRI) on mast cells and basophils (Rivera et al., 2008; Stone et al.,
2010). Antigenic crosslinking signals effector cell degranulation, histamine release, and
other physiological mediators associated with allergic responses (Rivera et al., 2008;
Stone et al., 2010).
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Figure 1-1. Reaction mechanism of an IgE mediated allergic response.
Figure from Taylor and Baumert, 2012.

The onset of IgE-mediated symptoms is rapid, occurring within minutes to hours
after ingestion of the causative food (Taylor and Hefle, 2006). Pre-formed histamine, the
key physiological mediator, is responsible for immediate occurring symptoms including
inflammation, pruritus, urticaria, and dermatitis (Stone et al., 2010; Taylor and Hefle,
2006). A myriad of symptoms affecting multiple organ systems may occur, as described
in Table 1-1. Anaphylaxis is the most severe symptom associated with food allergies
affecting multiple organ systems (respiratory, cardiovascular, cutaneous, and
gastrointestinal) (Taylor and Hefle, 2006). Anaphylaxis develops rapidly upon exposure,
and may result in fatality if epinephrine is not quickly administered (Taylor and Hefle,
2002). Due to the vast array of potential symptoms, sensitized individuals will often
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experience a combination of symptoms rather than all potential symptoms (Taylor and
Hefle, 2002). The overall reaction severity is influenced by an individual’s sensitization,
the amount of protein ingested, and the length of time since last exposure (Asero et al.,
2007; Taylor and Hefle, 2002).
System affected
Cutaneous

Gastrointestinal

Generalized
Respiratory

Symptom
Angioedema
Dermatitis or eczema
Pruritus
Urticaria
Abdominal cramping
Diarrhea
Nausea
Vomiting
Anaphylaxis
Asthma
Laryngeal edema
Rhinitis

Table 1-1. Symptoms associated with IgE mediated allergic reactions
(Adapted from Taylor and Baumert, 2012)

Allergenic Food Proteins
Allergenic food proteins are classified based upon their route of sensitization as
either class 1 or class 2 allergens (Sampson, 2003).
Class 1 allergens are oral allergens and sensitize via the gastrointestinal tract (e.g.
peanut, egg, milk) (Han et al., 2012; Valenta et al., 2015). Oral allergens are able to elicit
systemic reactions, stable towards heat and acid treatments, resistant to proteolytic
degradation, and generally water-soluble (Breiteneder and Ebner, 2000; Sampson, 1999,
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2003). Class 1 allergens are able to both sensitize and elicit allergic reactions, and
considered as ‘complete food allergens’ (Wang, 2009). Class 2 allergens or inhalant
allergens are the result of sensitization via the respiratory tract and the primary cause of
oral-allergy syndrome (OAS). (Nowak-Wegrzyn, 2007). Exposure to pollen protein(s)
leads to cross-sensitization to class 2 food allergens, due to high homology between
pollen and class 2 allergens (e.g. apple, peach, celery) (Han et al., 2012; NowakWegrzyn, 2007; Sampson, 2003). Class 2 food allergens are unable to sensitize, but
capable of eliciting allergic reaction due to cross-reactivity (Wang, 2009; Yagami et al.,
2000). The class 2 allergens are highly susceptible to heat and proteolysis, degrading
conformational epitopes, making these proteins difficult to isolate and study (NowakWegrzyn, 2007; Sampson, 2003). Symptoms of OAS are localized to the oropharyngeal
area presenting mild symptoms, due to rapid protein degradation by heat and digestive
enzymes in oral mucosa (Nowak-Wegrzyn, 2007; Vieths et al., 2002).
In the United States, an estimated 7.6% of children and 10.8% of adults are
diagnosed with a food allergy (Gupta et al., 2018, 2019). In children, the most common
allergies are peanut, milk, shellfish, and tree nuts (Gupta et al., 2018). The most common
allergies in adults are to shellfish, peanut, milk, tree nut, and fish (Gupta et al., 2019).
Peanut proteins are one of the most extensively studied food allergens due to their high
prevalence rates in both children and adults. Currently, an estimated 2.2% of children
and 1.8% of adults are diagnosed with a peanut allergy, and nearly all individuals are
sensitized to multiple peanut proteins (Ara h 1, 2, 3, or 6) (Gupta et al., 2018, 2019).
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Diagnosis of Food Allergy
To properly diagnose an IgE mediated food allergy, individuals should seek
clinical diagnosis by a physician, as self-diagnosis is often unreliable (Taylor and Hefle,
2002). The combination of rapid symptom onset, symptoms originating from multiple
organs, and anaphylaxis strongly suggests an IgE mediated reaction (Chinthrajah et al.,
2015). In order to establish a true food allergy, physicians must confirm presence of IgE
to the suspected food or ingested material (Taylor and Hefle, 2002).
Food allergies are generally diagnosed using a combination of tools, including
patient clinical history, oral food challenges, and laboratory tests (skin, blood tests)
(Chinthrajah et al., 2015; Sicherer and Sampson, 2010). Understanding the patient
clinical and dietary history is an important component in establishing the implicated
foods in relation to the time of ingestion and onset of symptoms (Chinthrajah et al.,
2015). Physicians utilize several laboratory diagnostic methods for food allergy
including skin prick tests (SPT), analysis of serum, and component resolved diagnostic
(CRD) tests (Chinthrajah et al., 2015). Various factors can impact SPT accuracy
including the protein extract composition, skin prick site (e.g. arm, back), elapsed time
before reading results, variability in result measurements, and individual patient
differences (Bernstein et al., 2008; Sicherer and Wood, 2013). Determination of specific
IgE by in vitro serum immunoassays may also be performed (Hamilton and Franklin
Adkinson, 2004). CRD diagnosis, which identifies peptides originating from an
allergenic protein, are used to assess the level of IgE binding to peptides or protein
fragments, and have recently been adopted as a diagnostic tool in OAS diagnoses
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(Chinthrajah et al., 2015). All the diagnostic tests described (SPT, serum analyses, CRD)
only demonstrate sensitization (Chinthrajah et al., 2015; Sicherer and Sampson, 2010).
Ideally, an oral food challenge is performed to truly demonstrate allergenic
reactivity and confirm results of laboratory tests (Bock et al., 1988). The gold standard
for diagnosing true food allergy is the double blind placebo controlled food challenge
(DBPCFC) in which both participating parties (e.g. physician and subject) are unbiased to
testing materials (Chinthrajah et al., 2015; Sampson, 1988). During a DBPCFC,
increasing doses of an allergenic food, most often within a matrix vehicle, is fed to a
patient in a blinded manner (Bock et al., 1988; Sampson et al., 2014). If a DBPCFC
cannot be administered due to patient concerns, an alternative open food challenge or
single-blind food challenge may be performed (Chinthrajah et al., 2015). Additional
factors useful in diagnosing food allergy include a thorough understanding of family
history, dietary history, suspected causative foods, elapsed time before symptoms began,
the type and severity of symptoms, and if other medications or alcohol were ingested
prior to elicitation of symptoms (Chinthrajah et al., 2015). Once diagnosed with a food
allergy, individuals are advised to practice avoidance diets since no cure has been
established (Taylor and Baumert, 2012). Avoidance diets can be difficult to manage due
to potential cross-contamination of products during manufacturing, leaving the
consumers to rely on adequate labeling (Taylor and Baumert, 2012).

PEANUT PROTEINS
Peanuts (Arachis hypogaea) are leguminous plants known for their high protein
density and oil contents (Becker and Jappe, 2014; Sebei et al., 2013). Peanuts contain
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25% protein by weight, are generally consumed after roasting and found in other
prepared food products (e.g. peanut butter, snack products, baked confections)
(Koppelman et al., 2016; Oerise et al., 1974; Sebei et al., 2013). Peanuts are the most
diagnosed food allergy, with 2.5% of children diagnosed, whereas only 1.8% of adults
are diagnosed with peanut allergy (Gupta et al., 2011, 2017, 2019). Furthermore, the
prevalence of peanut allergy has increased in children from 0.4% in 1997 to 1.4% in 2010
(Sicherer et al., 2010). Peanuts are considered one of the most important food allergens
due to its high prevalence, severity, and potency (Blanc et al., 2009; Klemans et al., 2013;
Koppelman et al., 2005). Several varieties of peanuts (Virginia, Spanish, Valencia, and
Runner) commonly produced in the US today, exhibit highly similar protein contents and
compositions (Koppelman et al., 2016). Individual allergenicity is largely unaffected by
the peanut varietal as shown by a comparison of protein profiles and IgE-binding
capacities among varietals (Koppelman et al., 2016). For these reasons and public health
interest, peanuts have been a major research focus of the allergen community and were
chosen for this study.

Major Allergenic Peanut Proteins
Peanuts have been cultivated for thousands of years, originating in South America
in modern day regions of Bolivia, Brazil, and Paraguay (Becker and Jappe, 2014;
Gregory et al., 1980). A. hypogaea is the modern day cultivated peanut species
expressing an allotetraploid genome and is the resultant product of two diploid ancestral
species, A. duranensis and A. ipaensis (Bertioli et al., 2019; De Carvalho Moretzsohn et
al., 2004; Gregory et al., 1980). The major allergenic peanut proteins of A. hypogaea are
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seed storage proteins, whose function is to provide a reservoir of amino acids during
plant growth (Dunwell et al., 2004; Müntz, 1998; Mylne et al., 2014; Shewry et al.,
1995). At present, 17 peanut proteins have been identified as allergens by Nomenclature
Sub-Committee (World Health Organization/International Union of Immunological
Sciences), and of these, four (Ara h 1, 2, 3, and 6) are considered major allergens. Peanut
proteins are classified by solubility according to Osborne fractionation (saline soluble
globulins, water soluble albumins, or alcohol soluble prolamins) and sedimentation
coefficient(s) (e.g. 11S, 7S, 2S) (Branlard and Bancel, 2007; Breiteneder and Ebner,
2000; Osborne, 1907). The major allergenic peanut proteins Ara h 1 and 3 are classified
within the cupin superfamily, whereas Ara h 2 and 6 are classified in the prolamin
superfamily (Mueller et al., 2014).

Cupin superfamily
Ara h 1 (7S vicilin) and Ara h 3 (11S legumin) are both classified as cupins due to
their similar conserved β-barrel structures (Dunwell, 1998). The cupins characteristically
exhibit a bicupin structure due to the presence of two structural domains (Dunwell et al.,
2004; Mills et al., 2002). These structural commonalities confer high thermal stability
and resistance to gastric digestion, a trait common among allergenic proteins (van Boxtel
et al., 2008; Koppelman et al., 1999, 2010; Maleki et al., 2000). Although Ara h 1 and 3
exhibit similar structural conformations, the two proteins only share 22% sequence
identity based on alignments (data not shown). Cupins characteristically denature due to
extensive heating (70 – 95°C) leading to the formation of large aggregates (van Boxtel et
al., 2008; Koppelman et al., 2003; Yamauch et al., 1991).
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Ara h 1
Ara h 1, the 7S vicilin, has a monomeric molecular weight of 64.5 kDa, and
readily associates into a trimer (~193.5 kDa) stabilized by non-covalent forces (e.g.
electrostatic, hydrophobic, disulfide bonds) (van Boxtel et al., 2006; Burks et al., 1991;
Schmitt et al., 2010). Ara h 1 is highly susceptible to heating (>80°C) leading to the
forming higher order molecular structures (MW ~500–600 kDa), particularly with an
increase in secondary structures (e.g. β-sheets) (van Boxtel et al., 2006; Chruszcz et al.,
2011; Koppelman et al., 1999). Ara h 1 is glycosylated at residues 521 – 523, with a
single glycosylation site (NAS), similar to other 7S vicilins (e.g. pea, soybean), and is
readily purified with concanavalin-A by lectin binding chromatography (Van Ree et al.,
2000)
Ara h 1 is translated as a pre-pro-protein and undergoes two cleavage events prior
to producing mature Ara h 1 (Hurlburt et al., 2014). The signal peptide (amino acids 125), responsible for directing the protein to the storage vacuole, is cleaved off after
protein transport (Coleman et al., 1985; Hurlburt et al., 2014). Following translocation,
the N-terminal peptide sequence (amino acids 26-84) undergoes cleavage by proteases in
the vacuole, resulting in the mature Ara h 1 protein (Aalberse et al., 2019; Hurlburt et al.,
2014). Within the N-terminal peptide region, three IgE binding epitopes exist, with two
of these determined as major epitopes (Aalberse et al., 2019; Burks et al., 1997; Wichers
et al., 2004). The existence of allergenic proteins or epitopes present in other N-terminal
regions was similarly demonstrated for English walnuts (Jugulus regia) (Downs et al.,
2014). Aalberse (2019) recently demonstrated the N-terminal peptide strongly binds IgE
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from allergic patient serum, thus it should be considered as a distinct allergenic molecule
and sensitizing protein (Aalberse et al., 2019). The purified Ara h 1 is truncated on its Nterminal side, lacking this pro-peptide region (Wichers et al., 2004). Assays utilizing
purified Ara h 1 will not include this N-terminal peptide and may therefore lead to
insufficient results (Wichers et al., 2004).

Ara h 3
Ara h 3 was initially identified as a 14 kDa protein however, through the use of
cDNA cloning, it was later determined to exist as a 60 kDa monomer (Eigenmann et al.,
1996; Rabjohn et al., 1999). The 14 kDa protein, originally identified as Ara h 3, was
characterized as a breakdown product of the N-terminal region (Rabjohn et al., 1999).
Further analysis of the amino acid sequence revealed Ara h 3 is highly homologous to
other 11S globulin proteins found in soy and pea (Rabjohn et al., 1999). Ara h 3 is
known to act as a trypsin inhibitor, exhibiting highly homologous N-terminal regions to
putative trypsin inhibitor proteins (Dodo et al., 2004).
Similar to other 11S seed storage proteins, Ara h 3 associates into hexameric
complexes (~360 kDa) composed of two aggregated trimers (Shewry et al., 1995). To
achieve its characteristic hexameric conformation, Ara h 3 is initially translated as a ‘prepro-globulin’ and must undergo post-translational processing (Koppelman et al., 2003).
The translated Ara h 3 precursor protein is sent to the storage vacuole, where it associates
into trimers (Guo et al., 2008; Rabjohn et al., 1999). Endopeptidase cleavage at the
flexible loop region produces acidic and basic subunits covalently linked together by a
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disulfide bond (Koppelman et al., 2003). Each subunit represents a cupin domain,
yielding the mature Ara h 3 protein (Piersma et al., 2005; Scott et al., 1992).
Ara h 3 exists as multiple protein fragments at 14, 25, 42, and 45 kDa under
protease inhibited extraction conditions (Koppelman et al., 2003). The N-terminal acidic
chain is present in two MW bands on a reducing gel at 12 kDa and 42-45 kDa (Piersma et
al., 2005). The C-terminal, or basic chain, exists as a 25 kDa fragment (Piersma et al.,
2005).
As observed in other 11S globulins, Ara h 3 exists as multiple isoforms encoded
by multi-gene families (Mouzo et al., 2018; Piersma et al., 2005; Yan et al., 2005). These
genes are located on one or more chromosomes and present in highly homologous gene
clusters (Mouzo et al., 2018; Piersma et al., 2005; Yan et al., 2005). The many isoforms
of Ara h 3 produced from multiple genes, generating a variety of gene products, and
potential truncation(s) at the N- and C-termini generates a larger probability of sequence
isoform variants (Bertioli et al., 2019). The contribution that each isoform makes to
overall allergenicity is still unknown, due to the challenge of purifying individual protein
isoforms.
Rabjohn and co-workers identified four IgE-binding epitopes in Ara h 3, all
located within the acidic subunit (Rabjohn et al., 1999). Jin and co-workers demonstrated
these epitopes are all solvent exposed owing to their allergenicity (Jin et al., 2009). Many
IgE epitopes are not fully elucidated since many of these epitope studies have been
performed on recombinant proteins, however the recombinant versions lack the inherent
variation present in naturally produced Ara h 3 (Piersma et al., 2005).
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Prolamins
The 2S albumins, Ara h 2 and 6, are considered the most potent elicitors of
allergic reactions in peanuts (Flinterman et al., 2007; Klemans et al., 2013; Peeters et al.,
2007). These proteins exhibit strong similarity, sharing 59% sequence identity, and
similar tightly bound structures (Koppelman et al., 2005). Together, the 2S albumins
were determined as potent allergens by histamine degranulation studies and rat basophil
leukemia cell-based immunoassays (Blanc et al., 2009;; Zhuang and Dreskin, 2013). Ara
h 2 and Ara h 6 are considered strong clinical predictors of peanut allergy as determined
by in vitro measurements (Klemans et al., 2013; Koppelman et al., 2005; McDermott et
al., 2007). When combined for diagnostic testing, Ara h 6 and Ara h 2 can effectively
predict peanut allergy with 85% specificity (Koid et al., 2013).
In peanuts, the 2S albumin proteins are present as monomers, in contrast to most
other 2S albumins, which exist as heterodimers (Burks et al., 1992; Shewry et al., 1995;
Suhr et al., 2004). Both Ara h 2 and Ara h 6 exhibit similar structures of tightly coiled
helices stabilized by four or five disulfide bonds, respectively, which imparts high
stability against thermal treatments and gastric digestion (Hazebrouck et al., 2012;
Mueller et al., 2011; Sen et al., 2002). Digestibility studies using both gastric and
intestinal proteases demonstrate the peanut 2S albumins retain their internal secondary
structures (Apostolovic et al., 2016; Astwood et al., 1996; Koppelman et al., 2010;
Lehmann et al., 2006; Sen et al., 2002; Suhr et al., 2004). Another digestibility study
demonstrated the N- and C-termini of peanut 2S albumins are the most susceptible to
proteolysis (Apostolovic et al., 2016). Both Ara h 2 and 6 are capable of generating
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large, stable fragments after digestion with proteolytic enzymes pepsin and chymotrypsin
(Apostolovic et al., 2016). These digestive resistant peptides (DRP) demonstrated similar
IgE binding and secondary structures to the intact protein (Apostolovic et al., 2016).

Ara h 2
Ara h 2 exists in two isoforms, Ara h 2.01 (16.3 kDa) and 2.02 (18 kDa) (Chatel
et al., 2003). The slightly larger isoform, Ara h 2.02, has a 12 amino acid insert
beginning at residue 71 (Apostolovic et al., 2016; Chatel et al., 2003). Comparison of
IgE binding between the two isoforms indicated increased IgE binding to Ara h 2.02,
which has an additional copy of the peptide sequence DPYSPS (Chatel et al., 2003; Hales
et al., 2004). This inserted peptide sequence has been attributed to increased IgE binding
(Albrecht et al., 2009; Stanley et al., 1997).
As previously described, Ara h 2 exists as a tightly bound coil, stabilized by four
disulfide bonds conferring thermal and digestion resistance (Mueller et al., 2011).
Several studies have reported the presence of digestion-resistant peptides (DRP) from
Ara h 2 (Koppelman et al., 2010; Sen et al., 2002). Sen and co-workers described native
Ara h 2 produces a stable 10-kDa peptide fragment after in vitro digestion with three
gastroduodenal proteases (pepsin, chymotrypsin, trypsin) (Sen et al., 2002). These larger
peptide fragments are capable of eliciting allergic reactions, as demonstrated by IgE
binding to DRPs (Apostolovic et al., 2016), and have been detected in human serum and
breast milk after consumption (Baumert et al., 2009; Bernard et al., 2014).
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Ara h 2 is a strong clinical predictor for peanut allergy, and shows frequent posttranslational modifications of proline residues, attributed to its potency (Blanc et al.,
2009; Kulis et al., 2012; Li et al., 2010). Bernard and co-workers demonstrated increased
IgE binding to hydroxylated prolines in Ara h 2 (Bernard et al., 2015). They reported IgE
binding was strongest to hydroxylated prolines of linear Ara h 2 epitopes, whereas IgE
binding was noticeably weaker to peptides lacking hydroxyproline residues (Bernard et
al., 2015). The presence of hydroxyproline residues with increased IgE binding indicates
the relevance of Ara h 2 as a highly potent and severe allergen with consequent
usefulness for clinical diagnostics (Bernard et al., 2015).

Ara h 6
Ara h 6 (14.5 kDa) is highly homologous to Ara h 2 both in sequence (59%
homology) and structure, with nearly identical α-helical regions (Apostolovic et al., 2013;
Koppelman et al., 2005). Five disulfide bridges stabilize the tightly coiled helices (Suhr
et al., 2004). Two isoforms exist for Ara h 6, with only minor sequence differences
(Bernard et al., 2007). Ara h 6 exhibits similar seroprevalence to Ara h 2, with both
thought to elicit severe reactions in sensitized individuals (Codreanu et al., 2011;
Flinterman et al., 2007). Both in vivo (SPT, basophil degranulation) and in vitro (IgE
immunoblots) tests were used to establish Ara h 6 as a major allergen, which was not
initially considered (Koppelman et al., 2005; Peeters et al., 2007). Presence of a posttranslationally cleaved Ara h 6 has demonstrated clinical reactivity to a polyclonal
antibody when extracted from four different peanut cultivars (de Jong et al., 2018). Post
translational cleavage for Ara h 6 differs compared to other plant species in which most
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2S albumins are synthesized as one precursor peptide and then cleaved into two chains
and exist as heterodimer (de Jong et al., 2018; Shewry et al., 1995).

Minor Peanut Allergens
There are several other peanut proteins which are considered minor peanut
allergens, and important clinically, but not as prevalent as the major peanut allergens
previously described. In an allergic population, minor allergens are defined as proteins
which bind serum IgE in less than 50% of allergic subjects (Matricardi et al., 2016;
Mueller et al., 2014).
All other IUIS identified peanut allergens (Ara h 5, Ara h 7-17) are considered
minor allergens (Mueller et al., 2014). Ara h 7 and Ara h 9 are classified as prolamins
(Kleber-Janke et al., 1999). Ara h 7 shares a similar structure to Ara h 2 and 6 whereas
Ara h 9 is an nsLTP (non-specific lipid transfer protein) (Kleber-Janke et al., 1999;
Krause et al., 2009). Ara h 5 and 8 are categorized as Class 2 allergens, causing cross
reactivity with inhalant allergens (Becker et al., 2018). Ara h 5 is similar to Bet v 2,
whereas Ara h 8 is cross-reactive to Bet v 1 (Asarnoj et al., 2012; Mittag et al., 2004).
Ara h 8 has hydrophobic regions similar to Bet v 1, known to bind lipids and prevent
protein digestion (Petersen et al., 2014).
Ara h 10 and 11 are oleosins existing in association with oil bodies (Pons et al.,
2002; Schwager et al., 2015). These proteins are generally present as multimeric
conformations, either as dimers or oligomers (Schwager et al., 2015). Oleosins are
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generally underrepresented in commercially prepared extracts which generally use
aqueous extractions (Schwager et al., 2015).
The defensins, Ara h 12 and 13, are cysteine rich proteins responsible for
protection against pathogenic fungi, and exist as dimers (Sagaram et al., 2011).

DIGESTION, ABSORPTION, AND TRANSPORT PROCESSES OF PROTEINS
Unlike most dietary proteins, which are thought to be degraded into individual
amino acids, di-, or tripeptide fragments; allergenic food proteins may remain largely
intact as large peptide or protein fragments after gastric digestion (Chambers et al., 2004;
Wickham et al., 2009). These partially digested macromolecules are transported across
the gut epithelium and enter into circulation where they are capable of eliciting an
allergic reaction in sensitized individuals (Miner-Williams et al., 2014). However, these
specific transport processes for larger allergenic protein fragments are less understood
due to a lack of in vivo detection methods for allergenic food proteins in human blood.
Evidence of intact, or largely intact, dietary food proteins entering the
bloodstream, particularly allergenic proteins, has been reported for ovalbumin, βlactoglobulin, and the peanut 2S albumin proteins, Ara h 2 and 6 (Baumert et al., 2009;
Husby et al., 1985, 1986; JanssenDuijghuijsen et al., 2017; Paganelli and Levinsky,
1980). Initial investigations focusing on the uptake of allergenic proteins indicated some
of the ingested protein (ovalbumin) remained intact and detectable by immunoassay
following size separation chromatography (Husby et al., 1985). Likewise, recent
investigations focused on peanut, a highly prevalent and potent food allergen, have
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demonstrated detectable peanut proteins, Ara h 2 and 6, in human serum by
immunoassays (Baumert et al., 2009; JanssenDuijghuijsen et al., 2017). Immunoassay
detection methods are challenging due to the low abundance of target analytes and
potential interactions with other matrix proteins and consequently, may not be the most
suitable method for in vivo protein detection due to their limited analytical targets and
dependence on antibody-antigen binding (JanssenDuijghuijsen et al., 2017). However,
improvements to in vivo detection methods has been challenging due to the unknown
state of allergenic proteins after consumption, gastrointestinal digestion, and transport in
vivo. Here, we will examine the properties of allergenic proteins after consumption and
the process of transportation

Digestion of Dietary Proteins
Dietary protein, a vital macromolecule for human health and nutrition, is mostly
digested in the gastrointestinal tract for rapid nutrient absorption (Erickson and Kim,
1990; Miner-Williams et al., 2014). Contrastingly, allergenic food proteins, which are
highly resistant to digestion, remain intact or partially intact after gastric digestion
(Astwood et al., 1996; Bannon, 2004). The purpose of digestion is to reduce food
particle size, primarily within the oral cavity and stomach, allowing the release and
absorption of vital nutrients into systemic circulation (Kong and Singh, 2008). As a
result, digested dietary protein is readily absorbed for nutritional and metabolic processes
(Kong and Singh, 2008).
Gastrointestinal digestion is broadly described in three phases, the (1)
intraluminal phase, (2) small intestinal phase, and (3) transport and absorption phase
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(Erickson and Kim, 1990). The first stage of digestion begins in the mouth, the
beginning of the digestive tract, where food is mixed with saliva and reduced in particle
size (Kong and Singh, 2008). Saliva, a mixture of water, electrolytes, mucus, and
enzymes, is responsible for solubilizing the food bolus for transport to the stomach
(Untersmayr and Jensen-Jarolim, 2006). The oral mucosa is the first potential site of
antigen uptake during digestion (Dirks et al., 2005; Untersmayr and Jensen-Jarolim,
2006). Dirks et al., 2005 evaluated blood samples by histamine release assays from
subjects who were instructed to chew raw peanuts but to not swallow the food material.
The collected blood samples triggered mast cell activation and histamine release,
supporting protein absorption can occur as early as the oral mucosa in the digestive tract
(Dirks et al., 2005).
The food bolus then travels through the esophagus and into the stomach, where it
encounters gastric juices composed of mucus, hydrochloric acid (HCl), and other
proteases (Untersmayr and Jensen-Jarolim, 2006). The bicarbonate containing mucus
layer is responsible for providing protection to the gastric mucosal lining (Allen and
Flemström, 2005). HCl reduces the stomach pH, activating pepsinogen autocatalysis
producing active pepsin, the primary stomach protease (Erickson and Kim, 1990).
After partial protein digestion in the stomach, the food bolus enters the small
intestine where pancreatic digestion occurs (Erickson and Kim, 1990). Here, alkaline
pancreatic juices containing proteolytic enzymes (trypsin, chymotrypsin, elastase, and
carboxypeptidase) are secreted as inactive zymogens from the pancreas (Erickson and
Kim, 1990). The acidic food bolus activates the pancreatic enzymes by decreasing the
pH of the alkaline small intestine to pH 6.0 – 6.5, while simultaneously deactivating the
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gastric proteases (Erickson and Kim, 1990; Rune and Viskum, 1969). Trypsin is a key
digestive enzyme activated by action of enteropeptidase, an enzyme located in the
duodenal enterocytes (Erickson and Kim, 1990; Rinderknecht, 1993). Activation of
trypsin initiates a signaling cascade activating the remaining pancreatic enzymes with
different cleavage sites (Matthews, 1975). The pancreatic digestion phase is fundamental
for production of short polypeptides and free amino acids necessary for rapid protein
absorption (Erickson and Kim, 1990). During the last portion of gastric digestion, the
intestinal brush border peptidases act upon remaining peptides and produce a mixture of
di- and tripeptides, as well as free amino acids for transport across the intestinal
epithelium (Erickson and Kim, 1990).
Gastric digestion and transit time takes approximately two hours (Untersmayr and
Jensen-Jarolim, 2006). The rate of digestion is influenced by several factors including
the food matrix, chemical and physical properties of the food(s), and other physiological
processes occurring within the GI tract (Kong and Singh, 2008).

Dietary Protein Absorption
Protein absorption has been studied using both in vitro and in vivo assays.
Several in vitro studies have used Ussing chambers, requiring small sections of intestinal
tissue (ex vivo), mimicking small intestinal environment and absorption (Reitsma et al.,
2014). Cell lines, including Caco-2 and HT-29, have also been utilized in many protein
absorption studies (Reitsma et al., 2014). Ideally, in vivo studies are the most relevant
method for studying protein absorption, however few studies focused on in vivo protein
uptake (Husby et al., 1985, 1986; Paganelli and Levinsky, 1980). The gastrointestinal
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tract, where a majority of absorption occurs consists of several systems working in
sequence to absorb dietary molecules including proteins (Samadi et al., 2018). Here, we
review the gastrointestinal environment and absorption mechanisms for both sensitized
and non-sensitized individuals.

Organization of the Gastrointestinal Barrier
In order to understand gastric transport and behavior of allergenic proteins, we
must first understand the complex structure of the small intestine, where a majority of
digestion occurs (Kong and Singh, 2008). The intestinal epithelium consists of multiple
structured, yet differentiated layers working collectively to prevent uptake of harmful
antigens whilst allowing absorption of nutritive molecules (Gigante et al., 2011; Heyman,
2005; Reitsma et al., 2014).
In healthy individuals, a tight monolayer of intestinal epithelial cells is formed,
preventing passage of undesired molecules (Samadi et al., 2018). The surface of the
epithelium is highly folded and organized into villi and crypts resulting in an increased
surface area of the intestinal lumen (Peterson and Artis, 2014; Samadi et al., 2018). Four
types of intestinal epithelial cells (IECs) are generated from intestinal epithelial stem cells
including absorptive enterocytes, mucus producing goblet-cells, anti-microbial secreting
Paneth cells, and enteroendocrine cells (Bevins and Salzman, 2011; Peterson and Artis,
2014; Samadi et al., 2018). Upon cell differentiation, the enterocytes form a barrier
preventing passage of larger molecules by simultaneous producing tight junction proteins
and additional membrane proteins connecting enterocytes on their apical sides (Heyman,
2005; Samadi et al., 2018). Other compounds including secretive IgA, mucus, and α-

31
defensins, further prevent the absorption of harmful molecules across the intestinal
epithelium (Samadi et al., 2018). Figure 1-2 illustrates the organization of intestinal
epithelium (Samadi et al., 2018).
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Figure 1-2. Structure of gastrointestinal epithelium. Adapted from Samadi et al., 2018

The mucosal immune system is located immediately below the intestinal
epithelium and contains a significant number of immune cells (Samadi et al., 2018). It is
the primary organ system involved in oral tolerance acquisition and the development of
food allergy (Berin and Shreffler, 2016). The intestinal epithelial cells is responsible for
regulating intestinal permeability and contributes significantly to mucosal immune
responses (Samadi et al., 2018). The gastrointestinal epithelium functions to protect the
mucosal immune system from harmful substances from the external environment (Berin
and Sampson, 2013). Within the intestinal mucosca, the antigen-presenting cells and
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macrophages respond to microbiota and other molecules signaling secretion of
immunoregulatory cytokines (Berin and Sampson, 2013).
The mucosal immune system is made up of several immune cells including,
CD4+, CD8+ regulatory and effector T cells, B-cells (antibody secreting), dendritic cells,
macrophages, and eosinophils (Berin and Sampson, 2013). A key challenge of the
mucosal immune system is differentiating between harmful and harmless molecules
during protein uptake (Berin and Sampson, 2013)

Transport of Digested Proteins, Peptides, and Amino Acids
The route of allergenic protein transport and introduction into the immune system
may play key roles in sensitization. Previous in vitro studies have utilized cell culture
lines, model digestive systems, or animal models to assess allergenic protein absorption,
but the most effective way to study protein absorption is by in vivo studies (Reitsma et
al., 2014). The sensitization route and initial protein exposure may therefore influence
reaction severity, the probability of sustained sensitization, or tolerance acquisition.
Following gastrointestinal digestion, 70% of proteins exist as small oligopeptides,
with the remainder present as free amino acids (30%). (Binder and Reuben, 2009;
Goodman, 2010). Free amino acids and peptides are transported from the small intestinal
to the portal blood via absorptive enterocytes (Erickson and Kim, 1990; Goodman, 2010).
Free amino acids are transported via multiple transport systems, with most amino acid
uptake utilizing active transport systems (Schultz and Curran, 1970). The amino acid
transport systems have broad and shared substrate specificities, allowing for the transport
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of multiple amino acids while utilizing several transport systems for individual amino
acids (Binder and Reuben, 2009; Goodman, 2010). In instances when amino acid
concentrations are high in the small intestine, and not requiring active transport,
facilitated or simple diffusion processes are additionally used (Erickson and Kim, 1990;
Goodman, 2010).
Oligopeptides are transported independent of the amino acids, occurring primarily
through the PEPT1 transporter, the major peptide transporter (Devlin, 2006). Amino
acids are more efficiently absorbed when transported in the form of peptides (Erickson
and Kim, 1990). PEPT1 is an active H+ coupled transport process, utilizing the
electrogenic difference between the luminal brush border (pH 6) and the enterocytic
cytoplasm (pH 7) facilitating oligopeptide uptake (Steel and Hediger, 1998). The PEPT1
has broad substrate specificity for di- and tri-peptides capable of transporting ~400
dipeptides and 8000 tripeptides (Daniel, 2004; Goodman, 2010). Di- and tri-peptides
absorbed by enterocytes at the brush border membrane, are hydrolyzed by intracellular
peptidases (Erickson and Kim, 1990; Goodman, 2010). However, Shimizu et al., 2004
estimated approximately 10% of proteins are able to traverse the epithelial barrier intact
using various peptide transport mechanisms (Shimizu, 2004).

Protein Transport Routes
In non-sensitized, healthy individuals, the absorption of dietary proteins occurs
via the absorptive enterocytes (i.e. transcytosis), where proteins travel from the intestinal
lumen to the portal blood (circulation) (Reitsma et al., 2014).

35
Sensitized individuals, who exhibit immune-mediated responses to allergenic
proteins, may demonstrate different protein absorption mechanisms. Para-cellular
transport and transport via mast cells (transcellular transport) are the key pathways for
protein transport in sensitized individuals, concluded from a thorough literature review
conducted by Reitsma et al., 2014. Para-cellular transport is regulated by tight junctions
allowing only small, generally hydrophilic compounds to be absorbed (Heyman, 2005).
The integrity of tight junctions in sensitized individuals is reduced due to abundance of
mast cells, which increases the amount of absorbed intact dietary protein (Berin et al.,
1998). Proteins transported via the para-cellular route do not encounter lysosomal
degradation in the enterocyte, and remain intact (non-degraded) after transport across the
gut epithelium (Shimizu, 2004).
Transcellular transport involves a variety of mechanisms including carriermediated transport, endocytosis, or passive diffusion (Reitsma et al., 2014). Carriermediated transport for proteins has not been well described in the literature, however
carrier-mediated transport of peptides (di- and tri-peptides) and amino acids are present in
the small intestine and were previously discussed. Endocytosis, the primary transcellular
pathway used, involves several intestinal cell types including enterocytes, M cells, and
mast cells (Reitsma et al., 2014). During endocytosis, proteins are endocytosed by a
specific cell (e.g. enterocyte) and transported across the intestinal barrier in small vesicles
(Reitsma et al., 2014). During transport, proteins are degraded by lysosomes, although a
minor amount of protein may remain intact or partially intact (Reitsma et al., 2014; So et
al., 2000).
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Normal Responses to Food Proteins and Oral Tolerance
During the normal course of digestion, nearly all food proteins (90%) are digested
into peptides or constituent amino acids and do not cause immunologically mediated
responses (Heyman and Desjeux, 1992). The remaining un-degraded proteins (~10%)
cross the intestinal epithelium intact, as evidenced by detection of allergenic food
proteins in serum (Baumert et al., 2009; Husby et al., 1985; JanssenDuijghuijsen et al.,
2017; Shimizu, 2004). In healthy individuals, these intact antigens are sampled by
immune cells after digestion, ultimately resulting in a state of acquired immune tolerance
(Chehade and Mayer, 2005). This acquired immune tolerance (e.g. oral tolerance) is
caused by the production of IgG, IgM, or IgA antibodies that bind intact dietary proteins
(Chehade and Mayer, 2005; Ko and Mayer, 2005). Oral tolerance is immunologically
defined as clonal anergy, a process resulting in no active response of the immune system
(Ko and Mayer, 2005).
A failure of oral tolerance results in development of IgE antibodies and a state of
sensitization (Chehade and Mayer, 2005; Pelz and Bryce, 2015; Wambre and Jeong,
2018). In infants, whose immune systems are immature, the exposure to digestively
stable allergenic food proteins has been suspected to cause sensitization (Sicherer and
Sampson, 2006). However, recent evidence suggests early introduction of allergenic
foods could prevent the development of food allergies in children (Du Toit et al., 2015).
Acquiring oral tolerance, or loss of sensitivity to a particular food, mitigates a
food allergy, and some individuals may even naturally acquire tolerance over time and
eventually outgrow an allergy (Wood, 2003). Tolerance acquisition is dependent on the
causative allergen but most often, children outgrow allergies to milk, wheat, soy, and egg
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(Wood, 2003). Allergy to peanuts, tree nuts, and shellfish are generally not outgrown and
sustained into adulthood (Chinthrajah et al., 2015). IgE antibodies directed against
conformational epitopes, such as in milk and egg proteins, are generally outgrown
(Sicherer and Sampson, 2010). Whereas, IgE antibodies directed against linear or
sequential epitopes, such as in peanuts or tree nuts, are associated with persistent allergy
(Järvinen et al., 2001). Several immunological factors are involved in the process of
tolerance acquisition, however the complete mechanism is not yet fully understood (Ko
and Mayer, 2005; Strobel and Mowat, 1998)
The state of an antigen during absorption, either as a soluble or an intact
particulate (insoluble) molecule influences tolerance acquisition (Ko and Mayer, 2005).
Soluble antigens are more tolerated than particulate antigens, as particulate antigens have
been shown to induce an immune response (Brandtzaeg, 2002; Sampson, 1999).
Encapsulated ovalbumin, a particulate antigen, when exposed only at level of the gut
associated lymphoid tissue (GALT), induced an immunologically mediated response,
whereas soluble ovalbumin protein ingested orally did not induce an immune mediated
response (Jain et al., 1996a , 1996b). Soluble antigens are largely absorbed by IECs,
which are present in high abundance in the intestinal epithelium (Ko and Mayer, 2005).
M cells, located above Peyer’s patches, absorb particulate antigens through expressed
surface receptors for particulate antigens (Ko and Mayer, 2005). Dendritic cells (DCs),
localized to the Peyer’s patches, intestinal lamina propria, and mesenteric lymph nodes,
act as key antigen presenting cells (APCs) capable of direct antigen sampling by
intercalating IEC’s, without disrupting the epithelial barrier (Ko and Mayer, 2005;
Rescigno et al., 2001). The overall factors contributing to antigenic protein uptake and in
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acquiring tolerance between sensitized and non-sensitized individuals is largely
unknown.
Food allergic individuals may participate in immunotherapy protocols to reestablish oral tolerance and achieve desensitization (Wang and Sampson, 2011). Several
types of immunotherapy protocols have been developed including oral immunotherapy
(OIT), sublingual immunotherapy (SCIT), and epicutaneous immunotherapy (EPIT)
(Koppelman et al., 2019; Sicherer and Sampson, 2010; Wang and Sampson, 2011).
Gaining an understanding of how individuals are sensitized will help the development of
immunotherapy protocols.

In vivo Detection of Allergenic Food Proteins
In vivo detection of dietary protein, particularly those classified as major
allergens, has been reported in serum, saliva, and breast milk, for several allergenic
proteins including ovalbumin, β-lactoglobulin, and the peanut 2S albumin proteins (Ara h
2 and 6) (Baumert et al., 2009; Husby et al., 1985; JanssenDuijghuijsen et al., 2017;
Paganelli and Levinsky, 1980). Initial investigations evaluated ovalbumin for dietary
protein uptake and indicated a portion of the ingested protein remained intact and
detectable by immunoassay following size separation chromatography (Husby et al.,
1985).
In many cases, detection by ELISA methods is challenging due to the low
abundance of target analytes (allergenic protein) and potential interactions with other
endogenous serum proteins (JanssenDuijghuijsen et al., 2017). As a result,
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immunoassays may not be the most suitable choice for in vivo protein detection due to
their limited specificity and reliance on antibody-antigen binding. Immunoassays are the
most commonly used analytical method for detection of allergenic food proteins and rely
on antibody recognition of epitopes present on an allergenic protein (Immer and Lacorn,
2015). However, if antigenic epitopes are unable to be detected, this could lead to under
estimations of the true allergenic protein concentration in vivo. Recent evidence has
described in vivo interactions occurring between peanut proteins (e.g. antigen) and
endogenous serum immunoglobulins (IgG) preventing recognition of the antigenic
epitopes by immunoassay capture antibodies (JanssenDuijghuijsen et al., 2017). There is
an imperative need for improved analytical methods, which are not reliant on antigenantibody binding and offers comparable sensitivity to immunoassays.

PRINCIPLES OF MASS SPECTROMETRY
The growing importance of MS in clinical medicine has enabled investigations of
protein biomarkers and other biologically relevant sera proteins (Gillette and Carr, 2013).
Recently, MS has been implemented in food allergen detection, providing an alternative
method for protein quantification in complex food matrices (Monaci et al., 2018). Food
allergens are typically present in low concentrations, but remain readily detectable by
LC-MS/MS methods (Monaci et al., 2018). Immunoassays are the most commonly
established technique for detection of allergenic food proteins, however recent
advancements in serum and food allergen proteomics, as well as mass spectrometers (e.g.
sensitivity, resolution, mass accuracy, duty cycle) has enabled clinical investigations of in
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vivo allergenic proteins (Gillet et al., 2016; Immer and Lacorn, 2015; Mann and Kelleher,
2008).
In bottom-up proteomics, mass spectrometers detect protein-derived peptides
from biological samples by measuring the mass-to-charge ratio (m/z) of gas phase ions
with high sensitivity (Lane, 2005). Historically, MS methods are used to determine the
relative abundance and absolute abundance of proteins, with the former being the most
predominantly employed method (Lane, 2005; Monaci et al., 2018). Recently, many
quantifiable, relative and absolute, targeted methods (e.g. parallel reaction monitoring
(PRM), multiple reaction monitoring (MRM) have been developed and implemented in
food allergen detection (Monaci et al., 2018).

MS Instrument Design
The overall purpose of a mass spectrometer is to identify the mass-to-charge
ratios of ions in the gas phase (Aebersold and Mann, 2003; Savaryn et al., 2016). In
principle, mass spectrometers consist of three primary components including the ion
source, mass analyzer, and detector (Aebersold and Mann, 2003). The analytes are
ionized, entering into the gas phase through various ionization methods including
electrospray ionization (ESI), atmospheric pressure chemical ionization (APCI), and
matrix-assisted laser desorption ionization (MALDI) (Aebersold and Mann, 2003; Lane,
2005). The mass analyzer, the key component of any MS platform, measures the massto-charge (m/z) ratio of gaseous phase ions (Aebersold and Mann, 2003). Lastly, the
detector is responsible for determining the abundance of each m/z identified by the mass
analyzer (Aebersold and Mann, 2003).
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Most often, the type of mass analyzer is used to describe, or often name, various
MS platforms (Savaryn et al., 2016). Several types of mass analyzers have been
developed including linear ion traps (LIT), quadrupole mass filters (QMF), quadrupole
ion traps (QIT), high-resolution Orbitraps, time-of-flight (TOF), and Fourier transform
ion cyclotron resonance (FT-ICR) (Aebersold and Mann, 2003; Savaryn et al., 2016).
For the purposes of this review, we will focus on the instrumentation of high-resolution
Orbitraps and triple quadrupole (quadrupole mass filters), as these instrument types were
utilized in our studies.

Orbitrap Instruments
The Orbitrap, the predominant instrument used for PRM experiments, offers
major advancements over previous instrument platforms including higher mass accuracy
(compared to ion traps), increased sensitivity and dynamic range (compared to time-offlight), and with a smaller footprint (compared to FT-ICR) (Eliuk and Makarov, 2015).
The Orbitrap is based on a Kingdon trap, where an electrostatic field is established in an
enclosed can by placing a wire along its axis (Eliuk and Makarov, 2015; Kingdon, 1923).
The Orbitrap itself consists of three electrodes including two outer cup shaped electrodes,
which face each other and an additional spindle shaped central electrode (Eliuk and
Makarov, 2015; Zubarev and Makarov, 2013). Ions enter the Orbitrap and due to the
electric fields traveling in a circular manner around the central electrode creating a
digitized image current (e.g. in time). The image current is processed by an ‘enhanced
Fourier Transformation’ algorithm (e.g. in frequency) and ultimately converted to a mass
spectrum (Michalski et al., 2011; Zubarev and Makarov, 2013).
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The Q-Exactive (QE) platform is a hybrid design pairing a QMF with an Orbitrap
mass analyzer (Michalski et al., 2011). The QMF allows for rapid isolation of selected
m/z ions during targeted acquisitions (Michalski et al., 2011). The addition of an S-lens,
immediately following injection from the ion source, improves ion filtering (Michalski et
al., 2011; Zubarev and Makarov, 2013). The QE platform is equipped with a C-trap and
a higher energy collisional dissociation (HCD) cell, where ion fragmentation occurs
(Michalski et al., 2011). The C-trap is a large ion storage device, separate to the Orbitrap
analyzer, where ions are collected in ‘packets’ and shuttled between the HCD cell and
Orbitrap analyzer (Eliuk and Makarov, 2015; Liebler and Zimmerman, 2013).

Triple Quadrupole Instruments (QQQ)
Triple quadrupole (QQQ) instruments, as their name implies, consist of three
quadrupoles. The first and third quadrupole act as mass filters for precursor and fragment
ions, respectively, with the second quadrupole acting as the collision cell (Croote and
Quake, 2016; Yost and Enke, 1978). The first and third quadrupoles are used for ion
selection providing two stage mass filtering, and increased sensitivity (Lange et al.,
2008). When used in MRM mode, QQQ instruments are non-scanning, and only acquire
spectral data for selected transitions, improving overall sensitivity by up to two orders of
magnitude compared to scanning type acquisitions (PRM, Full scan data-dependent
acquisitions (DDA)) (Domon and Aebersold, 2010; Lange et al., 2008).

43
MS Data Acquisition
Two types of MS acquisitions, top-down or bottom-up, are predominantly used in
proteomic studies (Chait, 2006; Monaci and Visconti, 2009). Top-down methods
measure the masses of intact proteins, wherein the intact protein mass and corresponding
fragment masses are measured (Catherman et al., 2014). Consequently, analytical
samples do not require enzymatic digestion (Catherman et al., 2014). For the purposes of
our studies, we utilized bottom-up methods, which will be the primary focus of this
section. Top-down methods have been thoroughly reviewed elsewhere (Catherman et al.,
2014; Toby et al., 2016).
Bottom-up methods measure digested peptide fragments after proteins undergo
enzymatic digestion generating smaller peptide fragments (Yates, 1998; Zhang et al.,
2013). Protein samples are reduced, alkylated, and enzymatically digested generally by
trypsin (Zhang et al., 2013). Trypsin has predictable cleavage sites at C-terminal arginine
(R) and lysine (K) amino acids, except after a proline (P), allowing peptide masses to be
accurately determined (Aebersold and Mann, 2003; Zhang et al., 2013).
In bottom-up experiments, using tandem MS, instruments are coupled with liquid
chromatography system (LC, therefore LC-MS/MS), wherein the digested peptides are
partially separated by a stationary chromatographic matrix and organic mobile phase
gradient (Croote and Quake, 2016). This additional level of peptide separation provides
improvements to overall sensitivity and detection within a single chromatographic run
(Croote and Quake, 2016). Following chromatographic separation, peptides are ionized
and desorbed into the gas phase when using ESI (Catherman et al., 2014; Croote and
Quake, 2016; Zhang et al., 2013).
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Peptide sequences are determined by comparing the parent ions detected on the
acquired mass spectra to a theoretical enzymatically digested in silico mass spectral
database generated from protein sequences in the database (Zhang et al., 2013). The
amino acid sequence of peptides is determined/confirmed from the fragment ions
detected in the mass spectra (MS2) resulting from the collision-induced dissociation
(CID; QTRAP) or higher-energy C-trap dissociation (HCD; QExactive) of the isolated
parent ion (Gillet et al., 2016). In order for peptides to be identified, the peptide
sequences must be present in the protein sequence database (Gillet et al., 2016). Peptides
are identified based upon the quality of peptide-spectrum matches and the false discovery
rate (Gillet et al., 2016). The false discovery rate (FDR), is calculated by comparing the
acquired data against the actual database and the decoy database using same analysis
conditions (Gillet et al., 2016). The decoy database may be generated by performing an
in silico digestion of the reversed amino acid sequences from the sequence database
(Gillet et al., 2016).

MS Acquisition Methods
MS methods vary depending on the type of experiment an investigator chooses to
conduct. All instruments are able to perform discovery mode (DDA) experiments and
targeted MS methods (e.g. Orbitraps), however some instruments (e.g. QQQ) are better
suited for targeted experiments. Differences between instrument sensitivity, resolution,
and scan speed affect overall detection in each given experiment.
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Discovery Methods
Thousands of peptides and proteins can be identified using discovery MS and
often referred to as ‘shotgun’ or ‘bottom-up’ proteomic methods (Domon and Aebersold,
2010). The sheer number of proteins identified by MS easily surpasses the number of
proteins identifiable by traditional affinity assays (Domon and Aebersold, 2010).
Affinity-binding assays rely on the analyte binding, which are highly specific and not
easily multiplexed, presenting a significant challenge in elucidating multiple proteins in a
matrix (Monaci et al., 2015).
In discovery acquisitions (DDA), peptides for experimental monitoring do not
need to be pre-determined (Domon and Aebersold, 2010). DDA provides a minimally
biased peptide sampling strategy wherein ions are selected for fragmentation based on
abundance following TopN selection, where N is often between 10 and 20 ions (Eliuk
and Makarov, 2015). However, discovery methods generally exhibit poorer overall
sensitivity due to the inherent variability among protein samples and stochastic ion
sampling (Gillette and Carr, 2013; Lange et al., 2008).

Targeted Acquisition Methods
Targeted MS methods, such as PRM and MRM, have been implemented for food
allergen detection and in some in vivo studies focused on allergenic proteins (Hands et
al., 2020; Monaci et al., 2015; Mose et al., 2019). Targeted MS methods can monitor
multiple pre-determined peptides and transitions using their specific m/z values and
chromatographic retention times (Lange et al., 2008; Picotti and Aebersold, 2012). In
comparison to discovery MS, targeted MS provides an alternative for detection of low
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abundance proteins, which may not be sampled in abundance driven discovery
acquisitions (Liebler and Zimmerman, 2013). In addition, targeted MS methods are
highly sensitive due to minimized background interferences (Domon and Aebersold,
2010). A well-developed targeted method encompasses pre-selected transitions, stable
peptide elution times, and detectable fragment ion intensities (Domon and Aebersold,
2010). Consequently, targeted MS methods have been quickly adopted in food allergy
research (e.g. clinical, industry) (Monaci et al., 2018).

Multiple Reaction Monitoring (MRM)
MRM is considered the most robust and reproducible method for targeted peptide
detection and, has been routinely implemented for routine protein analytical
measurements (James and Jorgensen, 2010). MRM methods reduce background noise
due to narrow selective mass windows for transitions (Lange et al., 2008). As a result,
MRM methods are quantifiable over a broad dynamic range spanning five orders of
magnitude (Lange et al., 2008).
As with any targeted MS experiment, MRM methods rely entirely on suitably
selected peptide targets and transitions (Rauniyar, 2015). In traditional MRM, only one
fragmentation step is performed, where the parent ion is fragmented producing daughter
ions (Figure 1-3) (Lange et al., 2008; Yost and Enke, 1978). During a quantifiable MRM
assay 3 – 5 transitions per peptide are monitored for a given protein (Picotti and
Aebersold, 2012). Quadrupole mass analyzers are lower-resolution compared to others
(time-of-flight, Orbitrap), but in QQQ instruments, they offer high selectivity, sensitivity,
and optimized duty cycles (Abbatiello et al., 2010; Sherman et al., 2009). MRM methods
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are considered the ‘gold standard’ for quantification in targeted proteomics, and a
suitable replacement for quantifiable immunoassays due to their high specificity for
selected transitions (Addona et al., 2009; Lange et al., 2008).

MRM Cubed (MRM3)
In complex matrices, MRM methods may not achieve the desired limit of
detection in samples with complex matrices and low analyte concentrations. Co-isolation
of ions with similar m/z values and other matrix interferences may still hinder detection
of low abundance compounds by using MRM alone (Ronsein et al., 2015). In certain
instrument platforms, like a QTRAP instrument, a secondary fragmentation step, MRM3
(“MRM cubed”), can improve selectivity, sensitivity and the signal-to-noise ratio (Von
Bargen et al., 2013). In MRM3, the previous fragment ion (MS2), is fragmented an
additional time resulting in a secondary fragment ions (MS3) (Figure 1-3) (Korte and
Brockmeyer, 2016). This additional fragmentation step has demonstrated up to a 30-fold
increase in signal intensity, while significantly reducing baseline noise (Hunter, 2010;
Korte and Brockmeyer, 2016). MRM3 has been successful in quantifying proteins and
peptide biomarkers from non-depleted serum or plasma (Fortin et al., 2009; Jeudy et al.,
2014). The QTRAP 6500+ has the capability to perform MRM3, wherein the third
quadrupole (Q3) acts as a linear ion trap (LIT) which captures and fragments the MS2
ions (Korte and Brockmeyer, 2016). The 3rd mass analyzer has the capability to record a
full scan spectrum of fragment ions or capture pre-defined m/z values for MS3 ions
(Korte and Brockmeyer, 2016).

48

Figure 1-3. Comparison of MRM and MRM3 acquisition methods.
Image adapted from Sciex (Plomley).
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Parallel Reaction Monitoring (PRM)
Parallel reaction monitoring methods (PRM) are an alternative targeted
acquisition method providing high sensitivity, resolution, and accurate quantification
with isotopically labeled peptides (e.g. heavy peptides) (Rauniyar, 2015). Due to
instrument design improvements (e.g. injection, dynamic range, sensitivity, and
resolution), PRM methods are frequently conducted on time-of-flight (TOF) or Orbitrap
type instruments (Peterson et al., 2012). In a PRM method, the selected precursor
peptides (MS1) are fragmented and all resulting fragment ions (MS2) are recorded in
parallel (Figure 1-4) (Ronsein et al., 2015). As a result, pre-selection of transitions
(precursor-fragment ion pairs) are not required since all transitions are monitored
(Ronsein et al., 2015). PRM methods have a broad dynamic range with quantification
spanning four orders of magnitude (Peterson et al., 2012). The benefit of high-resolution
selection allows for distinction between isobaric ions and reductions in background noise
interferences (Gallien et al., 2013; Rauniyar, 2015).
In some cases, the monitoring of multiple fragment ions from a given precursor in
PRM methods are more informative than traditional MRM (Ronsein et al., 2015). By
monitoring all fragment ions, the transition ratios can confirm detection of specific
peptides (Peterson et al., 2012). PRM methods provide less method development time,
less complex data analysis, and statistically similar quantification results (Doerr, 2012;
Duncan et al., 2009; Peterson et al., 2012; Sherman et al., 2009).
To improve sensitivity in some cases, PRM methods can be further multiplexed
(‘msx’), wherein the fragment ions are co-isolated and fragmented together (Sidoli et al.,
2016; Wilson and Vachet, 1996). The simultaneous fragmentation of different m/z ions
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reduces overall duty cycle times, increases signal-to-noise ratios and sample throughput
(Sidoli et al., 2016; Wilson and Vachet, 1996). The combination of these instrument and
method components allows development of various combinations of LC-MS/MS
methods producing highly sensitive and robust MS acquisition methods.

Figure 1-4. Comparison of PRM and MRM acquisition methods. Image
adapted from Zhou and Yin, 2016.
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Quantifiable MS Methods
The aim of many MS proteomic studies is to characterize and potentially quantify
targeted proteins of interest (Domon and Aebersold, 2010). Several methods have been
developed for estimating protein abundances, including both relative and absolute
quantification methods.

Relative Quantification
Relative quantification is achieved by either label-free or labeling methods of
peptide or protein analytes (metabolic, chemical) (Liebler and Zimmerman, 2013;
Lindemann et al., 2017). Label-free quantification is a very cost effective and highthroughput quantification strategy, allowing for comparison of a suite of proteins
(Lindemann et al., 2017). Protein quantification is determined by spectral counting or by
comparison of the peak area from a selected precursor-peptide signal intensity
(Bantscheff et al., 2007; Lindemann et al., 2017). Alternatively, protein quantification
can occur through labeling methods including both metabolic and chemical labeling
(Bantscheff et al., 2007). Metabolic labeling techniques include stable isotope labeling of
amino acids in cell culture (SILAC) or 15N labeling (Lindemann et al., 2017). Chemical
labeling based on in vitro chemical reactions between peptides and reagents produce a
heavy labeled peptide mixture (Lindemann et al., 2017). Other chemical labeling
methods includes isobaric tags for relative and absolute quantification (iTRAQ) or
tandem mass tags (TMT), which label peptide or proteins following digestion
(Lindemann et al., 2017; Ross et al., 2004).
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Absolute Quantification
True quantification, the gold standard for peptide quantification, is determined by
labeled synthetic peptides, such as AQUA (Absolute Quantification) peptides (Gerber et
al., 2003). Synthetically prepared peptides contain isotopically labeled amino acids 13C
and 15N resulting in a predictable mass shift, and these labeled heavy peptides behave
identically to their light (unlabeled) counterparts (Gerber et al.; 2003; Lindemann et al.,
2017). To quantify proteins, the concentrations of synthetically labeled peptides can be
directly compared to the signal intensity of its equivalent light peptide (Lindemann et al.,
2017).
MRM methods offer an absolute quantification method by the addition of
isotopically labeled peptides (Lange et al., 2008).

CONCLUSIONS
Peanut allergies have increased in prevalence and become a health concern for
many individuals. Peanuts are potent allergens causing severe reactions to those affected.
Due to the extensive interest in peanut proteins and their allergenic properties, numerous
studies have been published regarding digestive stability and uptake (Apostolovic et al.,
2016; Baumert et al., 2009; JanssenDuijghuijsen et al., 2017; Koppelman et al., 2010).
The illustrated digestive and thermal stability are key factors in the severity of allergic
reactions to peanuts with the 2S albumins considered the most potent peanut allergens.
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Several factors influence the development of food allergies, ultimately causing
modification(s) in absorption of these allergenic proteins. We suspect different
mechanisms are suspected to be involved in allergenic protein absorption; however, in
vivo testing has yet to be established to further demonstrate these effects. Furthermore,
diagnostic testing still relies on a DBPCFC’s.
Overall improvements in both immunoassay detection methods and the
understanding of allergenic protein behavior, particularly for peanut, has recently been
established. However, the detection of exogenous food proteins in serum remains
challenging.
Mass spectrometry is a powerful analytical tool with great sensitivity capable of
detecting multiple protein targets simultaneously. Mass spectrometry has been used in
other in vivo studies for low protein detection, but only been applied for in vivo detection
of allergens in a handful of studies. Targeted acquisition methods, MRM, MRM3 and
PRM, offer individual advantages to the detection of low abundance proteins due to their
increased selectivity and sensitivity.
A thorough understanding of the molecular and structural properties of individual
peanut allergens will enhance our understanding of allergenic protein uptake and
transport processes. The route(s) of protein uptake, as well the overall rate, may provide
better insights into an allergic reaction, and particularly those mechanisms which differ
greatly between sensitized and non-sensitized person.
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CHAPTER 2: EVALUATION OF DE-COMPLEXING STRATEGIES FOR IN
VIVO DETECTION OF FOOD PROTEINS IN HUMAN SERUM USING MASS
SPECTROMETRY

ABSTRACT
Food allergy is a serious and potentially life-threatening condition, caused by the
ingestion of allergenic foods. The proteins of allergenic foods are resistant to thermal
treatment and gastric digestion, and may enter into circulation as intact or partially intact
molecules (Baumert et al., 2009; Dirks et al., 2005; Husby et al., 1985;
JanssenDuijghuijsen et al., 2017). Food allergy prevalence rates have increased over the
past decade, and in particular, peanut allergy has increased 20% since 2010 (Gupta et al.,
2017; Jackson et al., 2013; Kotz et al., 2011; Lieberman et al., 2018; Rinaldi et al., 2012;
Sicherer et al., 2010). In efforts to understand this increasing prevalence rate, it is
important to understand in vivo protein transport and sensitization; however, limited
studies exist focusing on allergenic protein uptake and allergenic protein characteristics
following uptake.
Detection of peanut proteins in human body fluids (serum, breast milk, saliva) has
been observed at very low levels by immunoassay(s) with poor overall recoveries in
comparison to the amount of protein consumed (Baumert et al., 2009;
JanssenDuijghuijsen et al., 2017). The specific aim of this chapter is to evaluate multiple
serum de-complexation strategies, with the overall objective of developing an in vivo
discovery LC-MS/MS acquisition method for peanut proteins in serum. Shotgun LC-
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MS/MS is able to identify multiple peanut proteins and other serum proteins within a
single sample, making it a highly advantageous and informative method.
Initial analyses of subject serum collected after peanut consumption were negative
for peanut peptides when evaluated by a standard LC-MS/MS discovery acquisition
method. These subject serum samples were collected and analyzed in studies conducted
by Baumert et al., 2009. These subject sera samples were previously determined positive
by immunoassay, indicating our current discovery LC-MS/MS method is not sufficiently
sensitive (Baumert et al., 2009). As a result, we began our studies by evaluating various
de-complexation strategies for removal or separation of abundant serum proteins.
A variety of de-complexing strategies, including four commercial depletion kits,
an organic solvent fractionation method, and modified MS acquisition settings
(exclusion, inclusion lists) were evaluated using a model incurred matrix of human serum
and raw peanut extract (10:1 (w/w) protein) with detection by discovery LC-MS/MS.
Commercial depletion kits, targeting the abundant serum proteins, co-depleted
peanut proteins from the model matrices as determined by SDS-PAGE and LC-MS/MS.
The commercial depletion kits demonstrated a lack of specificity and simultaneously
removed peanut proteins from the analytical matrices, peanut or sera-peanut. We then
evaluated an organic fractionation technique to decrease sample complexity prior to LCMS/MS analysis. This cost-effective de-complexation strategy was useful in decreasing
sample complexity, however, we observed variability in fractionation patterns of
immunoglobulins and peanut proteins, dependent on individual sera (e.g. sensitized or
non-sensitized). Evaluations of MS acquisition settings, inclusion and exclusion lists, for
specified peptides (i.e. m/z events) were largely unsuccessful.
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Overall, each de-complexation strategy was successful in their described
functionality of depleting, fractionating, or including or excluding of specific mass events
but, were largely unsuccessful. We suggest evaluating non-depleted serum for future in
vivo analyses since de-complexation strategies are unfit for in vivo detection of allergenic
proteins in serum.

INTRODUCTION
Peanut allergy, is the most prevalent allergy in children and third most prevalent
in adults (Gupta et al., 2018, 2019). It is a highly severe and potent allergy, which can be
elicited by trace amounts of peanut protein in the most sensitive individuals (Klemans et
al., 2013; Sicherer and Sampson, 2007). Peanut allergens have been widely studied due
to their severity, prevalence, and ability to retain allergenicity into adulthood as most
children do not outgrow peanut allergy (Wood, 2003). Together, peanuts and tree nuts
account for a majority of anaphylactic cases reported (Sicherer and Sampson, 2007;
Sicherer et al., 2010). Due to its continued increasing prevalence, and limited
immunotherapy treatments, peanut allergy is a major public health concern.
It is suspected that proteins must enter into circulation in an immunologically
reactive form in order to elicit an allergic reaction (Heyman, 2005). In peanuts, the 2S
albumins contribute to overall allergenicity and potency, due to their thermostability and
resistance to gastric digestion (Sen et al., 2002; Suhr et al., 2004). The 2S albumins and
their tightly coiled helices resist digestion and retain secondary structural conformations
(Apostolovic et al., 2016). Consequently, Ara h 2 and 6 are clinically relevant proteins
for peanut allergy diagnosis based on effector-cell assays (Blanc et al., 2009; Kulis et al.,
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2012). These proteins are capable of desensitization in a mouse model, further
demonstrating their clinical relevance (Kulis et al., 2012; Zhuang and Dreskin, 2013). In
combination, these peanut allergen characteristics enhances their ability to retain
conformation and traverse the gastrointestinal barrier largely intact.
Previous studies have predominantly utilized immunoassay methods, which are
highly selective for pre-determined antigenic targets (antigen-antibody capture), for in
vivo allergenic protein(s) measurement (Koppelman and Hefle, 2006). These in vivo
studies demonstrated multiple analytical targets including Ara h 2, Ara h 6, or their
digestive resistant peptide (DRP) fragments, were present in human serum and breastmilk
after consumption (Baumert et al., 2009; JanssenDuijghuijsen et al., 2017). Baumert et
al., 2009 described detection of a digestion resistant peptide of Ara h 2 in healthy adult
serum and saliva using an inhibition ELISA to the DRP-Ara h 2 (Baumert et al., 2009).
Schocker et al., 2016 coupled immunoaffinity capture antibody and LC-MS/MS and
inhibition ELISA for detection of Ara h 2 in breastmilk (Schocker et al., 2016). More
recently, Ara h 6 was detected in subject serum collected after peanut consumption by
commercial ELISA (JanssenDuijghuijsen et al., 2017). One key challenge when using
ELISA methods is the unknown nature of allergenic proteins after uptake, which may be
modified during digestion and unrecognizable by capture antibodies (Reitsma et al.,
2014).
To further complicate matters of detection, the human serum proteome is a
dynamic and dense protein matrix (60 – 80 mg protein/ml serum) spanning twelve orders
of magnitude (Adkins et al., 2002; Anderson and Anderson, 2002). Only a few dozen
proteins account for the majority (99%) of serum protein content whereas thousands of
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proteins contribute to the remaining 1% (Anderson and Anderson, 2002; Pieper et al.,
2003). The lesser abundant proteins are of significant clinical interest due to their
potential impacts on human health and disease (Roche et al., 2009).
Due to the inherent complexity of serum, numerous depletion techniques have
been developed to remove the majorly abundant serum proteins (e.g. serum albumin,
immunoglobulins). Depletion methods selectively remove protein by immunoaffinity,
dye binding, or other physico-chemical methods, and most often targeting multiple
proteins (Gianazza and Arnaud, 1982; Leatherbarrow and Dean, 1980). Although
effective, there is potential of co-elution of low abundant proteins during depletion of the
target proteins (Roche et al., 2009). Removal of the abundant serum proteins inherently
decreases sample complexity, improving overall detection of lesser abundant proteins,
including biomarkers or, for our purposes, allergenic food proteins. The objective of this
study was to evaluate a variety of de-complexing strategies for removal of abundant
serum proteins.
The utilization of discovery LC-MS/MS allows for the simultaneous identification
of serum proteins involved in IgE-mediated reactions (Gillet et al., 2016). We would be
able to identify proteins upregulated during an immunologically mediated response
(Gillet et al., 2016), making discovery MS an advantageous method for improving our
understanding of the mechanisms associated with allergenic protein uptake.
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MATERIALS AND METHODS
Reagents
All reagents used were of analytical grade for all experiments. All reagents used
for LC-MS/MS sample preparations and analyses were of MS grade.

Preparation of Peanut Flours
Raw and roasted peanut extracts were prepared at two extraction buffer
concentrations, 0.1 and 0.01 M phosphate buffered saline (PBS). The prepared raw
peanut extracts were used as positive controls in subsequent LC-MS/MS method
developmental experiments.
Raw red-skin peanuts (Wor-Fung blanched peanuts, distributor K.N.T.C, South El
Monte, CA 91733, USA), purchased locally, were used to prepare raw peanut flour.
Peanut skins were removed and peanuts were washed five times with distilled water and
air-dried. Raw peanuts were ground in a Magic Bullet (Homeland Housewares, LLC)
blender. Ground peanuts were defatted (1:5 w/v peanut:hexane) three times, filtered, and
air-dried. The prepared, defatted raw peanut flour was ground once more as described
previously.
Roasted peanut extracts were prepared from partially defatted (12%) light roasted
peanut flour purchased from Golden Peanut Company (Alpharetta, GA, USA).
Raw and roasted peanut flours were extracted 1:50 (w/w) in 0.1 or 0.01 M PBS in
a 60°C sonicating water bath for 20 minutes, followed by centrifugation (3,500 x g) at
10°C for 10 minutes (Beckman GS-15R centrifuge). The supernatants (aqueous phase)
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were removed and clarified by centrifugation (17,000 x g) for 10 minutes (Thermo
Scientific™ Sorvall Legend Micro 17). Clarified extracts were pooled and centrifuged
(3,500 x g, 10 minutes, 10°C) (Beckman GS-15R centrifuge) to achieve a homogenous
extraction solution. Extracts were dialyzed using 3500 MWCO dialysis cassettes
(Thermo Scientific™ Slide-A-Lyzer™ Dialysis Cassettes, Cat. No. 66330, Pierce
Biotechnology, Rockford, IL, USA) overnight at room temperature to 0.1 or 0.01 M PBS,
respectively, with two buffer exchanges. Dialyzed samples were stored in 1 mL aliquots
at -20°C until needed for further analysis.
Peanut extracts were characterized by reducing SDS-PAGE and protein
concentration was determined by 2D Quant Kit (GE Healthcare Bio-Sciences, Prod. No.
80648356, Piscataway, NJ). The 2D Quant assay determines the protein concentration by
precipitation followed by re-suspension in a copper ion solution (GE Healthcare).
Triplicate extracts were evaluated by the 2D Quant kit for protein concentration.
SDS-PAGE was performed under reducing conditions using NuPAGE Bis-Tris
Mini Gels 4-12% (1.0 mm, 12 wells) and constant voltage (200V) for 40 minutes in an
XCell SureLock Mini Cell Electrophoresis System (Invitrogen Life Technologies). Raw
and roasted peanut extracts were diluted (1.5x) in 4 x concentrated Laemmli buffer and
1% β-mercapto-ethanol (BME). Extracts were reduced by heating at 95°C for 5 minutes.
Samples (20 µL) were loaded into each gel well. Precision Plus Protein Dual Xtra
Standards (Bio-Rad) were used as the molecular weight (MW) standard. Gels were
stained overnight in Coomassie Brilliant Blue R-250 (Bio-Rad) stain. Gels were destained (Coomassie Brilliant Blue R-250 destaining solution, Bio-Rad), rehydrated, and
imaged.

79
Unless otherwise noted, raw peanut extracts were used for preparation of model
matrices in all subsequent experiments.

Preparation of Model Matrices for Discovery LC-MS/MS Method
Development
Subject serum were collected before (baseline) peanut consumption by Baumert et
al., 2009 for immunoassay evaluation. Subject sera was then collected after peanut
consumption at specified time points (0.5, 1, 2, 3, 4, 6, 8, and 24 hours). Subjects were
instructed to consume 25 g roasted peanut flour, administered in capsules with 0.83 g
roasted peanut flour per capsule. According to Baumert et al., 2009, venous blood (10
mL) was collected using a heparin lock inserted into an arm vein. Blood was processed
into serum and stored at -20°C. Serum was stored long-term at -80°C for use in later
studies.
Baseline serum was used in preparation of model-matrices. Serum and raw
peanut extract (1.34 µg/µL) were individually diluted 10-fold in 0.01 M PBS, and
combined, 10:1 (w/w) serum:peanut. Model matrices were prepared to achieve the
desired protein amount (µg) for the subsequent experiments described below. Control
samples (sera, peanut) were individually and equivalently prepared to the model matrices
by mixing with 0.01 M PBS to the desired protein amount. Samples were vortexed to
mix and incubated on ice (30 minutes) until needed for further analysis.
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Discovery LC-MS/MS Acquisition Method Optimization
Using the serum-peanut matrix, and equivalently prepared individual serum and
peanut extract controls, we optimized the LC-MS/MS acquisition settings to enhance
detection of low abundant peptides.

In-Solution Reduction, Alkylation, and Trypsin Digestion for LC-MS/MS
Analysis of Model Matrices
An in-solution trypsin digestion from Thermo Scientific™ (Thermo Scientific™
In-Solution Tryptic Digestion and Guanidination Kit, 89895, Pierce Biotechnology,
Rockford, IL, USA) was modified for sample preparation. The serum-peanut matrix was
diluted to 2 µg/µL, and 8 µL were taken for tryptic digestion. Proteins were diluted with
50 mM ammonium bicarbonate and reduced with 100 mM dithiothreitol at 95°C for 5
minutes. Reduced samples were alkylated with 100 mM iodoacetamide, in the dark at
room temperature for 20 minutes. Trypsin (100 ng/µL made in 5 mM acetic acid) was
added and incubated for 3 hours at 37°C. A second addition of trypsin was added and
continued to digest overnight at 30°C, achieving a final enzyme:protein ratio 1:50 (w/w).
Digestion was stopped by freezing samples. Digests were de-salted using C18 spin
columns (Pierce C18 spin columns, Thermo Scientific™, Rockford, IL, USA) according
to the manufacturer’s instructions, and eluted in 70% acetonitrile. De-salted peptides
were dried to completion under a vacuum by centrifugal evaporation (Jouan RC-10.10;
RCT-90; Winchester, VA, USA). Peptides were re-suspended to 0.2 µg/µL in 0.1%
formic acid, 5% acetonitrile. Re-suspended peptides were injected (5 µL) for LCMS/MS.
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LC-MS/MS Acquisition using DDA
Peptide digests (5 µL) were chromatographically separated using an UltiMate
3000RSL® liquid chromatography (UPLC) system (Thermo ScientificTM) equipped with
a Hypersil Gold C18 1.9 μm, 100 x 1 mm reversed phase column (Thermo ScientificTM)
with a pre-column (20 x 2.1 mm reversed phase, 1.9 µm, Thermo ScientificTM) set at
35°C. Mobile phase A contained 0.1% (v/v) formic acid in water and mobile phase B
contained 0.1% (v/v) formic acid in acetonitrile. Peptides were separated using a linear
gradient of 2 – 40% mobile phase B over 70 minutes at a flow rate of 60 µL/min.
Following the gradient elution, the column was washed (60 µL/min) for 5 minutes at 98%
mobile phase B, followed by 100% methanol for 5 minutes (60 µL/min). The separation
column was re-equilibrated at 2% mobile phase B (180 µL/min) for 15 minutes. The
flow rate was reduced to 60 µL/min prior to the next sample injection.
DDA were performed on a Thermo Q Exactive PlusTM Hybrid QuadrupoleOrbitrapTM mass spectrometer (Thermo ScientificTM) operating in positive ion mode. The
MS acquisition settings adjusted were dynamic exclusion time, MS2 fill time (Ctrap fill
time), Top N acquisition, peptide charge states for MS2 acquisition(s), and automatic
gain control (AGC) target. The settings described in Table 2-1 were optimized to
improve detection of low abundant proteins.
Survey scan mass spectra (400 – 1400 m/z) were acquired at a nominal resolution
of 70,000 FWHM (200 m/z) and an AGC target of 3e6. Fragmentation spectra were
acquired at a nominal resolution of 70,000 FWHM, normalized collisional energy (NCE)
set at 27, and an AGC target of 1e5. The electrospray ionization settings were as follows:

82
sheath gas 15 AU, spray voltage 3500 V, capillary temperature 320°C, S-lens RF level
60.
Each method, described in Table 2-1, was evaluated sequentially for each
analytical sample (1) sera, (2) peanut, and (3) sera-peanut.

Method
1
2
3

Dynamic
exclusion
(seconds)
3
30
20

TopN

Charges

MS2 fill
time (msec)

10
20
20

1, 2, 3, 4, 5, 6
2, 3
2, 3, 4

60
60
240

Table 2-1. Discovery LC-MS/MS acquisition settings for
improvement in detection of low abundance peptides.

LC-MS/MS Data Analysis
Data were analyzed using PEAKS version 8.5 (Bioinformatics Solutions Inc.,
Waterloo, Ontario, Canada) software against two publically available databases from
UniProt, (1) Homo sapiens and (2) Arachis hypogaea. Protein identifications were made
by searching a (A) sequence database of peanut (Arachis hypogaea, taxon identifier
3818), and (B) sequence database of human (Homo sapiens, taxon identifier 9606) as
available in UniProt on 08/31/2016. Mass spectral data were normalized for the total ion
current (TIC) and semi-quantified using label-free quantification. The following criteria
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were used for protein identification: no missed tryptic cleavages, fixed modification of
carbamidomethylation of cysteine; variable modifications of methionine, oxidation, and
hydroxylation of proline; parent mass error tolerance 2 ppm, fragment error tolerance
0.02 Da; and an FDR set to 1%.

Initial Evaluation of Subject Serum Samples and Model Matrices of SeraPeanut Matrix
Initial in vivo evaluations for peanut protein in serum were conducted by Baumert
et al., 2009 by competitive immunoassay. The 60 minute time point was selected for
initial discovery LC-MS/MS evaluations due to the high reported concentration by DRPspecific ELISA (Baumert et al., 2009). Over a 24 hour consumption period, the average
absorption reported was 131 ng DRP-Ara h 2/mL serum.

In-Solution Reduction, Alkylation, and Trypsin Digestion of Subject Sera
Samples
Subject sera (baseline, 60-minute) were prepared for LC-MS/MS analysis using
the in-solution trypsin digestion, as described previously (page 80). Alternatively, after
de-salting, peptides were eluted in 50% (v/v) acetonitrile, and then dried to completion
under a vacuum by centrifugal evaporation (Jouan RC-10.10; RCT-90; Winchester, VA,
USA). Peptides were re-solubilized in 0.1% formic acid, 5% acetonitrile to a final
concentration of 0.5 µg/µL. Peptide digests were injected (2 µL) in duplicate for LCMS/MS acquisitions.
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LC-MS/MS Acquisition Settings
Data dependent acquisitions (DDA) were performed using the optimized
discovery method, method 3, as previously described (page 81).

LC-MS/MS Data Analysis
Data were analyzed using PEAKS version 8.5 (Bioinformatics Solutions Inc.,
Waterloo, Ontario, Canada) software, as previously described (page 82).

Development of Exclusion and Inclusion Lists

A. Exclusion List Development
Data collected from baseline serum samples used in the preceding experiment
were analyzed for use in the exclusion list. The optimized LC-MS/MS chromatographic
method and acquisition settings were used to generate the exclusion list previously
described. Acquired data were analyzed using PEAKS version 8.5 (Bioinformatics
Solutions Inc., Waterloo, Ontario, Canada) against the publically available Homo sapiens
(taxon identifier 9606) database (UniProt) as available on 8/31/2016, using the previously
described data analysis settings (page 82). The most abundant identified H. sapiens m/z
events were selected (top 5,000 events) and collated into an exclusion list included in the
LC-MS/MS acquisition methodology. These selected m/z’s were cross-referenced
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against the generated peanut data to eliminate identical m/z’s. Charge states of 1+, 5 to
9+ were excluded from acquisition.

B. Inclusion List Development
We similarly investigated inclusion lists in combination with the LC-MS/MS
acquisition workflow. The inclusion lists were developed and applied in the same
manner as exclusion lists.
Inclusion lists were generated by obtaining spectral data from duplicate digestions
of sera-peanut (prepared with baseline sera) and peanut (alone). Sera-peanut (10:1
(w/w)) and an equivalent volume of peanut were enzymatically digested and prepared for
LC-MS/MS analysis. Analytical samples were prepared in a volumetrically equivalent
manner, insuring comparability. The same in-solution trypsin digestion protocol and desalting protocol were followed as described in the previous section, (page 83). Digests
were re-suspended in 0.1% formic acid, 5% acetonitrile to a concentration of 0.5 µg/µL.
The optimized LC-MS/MS chromatographic method and acquisition settings were used
to generate the inclusion list. Digested and re-suspended samples were injected (2 µL) in
duplicate.
Inclusion lists were evaluated against a tryptic digest of subject serum (60
minutes), collected after consumption (Baumert et al., 2009). Only those parent ions with
2, 3, or 4+ charge states were included.
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C. Exclusion and Inclusion List Evaluation
The prepared exclusion and inclusion lists were evaluated against subject serum
samples (Baumert et al., 2009) collected after peanut consumption (60 minutes) and
prepared for analysis as described previously (page 83). The standard LC-MS/MS
acquisition workflow was used for evaluation of each individual list, exclusion and
inclusion, as well as the use of the two lists together (page 81; method 3). Only those
parent ions with 2, 3, or 4+ charge states were included. Digested and re-suspended
samples were injected (2 µL) in duplicate.

D. LC-MS/MS Data Analysis
All data for exclusion and inclusion lists were analyzed using PEAKS version 8.5
(Bioinformatics Solutions Inc., Waterloo, Ontario, Canada) against the appropriate
database, as previously described (page 84). For exclusion lists, the top 5,000 serum
specific m/z events were used. For inclusion lists, all peanut specific m/z events, up to
the top 5,000 identifications, were included in an inclusion list. All data analysis
parameters remained unchanged from those previously described (page 82).

Evaluation of Commercial Depletion Kits
The following commercial depletion kits (1) Pierce Top2 Abundant Depletion
spin columns (albumin, IgG), (2) PureProteome Albumin magnetic beads (albumin), (3)
Pierce albumin depletion kit (cibacron dye binding), and (4) BioVision Protein G
Sepharose (IgG depletion), were evaluated for removal of targeted serum proteins. Table
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2-2 describes the mechanisms employed and serum proteins targeted by each depletion
method.
Depletion kits were evaluated for target protein specificity using two key criteria
(1) effective depletion of targeted serum proteins and (2) absence of depletion of peanut
proteins (e.g. peanut proteins remain in depleted analytical samples). A model matrix of
human serum and (raw) peanut extract (10:1 (w/w) protein) were analyzed for specific
protein removal. The serum and peanut extract were individually diluted 10-fold prior to
combining. Control samples were prepared using equivalent volumes of (a) serum or (b)
peanut extract, substituted with 0.01 M PBS for each removed matrix component.
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Depletion kit
Pierce Top2
Abundant Depletion
columns
PureProteome
Albumin Magnetic
Beads

Manufacturer

Targeted
proteins

Depletion
mechanism

Pierce

Albumin,
IgG

Resin, spin
columns, anti-HSA,
anti-IgG

EMD
Millipore

Albumin

anti-HSA

Pierce Albumin
Depletion Kit

Pierce

Albumin

BioVision Protein G
Sepharose

BioVision

IgG

Immobilized
Cibacron blue dye
agarose resin
Protein G
conjugated to
Sepharose beads

Maximum
protein load
(µg)
600 µg sera
protein
1:30 (v/v)
serum:depletion
slurry
2,000 µg (2
mg) human
serum albumin
1:2 (v/v)
serum:resin

Table 2-2. Commercial serum depletion kits for evaluation in de-complexing
strategies

Pierce™ Top2 Abundant Depletion Spin Columns (albumin, IgG)
The Pierce Top2 Abundant Depletion spin columns were evaluated for removal of
albumin and IgG from serum. The depletion spin columns contained immobilized antihuman serum albumin and anti-IgG antibodies for protein removal. Samples were
depleted according to manufacturer’s instructions, described as follows. The prepared
analytical samples, serum-peanut, serum, and peanut, were applied to depletion spin
columns (10 µL). Spin columns were mixed using an end-over-end mixer for 30 minutes
at room temperature. After mixing, depleted serum was eluted into a collection tube and
centrifuged for 2 minutes at 1,000 x g (Thermo Scientific™ Sorvall Legend Micro 17).

89
Depleted samples were prepared for LC-MS/MS analysis as previously described (page
80).
Control, non-depleted samples were simultaneously prepared. During depletion,
the original sample volume is diluted after mixing with the depletion resin slurry.
Therefore, non-depleted samples were prepared equivalently by diluting non-depleted
samples (serum-peanut, serum, peanut) in 0.01 M PBS to the same volume. Nondepleted controls were prepared for LC-MS/MS as described below.

i.

In-Solution Reduction, Alkylation, and Trypsin Digestion for LCMS/MS Analysis

All samples, depleted and non-depleted, were prepared for LC-MS/MS analysis,
as previously described (page 80). However, during this experiment, 4 µL of each
sample (maximum 10 µg protein) were diluted to a final concentration of (0.5 µg/µL)
with 50 mM ammonium bicarbonate (ABC). Following de-salting, peptides were eluted
in 50% acetonitrile and dried. Peptides were re-solubilized in 5% acetonitrile, 0.1% (v/v)
formic acid to a maximum concentration of 0.25 µg/µL prior to injection on LC-MS/MS.
DDA analysis was conducted by injecting samples (2 µL) in duplicate, with a maximum
protein load of 500 ng on column, using the previously optimized method (page 84).
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ii.

Modification of Salt (NaCl) Concentration of Pierce Top2 Albumin
Depletion Kit

To reduce potential binding of peanut proteins to the depletion matrix, we
evaluated the elution buffer salt concentration (NaCl) for recovery of peanut proteins
using the Pierce Top2 Abundant Depletion spin columns. After depletion, samples were
eluted in 0.01 M PBS, 0.15 NaCl, 0.02% azide, pH 7.4. To assess column binding
specificity, the peanut only matrix was evaluated identically to the previously described
methodology (Pierce™ Top2 Abundant Depletion Spin Columns (albumin, IgG)). The
salt (NaCl) concentration(s) of the kit elution buffer, (0.01 M PBS, 0.15 M NaCl, 0.02%
azide, pH 7.4) were prepared at the 0.15, 0.25, 0.50, 0.75, 1.00 M NaCl. Depleted eluates
were evaluated for the presence of peanut proteins by discovery LC-MS/MS, as described
previously (pages 80). SDS-PAGE was not performed on these samples.

iii.

LC-MS/MS Data Analysis

Acquired data were processed using PEAKS version 8.5 (Bioinformatics
Solutions Inc., Waterloo, Ontario, Canada). Protein identifications were made by
searching a (a) sequence database of peanut (Arachis hypogaea, taxon identifier 3818),
and (b) sequence database of human (Homo sapiens, taxon identifier 9606) as available in
UniProt on 8/31/2016. Mass spectral were normalized for the total ion current (TIC) and
semi-quantified using label-free quantification. The following criteria were used for
protein identifications: no missed tryptic cleavages, fixed modification of
carbamidomethylation of cysteine; variable modifications of methionine, oxidation, and
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hydroxylation of proline; parent mass error tolerance 2 ppm, fragment error tolerance
0.02 Da; FDR 1%; charge states of +2, +3, and +4.

PureProteome™ Albumin Magnetic Beads
PureProteome™ Albumin Magnetic Beads (LSKMAGL10, EMD Millipore,
Billerica MA, USA), were evaluated in a similar manner to the previously described
depletion kit (Pierce Top2 Abundant Depletion Columns). Depleted and non-depleted
samples (serum-peanut, serum, and peanut) were evaluated for specific removal of
albumin and recovery of peanut proteins by discovery LC-MS/MS. The PureProteome™
Magnetic Beads bind albumin by immunoaffinity capture. The anti-albumin antibodies
are coupled to magnetic beads, facilitating efficient separation of bound albumin and
capture antibodies. Following incubation and separation, the unbound sample fraction, or
depleted fraction, was removed and prepared for LC-MS/MS.
Control (non-depleted) samples were prepared in a volumetrically equivalent
manner by diluting samples in 0.01 M PBS to the same volume as depleted samples. The
maximum concentration of the non-depleted samples was 2.1 µg/µL.
Tryptic digestion was performed, in a volumetrically equivalent manner using the
previously described protocol (page 80) modified in-solution trypsin digestion (Thermo
Scientific™, 89895) by diluting a maximum of 10 µg protein in 50 mM ammonium
bicarbonate to a maximum concentration of 0.6 µg/µL. All protein samples were
reduced, alkylated, trypsin digested, and de-salted, as described previously (page 80).
Following de-salting peptides were eluted in 50% acetonitrile and dried (page 83).
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Peptides were re-suspended in 0.1% formic acid, 5% acetonitrile. A total of 2 µL of each
sample, maximum 600 ng protein, was injected onto the analytical column for DDA
analysis using the previously developed acquisition method (page 84). Data were
analyzed as previously described (page 90).

Pierce™ Albumin Depletion Kit
The Pierce™ Albumin Depletion Kit (85160, Pierce Biotechnology, Rockford,
IL, USA) depletes albumin by immobilized Cibacron Blue dye agarose resin. This
depletion kit was evaluated using the same model matrices (serum-peanut, serum, peanut)
as described previously (Pierce™ Top2 Abundant Depletion spin columns).
Albumin depletion resin, spin columns, and binding/wash buffer (0.025 M Tris,
0.075 M NaCl; pH 7.5) were provided with the kit. Following the manufacturer’s
instructions, spin columns were equilibrated by applying albumin depletion resin (400
µL) followed by binding/wash buffer (200 µL). After column equilibration, 50 µL of
each analytical sample was applied and incubated for two minutes, and centrifuged
(12,000 x g, 1 minute; Thermo Scientific™ Sorvall Legend Micro 17). The flow-through
was retained and reapplied to the column. This process of sample application and
centrifugation was repeated four times on the flow-through fractions to ensure albumin
removal. Depleted eluates were retained for discovery LC-MS/MS analysis. Nondepleted (control) samples were prepared equivalently, by diluting control samples in
0.01 M PBS to the same final volume as depleted samples.
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i.

In-Solution Reduction, Alkylation, and Trypsin Digestion for LCMS/MS Analysis

Depleted and non-depleted samples were prepared in duplicate using the
previously described digestion methodology (page 80), and evaluated by discovery LCMS/MS (page 84). Samples were prepared in a volumetrically equivalent manner
allowing all digests to be prepared identically. In total, 12 µL (maximum 30 µg protein)
were used for digestion, and trypsin digestion parameters were adjusted for a 30 µg total
protein digest. Following de-salting peptides were eluted in 50% acetonitrile and dried to
completion (page 83). Prepared digests were re-suspended in 0.1% formic acid, 5%
acetonitrile to a maximum final concentration of 0.5 µg/µL. Discovery LC-MS/MS runs
were conducted by injecting (2 µL) in duplicate. Data analysis parameters for all
depletion kits are described on page 90.

ii.

Modification of Salt (NaCl) Concentration of Pierce™ Albumin
Depletion Kit

We additionally evaluated the effect of salt concentration on depletion efficacy
and recovery of peanut proteins in eluates. To do so, the salt (NaCl) concentration of the
kit elution buffer (0.025 M Tris, 0.075 M NaCl; pH 7.5) was evaluated at 0.5, 0.6, 0.7,
0.8, 0.9, 1.0, 2.0 M Tris-NaCl concentrations. For this experiment, serum-peanut and
peanut (control) samples were analyzed. The depleted eluates were evaluated for the
presence of peanut proteins visually by SDS-PAGE, as described below. LC-MS/MS
analysis was not conducted on these samples.
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iii.

Modification of Binding/Wash Buffer pH of Pierce™ Albumin
Depletion Kit

We evaluated the effect of pH of the binding/wash buffer (0.025 M Tris, 0.075 M
NaCl; pH 7.5) for depletion efficacy and recovery of peanut proteins in eluates. The pH
levels evaluated include 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, and 7.5. The buffer pH was
adjusted by preparing in-house solutions of 0.025 M Tris, 0.075 M NaCl at their
respective pH’s. Depleted samples eluted with their respective pH buffers were
evaluated by SDS-PAGE, as described below. LC-MS/MS was not performed on these
samples.

iv.

SDS-PAGE of Pierce™ Albumin Depletion Kit (NaCl, pH)

Depleted eluates, prepared at modified NaCl concentrations or pH levels, were
evaluated for the presence of peanut proteins using 1D-gel electrophoresis. SDS-PAGE
was performed using NuPAGE Bis-Tris Mini Gels 4-12% (1.0 mm, 12 wells) under
reducing conditions and constant voltage (200V) for 40 minutes in an XCell SureLock
Mini Cell Electrophoresis System (Invitrogen Life Technologies).
Fifteen microliters of NaCl sample eluates and 22.5 µL of pH level eluates were
diluted in 4 x concentrated Laemmli buffer and 1% β-mercapto-ethanol (BME). All
samples were reduced by heating for 5 minutes at 95°C and 20 µL each were loaded into
each gel well. Precision Plus Protein Dual Xtra Standards (Bio-Rad) were used as the
molecular weight (MW) standard. Gels were stained using Coomassie Brilliant Blue R250 (#1610436, Bio-Rad) stain, followed by de-staining, rehydration, and imaging
(Coomassie Brilliant Blue R-250 Destaining solution, #1610438, Bio-Rad).
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BioVision Protein G-Sepharose (IgG Depletion)
We evaluated depletion of IgG, in efforts to decrease sample complexity prior to
LC-MS/MS analysis for peanut proteins in serum. IgG depletion studies were performed
in a similar manner as those described previously. However, for this depletion
experiment, we used a commercially available serum (ImmunO, human serum sterile, MP
Biomedicals LLC, Solon, OH, USA) for preparation of the matrix samples. Equivalently
prepared samples of sera-peanut, sera, and peanut (60 µL) were added to 40 µL Protein
G-Sepharose (BioVision 6511) resin and 200 µL binding buffer (0.01 M PBS, pH 7.4).
Samples were incubated at 4°C for two hours in an end-over-end rotator. After
incubation, depleted sample(s) (80 µL) were removed. The remaining resin was washed
three times with binding buffer (200 µL), removing only 150 µL during the final wash in
order to keep the Protein-G resin suspended.
Control, non-depleted, samples were prepared similarly by diluting controls with
0.01 M PBS to the same final concentration of IgG depleted samples.
IgG depleted and non-depleted (control) samples were evaluated by SDS-PAGE
on an equal weight basis under reducing conditions using NuPAGE Bis-Tris Mini Gels 412% (1.0 mm, 12 wells) (Invitrogen Life Technologies). Depleted and non-depleted
samples were diluted with 4 x Laemmli buffer with 1% β-ME and reduced at 95°C for 5
minutes. Equal weights of protein(s) were prepared and loaded into each gel well. In
summary, 11 µg serum protein, 1 µg peanut protein, and 12 µg combined sera-peanut
were loaded for both depleted and non-depleted controls for equivalent comparisons. 1D
electrophoresis was conducted as previously described (page 94).
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Organic Solvent Fractionation
We investigated the use of organic solvent fractionation as a method for sample
de-complexation. Here, we separated our analytical sample by solubility into three
soluble fractions and an insoluble pellet. Using this methodology, we are able to retain
the entirety of the sample (serum, serum-peanut) while reducing background
interferences.
Our methodology was adapted from a previously published method by Liu et al.,
2014. One volume serum was combined with ten volumes isopropanol (IPA) with 1%
trichloroacetic acid (TCA) by weight. Commercially prepared serum (ImmunO, human
serum sterile, MP Biomedicals LLC, Solon, OH, USA) was used for our model matrix
samples. As conducted before, samples of serum, peanut, and serum-peanut samples
were prepared in a volumetrically equivalent manner. Samples were fractionated and
evaluated by SDS-PAGE and LC-MS/MS using the optimized methodology for detection
of low abundance peptides (page 83). Samples were vortexed for 2 minutes, followed by
centrifugation (Beckman GS-15R centrifuge) at 1,500 x g at 5°C for 5 minutes. The
supernatants were removed and retained for analysis. The remaining pellets were resuspended in methanol (200 µL) and centrifuged (Thermo Scientific™ Sorvall Legend
Micro 17) at 1,500 x g for 2 minutes at room temperature. The supernatant was removed
and retained. Due to the volatile and evaporative nature of the two retained supernatants,
isopropanol-TCA and methanol, the collected supernatants were dried in a centrifugal
evaporator (Jouan RC-10.10; RCT-90; Winchester, VA, USA) and re-suspended prior to
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downstream analyses. Control samples were prepared identically and not subjected to
organic solvent fractionation.

SDS-PAGE of Organic Fractionated Samples
SDS-PAGE (NuPAGE Bis-Tris Mini Gels 4-12% (1.0 mm, 12 wells) (Invitrogen
Life Technologies)) was conducted on all fractions for each sample using equal protein
loading as determined by 2D quant. Each fraction was diluted with 4 x Laemmli buffer
with 1% β-ME and reduced by heating at 95°C for 5 minutes. In summary, 0.6 µg peanut
protein, 7 µg serum protein, and 7.6 µg total protein (sera-peanut) in each respective
sample were loaded into gel wells. 1D electrophoresis was conducted as previously
described (page 94)

In-Solution Reduction, Alkylation, and Trypsin Digestion for LC-MS/MS
Analysis
Each fraction was analyzed to determine protein (peanut and serum) fractionation
patterns by LC-MS/MS on an equal protein weight basis, as determined by 2D quant.
Control samples (sera-peanut, sera, peanut) were equivalently prepared (10:1 w/w). In
total, 20.3 µL of each sample were fractionated as described above. The supernatants
were dried under vacuum by centrifugal evaporation (Jouan RC-10.10; RCT-90;
Winchester, VA, USA), followed by re-suspension in 5% acetonitrile to a final volume of
31.5 µL. Control, non-fractionated liquid samples, were also prepared to a final
concentration of 5% acetonitrile in 31.5 µL total sample volume (0.9 µg/µL for sera-
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peanut, the most concentrated sample). Tryptic digestion was performed based on 30 µg
total protein in digestion. Following re-suspension and dilution the samples were diluted,
reduced, alkylated, and trypsin digested, and de-salted (C18) as described previously
(page 80). Following de-salting peptides were eluted in 50% acetonitrile and dried to
completion. Samples were re-suspended in 0.1% formic acid, 5% acetonitrile to a
maximum peptide concentration of 1 µg/µL. Re-suspended peptides were injected (1 µL)
in duplicate for discovery LC-MS/MS analysis using the previously described LCMS/MS method (page 84). Data were analyzed as previously described (page 82).

Evaluation of Multiple De-Complexation Methods (Organic Solvent
Fractionation and IgG Depletion)
We investigated the combination of two de-complexation techniques, organic
solvent fractionation and IgG depletion. Evidence of IgG interactions with peanut
proteins was recently published (JanssenDuijghuijsen et al., 2017). Therefore, our aim
was to incorporate IgG depletion in combination with organic solvent fractionation to
decrease sample complexity, improving likelihood of peanut protein detection by
discovery LC-MS/MS analysis.
For this study, we prepared two replicates of the same model samples (serapeanut, sera, peanut). The first set were used as controls and not de-complexed (e.g. no
IgG depletion or fractionated). The second set of samples were IgG depleted followed by
fractionation. SDS-PAGE was not performed on these samples. Samples were evaluated
by LC-MS/MS using the previously described detection method (page 84).
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Preparation of Matrix Samples
A set of volumetrically equivalent control samples (sera-peanut, sera, peanut)
were prepared as described previously (page 86). These samples were not IgG depleted
or fractionated.
A set of samples for de-complexation were prepared in a volumetrically
equivalent manner (sera-peanut, sera, peanut; 10:1 (w/w)), for IgG depletion and organic
solvent fractionation.
The aim of these evaluations was to assess the impact of IgG on peanut detection,
by determining recovery of peanut. To do so, we prepared an IgG depleted serum sample
using the same methodology as previously described (page 95). Following serum IgG
depletion, the peanut extract was added in a volumetrically equivalent manner to controls.
IgG depletion and fractionation were performed as previously described in their
appropriate methodology sections (95, 96).

IgG Depletion and Organic Solvent Fractionation
Samples (sera, sera-peanut) were IgG depleted as previously described. We
evaluated serum (non-depleted), IgG depleted serum with peanut extract, and serumpeanut. We analyzed commercial serum and serum collected from peanut allergic
subjects. The subject clinical allergenicity characteristics are described in Supplementary
Table 2-1. All sample preparations were subjected to IgG depletion prior to organic
solvent fractionation.

100
Following IgG depletion, samples were fractionated using the previously
described organic solvent fractionation protocol, (1) serum, (2) IgG-depleted serumpeanut, and (3) serum-peanut. The same fractions were collected as previously described
(page 96), (1) isopropanol-TCA supernatant, (2) methanol supernatant, and (3) pellet.
Following sample preparation, all control (e.g. liquid) samples and dried
supernatants were diluted or re-solubilized to 5% acetonitrile to a final volume of 31.5
µL. Tryptic digestion (maximum 30 µg protein in digestion) and de-salting (C18) were
performed on all samples as previously described (page 80). Following de-salting
peptides were eluted in 50% acetonitrile and dried to completion. Digested samples were
re-suspended (v/v) with 0.1% formic acid, 5% acetonitrile to a concentration of 0.5
µg/µL. Samples were injected (2 µL) in duplicate for LC-MS/MS analysis.
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RESULTS AND DISCUSSION
Evaluation of the Peanut Flours Preparation
Raw and roasted peanuts were extracted in two PBS buffer concentrations, 0.01
and 0.1 M. Protein concentrations of each extract were determined by 2D Quant assay.
The results of the protein concentration determination reflect the observations from the
SDS-PAGE (Table 2-3). For both peanut preparations, raw and roasted, extraction in
0.01 M PBS yielded the most protein, which will be used in subsequent experiments of
this chapter. Visualization of the SDS-PAGE gel indicated more protein was extracted
under 0.01 M PBS in both raw and roasted preparations (Figure 2-1).
Roasted peanut extracts were also prepared however, thermal processing
negatively affects the solubility of peanut proteins, particularly Ara h 1, which aggregates
at high temperatures (>85°C) (Koppelman et al., 1999). Although Ara h 1 is less
extractable in roasted peanuts, it is still present in the peanut seed and exposed to the
immune system upon consumption. In order to represent all major allergenic proteins,
raw peanuts were prepared and used in method evaluations.

Peanut
preparation
Raw
Roasted

Concentration Average
PBS (M)
µg/µL
0.01
2.07
0.1
1.10
0.01
0.54
0.1
0.39

Standard
deviation
±0.13
±0.44
±0.27
±0.08

Table 2-3. Protein concentrations of peanut extracts prepared in 0.1
or 0.01 M PBS determined by 2-D Quant assay (GE Healthcare).
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Figure 2-1. Evaluation of peanut protein extracts by reducing SDS-PAGE.
Lane (1) Protein marker standard, (2) raw peanut extracted in 0.1 M PBS, (3)
raw peanut extracted in 0.01 M PBS, (4) roasted peanut extracted in 0.1 M
PBS, (5) roasted peanut extracted in 0.01 M PBS
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Discovery LC-MS/MS Acquisition Method Optimization
A trypsin digested serum sample, prepared identically to the model matrix sample
(sera-peanut), was used for evaluation of LC-MS/MS acquisition methods. During LCMS/MS method development, a number of MS acquisition settings can be optimized to
improve sensitivity and detection of low abundance target peptides. A series of
instrument acquisition settings including dynamic exclusion time (seconds), MS2-fill
time (msec), TopN acquisition, and MS1 peptide charge states (Table 2-1) were
evaluated. All other instrument parameters were kept the same.
.

Method
1
2
3

#MS2 # peptide spectra
9392
1706
4238
731
9276
1569

# peptides
385
498
909

# proteins
133
206
323

Table 2-4. Results of discovery LC-MS/MS acquisition settings
for improvement of detection of low abundance peptides and
proteins.

Figure 2-2 illustrates the relative abnundance of peanut peptides detection by each
method. Table 2-4 contains the number of MS2 spectra, peptide spectra, individual
peptides, and individual proteins identified. Method 1, included the Top10 MS 1 ion
selection method, 3 s dynamic exclusion times 60 ms MS2 fill time and parent ions
(MS1) with +1 to +5 charges, does not provide adequate ion filtering prior to detection by
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the MS (Table 2-4). Method 1 reported the highest number of MS2 spectra and peptide
spectra; and reported the least amount of peptides and proteins identified. In Method 2,
parent ion charges of 2, 3+ were monitored, and dynamic exclusion time was increased.
This resulted in more peptides and proteins identifications, while also reporting lower
numbers of MS2 and peptide spectra (Table 2-4). Lastly, Method 3, monitored parent
ions, 2, 3, 4+, had a decreased dynamic exclusion time (20 msec), and an increased MS2
fill time (120 msec). This method identified the most peptides and proteins, while
reporting nearly similar figures of MS2 and peptide spectra than Method 1 (Table 2-4).
For these reasons, we chose Method 3 for use in all subsequent discovery experiments.

Figure 2-2. Optimization of LC-MS/MS discovery methods. For each
method (x-axis), the relative abundance of individual peanut peptides are
shown.
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Evaluation of Subject Serum Samples and Model Matrices of SeraPeanut Matrix
Initial analyses of subject serum collected after peanut consumption (Baumert et
al., 2009) were negative for peanut using an initial discovery LC-MS/MS method (data
not shown). The lack of detection of peanut proteins is unsurprising since the expected in
vivo concentration of peanut after consumption is estimated at extremely low
concentrations.
The subject serum used in our study were previously determined positive by
competitive immunoassay developed to detect DRP-Ara h 2 (Baumert et al., 2009). They
reported an average detection of 131 ng/mL of DRP-Ara h 2 over a 24-hour period after
consumption (Baumert et al., 2009). A second study conducted by JanssenDuijghuijsen
et al., 2017 analyzed collected serum after feeding trials using an Ara h 6 sandwich
ELISA. Here, they reported an average of 0.3 ng/mL Ara h 6, equivalent to 6 ng total
peanut protein/mL (JanssenDuijghuijsen et al., 2017). Based on these two studies, and
our results, the current LC-MS/MS method and sample preparation protocols are not
sufficiently sensitive for in vivo peanut detection.
These extremely low (ng/mL) concentrations are similar to the concentration of
cytokines which have been detected at very low levels ranging from 1-100 pg/mL (0.001
– 0.1 ng/mL) by the use of antibody capture and subsequent LC-MS/MS (Anderson and
Anderson, 2002; Schweitzer et al., 2002). The use of antibody capture methods are
beneficial in decreasing background noise, and would likely produce methods with
similar sensitivities to current ELISAs. However, we would not be able to assess changes
in protein structure, conformation, or free antigen. Due to the anticipated low
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concentrations of our target analytes (e.g. peanut proteins), we employed decomplexation strategies to improve overall detection.

Inclusion and Exclusion Lists
The MS instrument used within this chapter was the Thermo Q Exactive Plus™
Hybrid Quadrupole-Orbitrap™ MS (Thermo Scientific™) which has the ability to
exclude selected m/z events by using an exclusion list. An exclusion list is a useful tool
capable of excluding specified m/z events. Since serum is a protein rich matrix, it
generates a substantial number of serum specific m/z events that are recorded by the MS.
If a parent m/z (MS1) ion is defined in the exclusion list; this identified ion is excluded
from fragmentation (Koelmel et al., 2017). We evaluated the use of exclusion lists in
combination with discovery LC-MS/MS acquisitions. As such, we applied this
methodology to our model serum-peanut sample matrix and subject serum samples
(baseline, 60 minute).
During the initial DDA acquisitions of baseline serum, we used a ‘Top20’ data
acquisition method in which the twenty most abundant parent ions from MS1 are
collected for MS2 fragmentation, and, consequently the less abundant ions are not
recorded during a particular acquisition scan. By excluding the most abundant m/z
events identified in the standard LC-MS/MS acquisition workflow, we anticipate
improved detection of lower abundance peptides, and in particular peanut peptides in
subject serum.
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Exclusion List Evaluation
An exclusion list of serum specific m/z values was generated from LC-MS/MS
data of baseline (0 hour) serum samples. All peptides included in the exclusion lists met
the following criteria:
Exclusion list peptide criteria:
1. Charge states of 2, 3, or 4+
2. The top 5,000 serum identified m/z’s based on signal intensity
3. Identified within the chromatographic gradient
4. Serum specific m/z values

The top 5,000 serum specific m/z values were included in the exclusion list.
Serum specific m/z values were identified using PEAKS from the UniProt Homo sapiens
database. Subject serum collected after peanut consumption (60 minutes), or ‘active’
serum, were analyzed with the generated exclusion list. Acquired data were compared to
a peanut database (UniProt, Arachis hypogaea). No positive peanut peptides were
detected in subject serum when analyzed with an exclusion list (data not shown).

Inclusion List Evaluation
The inclusion lists for peanut specific peptides were generated in the same manner
as exclusion lists using prepared digested samples of peanut and sera-peanut. We
identified 23 peanut proteins and 143 unique peanut peptides. All identified peanut

108
specific m/z values were compiled into an inclusion list included during acquisition. No
positive peanut identifications were made when the inclusion list was included in the
analysis of ‘active’ subject serum (60 minutes post consumption) (data not shown).

Evaluation of Combined Exclusion and Inclusion Lists
The overall aim of combining exclusion and inclusion lists was to reduce
detection of the highly abundant serum proteins, which largely saturate the MS signal
detector. We hypothesized using both ion selection techniques together would improve
instrument sensitivity.
No positive peanut protein identifications were made when using the combination
of inclusion and exclusion lists, paired with LC-MS/MS (data not shown). This suggests
other de-complexation strategies are necessary to detect peanut proteins in serum. In
many instances the use of inclusion or exclusion lists yields positive results with other
complex matrices (e.g. human embryonic stem cells, characterization of human plasma
lipidome), however, we found these tools to be unsuccessful, likely due to the complexity
of the serum matrix (Bendall et al., 2008; Koelmel et al., 2017). Although we are able to
exclude the most abundant (top 5,000) parent m/z events (MS1), this was not sufficient to
identify peanut peptides in serum. Secondly, the pairing of a serum m/z exclusion list
with a peanut m/z inclusion list was still unable to detect peanut peptides.
Serum is a protein rich matrix exhibiting vast diversity among its constituent
proteins (Anderson and Anderson, 2002). Due to this extreme diversity, it is likely that
the low abundance serum proteins share similar sequence(s) and charge(s) to peanut
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specific peptides. In order to obtain a comprehensive serum proteome, a mass
spectrometer must be able to detect both the highly abundant proteins (e.g. albumin,
immunoglobulins) down the to the lowest abundance serum proteins (e.g. cytokines,
interleukins) (Anderson and Anderson, 2002). Serum proteins span ten orders of
magnitude (Anderson and Anderson, 2002), whereas the Q Exactive mass spectrometer
has a detectable range spanning only four orders of magnitude (Eliuk and Makarov,
2015). Therefore, in order to achieve detection at concentrations beyond the dynamic
range of the MS instrument, an analytical method which enhances detection of low
abundance peptides is needed.
For the first part of this chapter, we chose to first optimize the instrument scan
settings of discovery methods. Detection by DDA methods is desirable because it allows
other human proteins to be monitored during allergenic protein uptake. Another
advantage of using shotgun methods is the ability to track overall changes in protein
profiles using the acquired full-scan data, allowing the potential identification of
biomarkers associated with consumption of allergenic proteins.
Overall, adjusting MS acquisition settings was not sufficient for detection of
peanut proteins in serum. Due to the complexity of serum, and limitations of the
instrument’s dynamic range, further de-complexation methods are needed.
During this set of studies, we routinely injected approximately 500 ng of protein
(10:1 sera:peanut) on a micro-flow HPLC column (100 mm x 1.0 mm, 1.9 um). This
total amount of protein has been suitably detected in both discovery and targeted assays
of complex food matrixes, as determined by preliminary studies performed prior to the
beginning of this dissertation. We will use the optimized discovery method, Method 3,
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for our evaluations of detection. Consequently, we began our studies by evaluating
various de-complexation strategies, with an overall objective to reduce sample
complexity prior to LC-MS/MS analysis in order to detect peanut proteins in serum.

Evaluation of Commercial Depletion Kits
To evaluate the utility of various de-complexation strategies, we prepared a model
matrix of baseline subject serum (0 hour), collected by Baumert (2009) spiked with a raw
peanut extract. Since the anticipated in vivo concentration(s) of peanut protein are
expected to be extremely low, we opted to use a high concentrated spiked model matrix
(10:1 (w/w) serum:peanut) to robustly evaluate these de-complexation strategies. This
model matrix, sera-peanut, was prepared to mimic the final analytical sample matrix (i.e.
serum) collected from individuals after consuming peanut. The sera-peanut matrix was
used for evaluations throughout this chapter.
Commercial depletion kits were evaluated on a case-by-case basis, and we
summarize the results of all evaluated depletion kits here (Figures 2-3 to 2-6). Each kit
selected for this study utilized different depletion mechanisms. All selected kits
successfully removed their specified targeted serum proteins (Figures 2-4; 2-6).
However, three out of the four commercial depletion kits (Pierce™ Top2,
PureProteome™ Albumin, Pierce™ Albumin) either, partially or entirely removed peanut
proteins in peanut containing samples (sera-peanut, peanut), as detected by loss of peanut
peptides identified by PEAKS label-free quant. The IgG depletion kit (BioVision) was
the only kit that exhibited high specificity and did not remove peanut proteins. For
selected kits (Pierce™ Top2, Pierce™ Albumin) whose properties were adjusted (i.e. salt,

111
pH), no improvement in the recovery of peanut proteins (in serum matrix background or
absence of sera matrix background). For this section, we will primarily discuss the
results of the PureProteome™ Albumin depletion kit since many extraneous studies and
evaluations were performed using this kit. Depletion figures for Pierce™ Albumin
(Figures 2-3, 2-4) and PureProteome™ Albumin (Figures 2-5, 2-6) are shown below. No
figures are shown for Pierce™ Top2, due to poor label-free quantification (LFQ) results,
and lack of robust peptide detection. Data for the Pierce™ Top2 kits were evaluated
visually. LFQ requires three unique peptides for quantification, however, three unique
peptides could not be determined among evaluated matrix samples. Additionally, 3-fold
less protein was used for Pierce Top2 digestions in comparison to other kits evaluated,
another potential factor for poor peptide detection.
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Figure 2-3: Depletion of peanut proteins in (A) peanut only and (B) serapeanut matrices by the Pierce™ Albumin Depletion kit. The top 10 unique
peanut proteins are represented in order of relative abundance. Open
symbols represent non-depleted samples; closed symbols represent
depleted samples.
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Figure 2-4: Depletion of serum proteins in sera-peanut matrix by Pierce
Albumin Depletion kit. The top 10 peanut proteins are represented in relative
abundance, determined by label-free quant. Open symbols represent nondepleted samples; closed symbols represent depleted samples. Inset
demonstrates depletion of albumin only within this matrix using the same
depletion kit.

The Pierce™ Top2 and PureProteome™ Albumin kits are antibody based
depletion kits (anti-human serum albumin; anti-IgG). Antibody based methods are highly
specific; however we observed removal of peanut proteins (Figure 2-5), strongly
suggesting cross-reactivity between kit antibodies and peanut proteins. Commercially
developed depletion kits are largely designed to increase detection of endogenous
proteins in human serum such as cytokines, peptide biomarkers, hormone peptide, and
lipoproteins (Pisanu et al., 2018). Therefore, we cannot insure specificity against
exogenous food proteins.
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Figure 2-5: Depletion of peanut proteins in (A) peanut only and (B)
sera-peanut matrices by the PureProteome Albumin Depletion kit. The
top 10 peanut proteins are represented, determined by label-free quant.
Open symbols represent non-depleted samples; closed symbols represent
depleted samples.
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Figure 2-6: Depletion of serum proteins sera-peanut matrix by PureProteome
Albumin Depletion kit. The top 10 peanut proteins are represented by relative
abundance, determined by label-free quant. Open symbols represent nondepleted samples; closed symbols represent depleted samples. Inset
demonstrates depletion of albumin only within this matrix using the same
depletion kit.
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The Pierce™ Albumin depletion kit utilizes immobilized Cibacron blue dye resin,
and binds albumin through electrostatic or hydrophobic interactions (Gianazza and
Arnaud, 1982; Travis and Pannell, 1973). Since peanut proteins were simultaneously
removed during depletion, we modified the properties of selected depletion kits to reduce
peanut protein removal by the matrix depletion. The salt concentrations of the
wash/elution buffers of two kits Pierce™ Top2 Abundant Depletion spin columns and
Pierce™ Albumin depletion were modified to assess recovery of peanut proteins. For
both commercial kits, we observed no improvements in the recovery of peanut proteins at
varying concentrations of salt in the wash and elution buffers. In fact, when peanut alone
was applied to each respective depletion column, no peanut protein was recovered at the
various salt concentrations evaluated (Figure 2-7). We then evaluated the proteins bound
to the column matrix by heating columns (95°C, 5 minutes) after adding a solution of 4 x
concentrated Laemmli buffer and 5% β-mercapto-ethanol. SDS-PAGE analysis of the
aqueous phase revealed peanut proteins were primarily bound to the depletion column
matrix (data not shown). This binding pattern was observed in both peanut and serapeanut matrices. This suggests a high rate of non-specific binding to abundant proteins
through antibody and dye-binding mechanisms.
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Figure 2-7. Evaluation of Pierce™ Albumin Depletion kit wash and elution buffer
with modified NaCl concentrations by reducing SDS-PAGE. Lane (1) Protein marker
standard, (2) raw peanut extract (0.01 M PBS), (3) column flow through, lanes (4-12)
column flow through with wash buffer concentrations 0.075, 0.10, 0.15, 0.20, 0.25,
0.30, 0.35, 0.40 M NaCl, respectively

The protein binding interactions, both antibody binding and Cibacron dye-binding
(Pierce™ Albumin Depletion), could not be disrupted by modifying the salt
concentrations (Figure 2-7). The concentration of salt influences protein-surface or
protein-protein binding properties by altering the binding affinities of proteins (Tsumoto
et al., 2007). Cibacron dye-binding is an affinity based method, but is relatively non-
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specific and has been described to bind other serum proteins including lipoprotein,
antithrombin III, interferon, and other serum polypeptides (Gianazza and Arnaud, 1982;
Thompson et al., 1975).
We further evaluated the Pierce™ Albumin depletion kit (Cibacron dye binding)
by adjusting the pH and assessing recovery of peanut proteins by SDS-PAGE (Figure 28). No changes in elution of peanut proteins were observed at any pH level. This further
suggests non-specific binding by the depletion matrix. By modifying the pH, we altered
the ionic strength, which can influence protein-binding affinities and therefore protein
elution from the depletion matrix.
Our aim was to disrupt interactions occurring between peanut proteins and
capture antibodies. Decreasing the pH creates an increasingly acidic environment
causing changes to the antigen-antibody binding properties, protein conformation, and
partial denaturation (Hinderling and Hartmann, 2005; Kochansky et al., 2008). In the
biological system evaluated, reducing the pH alone was not sufficient to disrupt the
protein-binding interactions occurring between peanut, serum, and the depletion matrix.
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Figure 2-8. Evaluation of Pierce Albumin Depletion kit wash and elution
buffer with modified pH by reducing SDS-PAGE. Lane (1) Protein marker
standard, (2) raw peanut extract (0.01 M PBS), (3) column flow through,
lanes (4-12) column flow through with wash buffer pH 7.5, 7.0, 6.5, 6.0,
5.5, 5.0, 4.5, 4.0, 3.5, respectively.
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BioVision IgG depletion kits were successful in removing IgG from serum, while
not co-depleting peanut proteins. Protein G, is a bacterial produced protein, and binds the
Fc region of immunoglobulins with high affinity, and has been widely used for IgG
purification, with kits for IgG depletion readily available (Björck and Kronvall, 1984).
Due to the specificity of protein-G, we hypothesized protein-G would remove
IgG-peanut complexes, free IgG, and other IgG-serum complexes. JanssenDuijghssen et
al., 2017 demonstrated in vivo interactions occurring between exogenous peanut proteins
and endogenous IgG antibodies. We investigated removal of IgG using Protein-G
Sepharose as a means to co-isolate IgG-peanut complexes from non-allergic patient
serum. No LC-MS/MS data were acquired for IgG depletion experiments. SDS-PAGE
was used to evaluate fractions from Protein-G Sepharose IgG depletion (Figure 2-9). In
each panel, the non-depleted matrix is depicted in the first lane following the protein
marker (lanes 2, 6, 10). The unbound fractions (lanes 3, 7, 11) represent the analyzed
matrix after IgG depletion (e.g. serum post IgG depletion). The bound fractions (lanes 4,
8, 12) represent those proteins bound by Protein G Sepharose (e.g. depleted proteins from
matrix). IgG was successfully removed from serum containing matrices (sera-peanut and
serum alone) (lanes 3, 7). Peanut proteins were not depleted from the peanut containing
samples (sera-peanut and peanut alone) (lanes 8, 12). Here, we observed the suspected
IgG-peanut complexes were not depleted by Protein G Sepharose, as demonstrated by the
absence of peanut proteins in lane 4, the bound fraction from the serum-peanut matrix.
This suggests these complexes are unable to be removed from the serum matrix. Oda et
al., 2003 reported a change in IgG conformation occurs upon antigen binding, resulting in
the inability of Protein G Sepharose to bind complexed IgG, similar to our results (Oda et
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al., 2003). Additional interactions with albumin or other endogenous proteins could also
be influencing peanut behavior and overall detection. Due to the lack of peanut proteins
present in the protein-G sepharose fraction following depletion (Lanes 4, 8, 12), it is
evident IgG-peanut complexes were not effectively depleted. We suspect protein G is
only able to remove free IgG.
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Figure 2-9. Evaluation of BioVision Protein G Sepharose IgG depletion by SDSPAGE of prepared matrices (A) serum incurred with raw peanut, (B) serum, (C)
raw peanut. Lanes (1, 5, 9) Protein marker standard (kDa), (2) sera-peanut matrix
(non-depleted), (3) Unbound sera-peanut after IgG depletion, (4) Bound depleted
fraction from serum-peanut, (6) serum (non-depleted), (7) Unbound serum after
IgG depletion, (8) Bound depleted fraction from serum (10) peanut (non-depleted)
(11) Bound peanut after IgG depletion (12) Unbound depleted fraction from
peanut.
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Allergenic proteins induce specific antibodies including IgG1, IgG4, and IgE
(Aalberse et al., 2009; Jutel and Akdis, 2011). The antibody isotype IgG4 is induced
after extended and repeated exposures to allergenic proteins, typically in low doses.
These repeated, low-dose exposures, as performed in immunotherapy treatments, do not
generally elicit a full immunological response (Aalberse et al., 2009; Jutel and Akdis,
2011). Interactions between allergenic food proteins and IgG antibodies, the
predominant antibody class, have been reported in both allergic and non-allergic patients
(JanssenDuijghuijsen et al., 2017; Murphy, 2012; Platts-Mills et al., 2001; Wachholz and
Durham, 2004). For allergic patients undergoing immunotherapy, an increase in
prevalence of IgG4 antibodies has been attributed to the acquiring of tolerance (PlattsMills et al., 2001; Wachholz and Durham, 2004). This suggests non-symptomatic IgGfood protein interactions preclude IgE-food protein binding events (Platts-Mills et al.,
2001; Wachholz and Durham, 2004).
Reported interactions between endogenous IgG antibodies and allergenic food
proteins (peanut, Ara h 6), in non-allergic individuals, resulted in reduced detection by
immunoassay (JanssenDuijghuijsen et al., 2017). To understand the overall role of IgG
concentration on tolerance, more studies need to be conducted. We show similar findings
to reports by Oda et al., 2003 and JanssenDuijghuijsen et al., 2017. Furthermore,
interactions between allergenic food proteins and endogenous antibodies (IgG) prevents
adequate detection of exogenous peanut proteins, a key problem for in vivo analysis of
allergenic food proteins using ELISA. However, during LC-MS/MS sample preparation,
these complexes are disrupted due to reduction and trypsin digestion generating peptides.
Using this approach, IgG depletion is not advantageous for LC-MS/MS since IgG-peanut
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complexes are unable to be removed. Therefore, our serum matrix remains relatively
complex, but only by removing a small amount (i.e. free IgG) of protein.

Organic Solvent Fractionation
Organic solvent fractionation methods were investigated as an alternative to
depletion methods in order to retain serum composition. The most abundant serum
protein, albumin, is soluble in organic solvents (e.g. isopropanol, ethanol, methanol) and
is readily fractionated from serum (Liu et al., 2014; Michael, 1962). Samples for
evaluation were fractionated into three fractions, (1) isopropanol-TCA, (2) methanol, or
(3) pellet precipitate and were analyzed by LC-MS/MS and SDS-PAGE. The primary
goal of TCA organic fractionation is to enrich peanut protein relative to all other proteins
in the sample.
The organic solvent fractionation patterns of serum, peanut, and sera-peanut, and
their non-fractionated controls (stocks) are shown in Figure 2-10. A comparison of
fractionation patterns, shows a majority of the albumin protein is removed (MW band
66.5 kDa) into the isopropanol-TCA fraction. The albumin is not entirely removed, with
some remaining in the precipitated fraction (Figure 2-10).
We analyzed the fractionation patterns in more detail based on relative
abundance. Depending on the matrix background, peanut proteins demonstrated different
fractionation patterns (Figure 2-11). In the absence of a serum background, the peanut 2S
albumins, Ara h 2 and Ara h 6, primarily fractionated into fraction 1, the isopropanolTCA fraction. Whereas in the presence of a serum background (serum-peanut), these
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proteins primarily fractionated into fraction 2, the methanol fraction. The cupin proteins,
Ara h 1 and 3 exhibited similar fractionation patterns (Figure 2-11). In the absence of a
serum background, the cupins fractionated largely into the fraction 2, whereas in the
presence of a serum background, Ara h 1 fractionated largely into the precipitate.
The organic solvent fractionation method works well to remove albumin from the
serum matrix and reduce its complexity. However, this de-complexation strategy is
largely non-specific, and dependent upon protein solubility.
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Figure 2-10. Evaluation of organic fractionation patterns by reducing SDS-PAGE of
prepared matrices (A) serum, (B) incurred matrix serum-peanut, (C) raw peanut. Lanes
(1, 5, 9) Protein marker standard (kDa), (2) unfractionated serum, (3) serum in
isopropanol-TCA supernatant, (4) serum in pellet precipitate, (6) unfractionated serumpeanut, (7) serum-peanut in isopropanol-TCA supernatant, (8) serum-peanut in pellet
precipitate, (10) unfractionated peanut, (11) peanut in isopropanol-TCA supernatant,
(12) peanut in pellet precipitate.
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Figure 2-11. Evaluation of organic solvent fractionation by discovery LC-MS/MS in
(A) Ara h 1 (Q6PSU3), (B) Ara h 3 (A1DZF0), (C) Ara h 2 (Q6PSU2-4), (D) Ara h 6
(Q647G9) in model samples serum-peanut or peanut.
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Evaluation of Multiple De-Complexation Methods (Organic Solvent
Fractionation and IgG Depletion)
Our aim in combining two de-complexing strategies, IgG depletion and organic
solvent fractionation, was to improve detection of peanut proteins in serum. We
hypothesized the removal of IgG followed by organic solvent fractionation will greatly
reduce the background and potential interferences.
For this set of experimental results, we will focus on the fractionation patterns of
(1) the experimental control model matrix (sera-peanut) compared to (2) IgG depleted
sera followed by the addition of raw peanut extract (IgG depleted sera with peanut spike),
prepared with commercially prepared human serum (ImmunO). Based on our previous
results, IgG-peanut complexes are not removed during IgG depletion. Therefore, we
would expect only free IgG to be removed from our sera-peanut sample. To further
assess the effect of IgG depletion on our model samples, we depleted serum of IgG
followed by adding an equivalent volume peanut extract to the IgG depleted serum.
Prepared samples were then fractionated using our organic solvent method and analyzed
as before by discovery LC-MS/MS.
Comparison of the sera-peanut matrix before and after IgG depletion indicate no
noticeable differences in fractionation patterns in an allergic individual’s serum for all
major allergenic peanut proteins monitored. (Figure 2-12).
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Figure 2-12. Evaluation of organic solvent fractionation of IgG depletion of
serum-peanut matrix and no depletion of serum incurred with peanut by
discovery LC-MS/MS
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We observed differences in fractionation patterns based on the presence of
absence of IgG. In the control sera-peanut samples with commercially prepared serum,
the comparison of the relative abundance profiles of each peanut protein in each fraction
is presented in Figure 2-13. In the sera-peanut matrix, Ara h 2 fractionates primarily in
fraction 2, and is second most abundant in fraction 1. Ara h 6 was predominantly
abundant in fraction 2, similar to Ara h 2, however, it was second most abundant in the
precipitate. The cupin proteins (Ara h 1, Ara h 3), fractionated predominantly into
fraction 2 and secondarily fractionated into the precipitate.
After IgG depletion and the addition of peanut extract to the depleted sera, we
observed shifts in the fractionation patterns of peanut proteins (Figure 2-13). Ara h 2
fractionated largely into fraction 1, the isopropanol-TCA fraction, and then into fraction
2, the methanol fraction. This pattern differs from the sera-peanut matrix, where Ara h 2
abundance was highest in fraction 2. Ara h 6 was most abundant in fraction 2 and the
precipitate. This differs slightly compared to the sera-peanut control which was
predominantly present in fraction 2 and second most abundant in fraction 1, illustrating a
shift in fractionation of Ara h 6 due to IgG (Figure 2-13D). For the cupin proteins, Ara h
1 was present largely in fraction 2 and the precipitate, exhibiting no shift in fractionation
compared to the sera-peanut matrix. We observed Ara h 3 was present predominantly in
fraction 2 and second most abundant in fraction 1. This pattern is slightly different than
the sera-peanut pattern, in which case Ara h 3 was detected largely in fraction 2 and the
precipitate (Figure 2-13B).
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Overall, depletion of IgG from serum followed by the addition of peanut extract,
demonstrates a fractionation pattern more similar to peanut (alone) and less similar to
sera-peanut, the model matrix.
We then performed this same experiment of IgG depletion and organic solvent
fractionation using allergic subject serum. Evidence of different IgG profiles between
allergic and non-allergic individuals has been published in the literature (Aalberse et al.,
1983; Platts-Mills et al., 2001; Rowntree et al., 1987).
We analyzed peanut allergic subject serum of (1) control, sera-peanut matrix and
(2) IgG depleted sera followed by the addition of peanut (IgG depleted serum-peanut
spike) (Figure 2-14). We compared the fractionation profiles of peanut allergens from
the UniProt database. Data are represented by normalized abundance (e.g. the total
identified peak area). The IgG depleted allergic sera with peanut extract addition,
demonstrated a noticeably different fractionation pattern compared to the experimental
control, sera-peanut.
In the sera-peanut controls, the prolamins, Ara h 2 and Ara h 6 exhibited identical
fractionation patterns. Ara h 2 fractionated predominantly into fractions 1 and 2. Ara h 6
fractionated equally into fractions 1 and 2. Whereas Ara h 1 and Ara h 3 fractionated
largely into the precipitate.
In the IgG depleted-peanut spiked samples, Ara h 2 fractionated largely into
fraction 1 and secondarily into fraction 2. Ara h 6 fractionated equally into fraction 1 and
fraction 2. Overall, we observed no differences in fractionation patterns of the 2S
albumins dependent upon the presence or absence of IgG. Both, Ara h 1 and Ara h 3
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fractionated largely into fraction 2. The fractionation pattern differs greatly from the
sera-peanut control matrix.
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Figure 2-13. Evaluation of organic solvent fractionation of IgG depleted serum
(commercial) with peanut spike (post depletion) and serum (commercial)-peanut extract
by discovery LC-MS/MS in (A) Ara h 1 (P43237), (B) Ara h 3 (Q0GM57), (C) Ara h 2
(Q6PSU2), (D) Ara h 6 (A5Z1R0) in model samples serum-peanut or peanut.
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Figure 2-14. Evaluation of organic fractionation of IgG depleted serum (allergic) with
addition of peanut extract (post depletion) and allergic serum(allergic)-peanut matrix
by discovery LC-MS/MS in (A) Ara h 1 (P43237), (B) Ara h 3 (Q0GM57), (C) Ara h
2 (Q6PSU2), (D) Ara h 6 (A5Z1R0)
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The fractionation patterns between allergic and commercially prepared serum,
differ due to the presence or absence of IgG. The commercially prepared serum is a pool
of serum, which has undergone filtration prior to purchase. The commercial serum is not
guaranteed to be selected from non-allergic individuals.
We did not analyze baseline serum using this experiment, however upon review,
this would be a suitable comparison for evaluation of these two de-complexation
strategies. However, we can illustrate the differences in fractionation in allergic subjects
compared to the commercial sera, indicating IgG may have a prominent role in response
to allergenic food proteins (Chinthrajah et al., 2016; Koppelman et al., 2019; Vickery et
al., 2013).
Initial evaluations of the sera-peanut matrix before and after IgG depletion
showed no difference in fractionation patterns. We anticipate this is due to the
functionality of the IgG depletion not able to remove IgG-peanut complexes and/or only
removing free IgG. Therefore, we chose to not include the fractionation patterns of IgG
depleted sera-peanut.
We analyzed several patient serum samples (allergic and non-allergic) incurred
with peanut using TCA fractionation (data not shown), which indicated differences in
fractionation patterns of peanut proteins in various sera samples. In order to understand
differences in fractionation patterns and the role of IgG in individual sera, we would need
to profile many patients, if one exists. Due to the individualistic variability of patient
serum, and its influence on protein fractionation, we determined this method is unsuitable
for monitoring low abundance peanut proteins in serum.
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CONCLUSIONS
Discovery LC-MS/MS methods lack sufficient sensitivity to detect consumed
allergenic peanut proteins at low concentrations in vivo. In these methods, the most
abundant (e.g. top 10, top 20) precursor ions are selected and fragmented for MS/MS
analysis in stochastic manner (Gillette and Carr, 2013). Consequently, protein abundance
significantly influences data-dependent acquisitions and low abundance proteins may not
be routinely sampled and remain undetected (Domon and Aebersold, 2010; Gillette and
Carr, 2013). MS instruments often have necessary levels of sensitivity required for low
detection, however, a high signal-to-noise ratio from a complex sample (e.g. serum)
affects overall detection (Gillette and Carr, 2013).
We investigated multiple strategies to de-complex serum prior to LC-MS/MS
analysis, including optimizing MS acquisition settings, as previously discussed, and
physical serum de-complexation strategies. The use of exclusion and inclusion lists did
not yield positive results for peanut detection. The commercial depletion kits
successfully reduced sample complexity, however, were not successful for our
experiment due to the co-depletion of exogenous peanut proteins in serum. IgG depletion
was highly specific, however, provided little utility to achieving our overall aim. IgG
complexes (IgG-peanut) are unable to be depleted and therefore, we are only able to
deplete free, unbound IgG. One of the main limitations of commercial depletion columns
is their limited binding capacity. The maximum load of protein for the Pierce™ Top2
Abundant Depletion spin columns is 600 µg, equivalent to 7.5 – 10 µl non-depleted
serum. Working within this limitation and the known concentration of peanut after
consumption (131 ng DRP-Ara h 2/ml serum), we would need to achieve detection of
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13.1 ng Ara h 2 (262 ng total peanut protein) by discovery LC-MS/MS, assuming
complete absorption and no experimental losses. Lastly, the organic solvent fractionation
yielded variable results between sera types (commercial, peanut-allergic), and was further
complicated by the addition of IgG depletion. Due to inter-subject variability in
fractionation, these methods were not fit for the purposes of our study.
Each of the de-complexation strategies evaluated reduced the sample complexity
and total protein by selective protein removal, improving the signal-to-noise ratios (S/N)
and low abundance protein detection. Ideally, the employed depletion strategy is specific
to serum proteins only, however this was not the case based on the results presented.
Based on our results, we suggest development of a targeted MS method for
detection of peanut proteins in non-depleted serum. Due to the sampling limitations of
discovery LC-MS/MS methods, targeted methods are a suitable alternative for achieving
detection. Targeted methods, including MRM and PRM, have been successfully
employed for specific analyte detection, overcoming shortcomings of shotgun methods.
Targeted methods provide good sensitivity, reproducibility, and capable of quantification
(Lange et al., 2008).
In supplement to targeted LC-MS/MS methods, we suggest using non-depleted
serum for further investigations due to the co-isolation of peanut proteins by commercial
depletion methods and variability of peanut protein fractionation by organic solvent
methods. The use of non-depleted serum ensures peanut proteins remain in the subject
serum sample. However, detection of low abundance proteins in serum remains
challenging due to the depth and complexity of the human serum proteome, which will be
addressed by implementing targeted methods.
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CHAPTER 3: DEVELOPMENT OF TARGETED MASS SPECTROMETRY
METHODS FOR IN VIVO DETECTION OF PEANUT PROTEINS IN HUMAN
SERUM

ABSTRACT
Due to the complexity of human serum and the substantial number of peptides
generated after trypsin digestion, discovery MS is not ideal. Therefore, targeted methods
(PRM, MRM), will be used instead. The aim of this chapter was to develop a targeted
MS method to detect allergenic peanut proteins in non-depleted serum. To maintain
sample integrity, non-depleted serum will be analyzed to mitigate any losses of critically
relevant protein targets.
The model samples described in Chapter 2 (page 79) were used for targeted LCMS/MS method development. Peanut protein targets, representing the major allergenic
proteins, were selected using discovery driven peptide selection. Targeted LC-MS/MS
methods, PRM, MRM, and MRM3, were developed sequentially based on the required
level of sensitivity using our model samples (sera-peanut, sera, peanut). Sample
preparation, method chromatography, MS acquisition settings were further modified to
improve detection in subject sera.
Peptide targets were selected using discovery MS for the development of PRM
and MRM methods. We evaluated a sera-peanut matrix and observed similar LODs
using both PRM and MRM methods. The LOD for PRM in the sera-peanut matrix was
800 pg peanut protein (1.0 ppm peanut protein, 4.0 ppm peanut). The MRM LOD was
peptide dependent. For Ara h 1, Ara h 2, and Ara h 6 the LOD was 1240 pg peanut (1.53
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ppm peanut protein, 6.11 ppm peanut). For Ara h 3, the LOD was 3730 pg peanut
protein (4.58 ppm peanut protein, 18.3 ppm peanut). The LOD for the MRM3 method
was variable and inconsistent due to the lack of specific secondary fragment ions for
detection.
We further optimized the PRM method by injecting more protein for analysis.
Overall, the PRM methods were the optimal methods to use, and were able to detect
peanut peptides in serum on multiple occasions. However, due to a lack of robust
detection, these methods are not yet optimal. Further work is required to develop a
robust targeted detection method for in vivo detection of allergenic proteins.
The targeted methods were successful in detecting peanut proteins in the model
matrices. Evaluation of subject sera samples determined positive by Ara h 6 ELISA,
were evaluated using each of the targeted MS methods, but no reproducible positive
detections were observed. However, we were able to confidently detect multiple peptides
in several instances from different subject sera and at different time points, suggesting
our methodology is a probable candidate for routine evaluation.

INTRODUCTION
The prevalence of food allergies has been increasing in Western countries (Nwaru
et al., 2014; Sicherer et al., 2010). Consequently, there has been a steady increase of
peanut allergy prevalence, the most prevalent food allergy being in children (Nwaru et
al., 2014; Sicherer et al., 2010; Venter et al., 2010). Peanuts are highly potent allergens,
and can elicit reactions with ingestion of low doses in sensitized individuals (Clarke et
al., 1998; Hourihane et al., 2017; Koppelman et al., 2004). There is further evidence
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these ingested peanut proteins are present in serum, breast milk, and saliva, however
overall detection was very low (Baumert et al., 2009; JanssenDuijghuijsen et al., 2017b;
Schocker et al., 2016). The method of protein uptake, particularly intact proteins, has
been described in several reviews but has not been fully elucidated (Chehade and Mayer,
2005; Reitsma et al., 2014;). The role of allergenic protein absorption likely influences
sensitization mechanisms. In order for an allergic reaction to occur, the allergenic food
proteins must cross-link IgE specific antibodies in an immunologically intact form (Stone
et al., 2010; Taylor and Baumert, 2012;). It has been suggested the transport and
absorptive mechanisms employed differs between allergic (atopic) and non-allergic
(healthy, non-atopic) subjects (Reitsma et al., 2014). In sensitized individuals, there is a
decrease is the tight junction barrier function due to the presence of mast cells, which
consequently increases the transport of non-degraded or partially degraded allergenic
protein (Berin et al., 1998). Therefore, much focus has been placed on development of
an in vivo detection method to gain understanding in uptake and sensitization.
Several studies have focused on detection of peanut proteins in vivo, primarily by
ELISA methods and more recently by LC-MS/MS (Baumert et al., 2009; Hands et al.,
2020; JanssenDuijghuijsen et al., 2017b). ELISAs have been the primary methods of
choice for studying in vivo uptake, however these methods need additional confirmatory
methods to demonstrate antibody-binding specificity (Hands et al., 2020).
LC-MS/MS methods, which are used as an alternative to ELISAs, remain
challenging due to complexity of human serum. Therefore, the comprehensive
elucidation of low-abundance proteins by LC-MS/MS remains challenging to do the
broad dynamic range and few proteins accounting for a majority of abundance (Kumar
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Dey et al., 2019). There is limited literature published regarding in vivo detection of
allergenic food proteins, further, a majority of these studies utilize ELISA methods
(Baumert et al., 2009; JanssenDuijghuijsen et al., 2017a; JanssenDuijghuijsen et al.,
2017b; Schocker et al., 2016). Recently, two studies have employed the use of LCMS/MS methods to monitor the uptake of peanut proteins (Hands et al., 2020; Mose et
al., 2019). Hands et al., (2019) developed an MRM detection method for peanut proteins
spiked into commercial human serum. Additionally, Hands et al., (2020) used depletion
(MARS Hu-6) to remove majorly abundant serum proteins prior to MRM analysis.
However, in this study, no subject serum collected after peanut consumption were
analyzed using the developed method. Mose et al., 2019 evaluated multiple MS methods
(MRM, GeLC MS/MS using discovery MS, and SWATH) with spiked model matrix
(serum with Ara h 2) and subject serum collected after peanut consumptions. They
reported positive detection using MS methods for the spiked matrix samples (serum-Ara
h 2), but were unable to achieve detection with subject samples collected after
consumption (Mose et al., 2019). However, subject sera demonstrated reactivity through
basophil-histamine release assays of subject serum after ingestion (Mose et al., 2019).
This is suggestive that peanut proteins are present in vivo (i.e. serum) in an
immunologically reactive form, but not readily detectable by the bottom-up LC-MS/MS
methods.
Due to the ineffectiveness of depletion kits, as presented in Chapter 2,
investigators have adopted methods utilizing non-depleted serum and targeted MS
methods (Fortin et al., 2009; Kumar Dey et al., 2019; Percy et al., 2013). Fortin et al.,
2009 demonstrated detection of protein biomarkers at ppm concentration levels in non-

147
depleted serum using MRM3. Kumar Dey et al., 2019, investigated profiling nondepleted serum to aid in determining biomarker targets for Alzheimer’s disease using an
LC-MS3 (TOMAHAQ) method. Targeted MS methods are beneficial for their sensitivity
to pre-selected peptides, improving an instrument’s dynamic range, reducing interfering
background noise, and ability to easily multiplex (Picotti and Aebersold, 2012; Ronsein
et al., 2015). Targeted MS methods are able to detect individual allergenic protein
sequences provided within a database. For targeted methods, it is critical to have a robust
peptide selection method, especially in complex matrices to prevent false positive
identifications (Sherman et al., 2009).
In our investigations, we utilized three different targeted MS methods to increase
sensitivity, for detection of allergenic proteins in vivo. PRM based mass spectrometry
utilizes high resolution-accurate mass (HR-AM) instruments, and is highly specific since
all product fragment ions are analyzed in parallel. The HR-AM analyzer enables in PRM
scans the capability to distinguish between co-isolated ions, by determining each ion’s
fragmentation patterns (Duncan et al., 2009; Peterson et al., 2012; Sherman et al., 2009).
MRM methods have been the gold-standard quantification method due to their high
selectivity, sensitivity, reproducibility, and quantifiable accuracy for peptide detection
(Addona et al., 2009; Lange et al., 2008). MRM3 methods provide an additional level of
sensitivity, and are able to quantify low abundance peptides in non-depleted serum
(Fortin et al., 2009).
The objective of this chapter is to develop a series of targeted MS methods, in
order of increasing sensitivity, PRM, MRM, and MRM3, for unique peanut peptide
targets selected by DDA selection process. We anticipate needing high levels of
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sensitivity with corresponding low levels of detection based on the currently available in
vivo protein absorption data. In this chapter, subject serum collected by
JanssenDuijghuijsen et al., 2017b, which was determined positive by an Ara h 6 ELISA,
were evaluated by the targeted methods developed. Ara h 6, a preferential immunoassay
target due to its digestive stability, was detected at extremely low concentrations (0.3
ng/mL Ara h 6) in human serum (JanssenDuijghuijsen et al., 2017b). Ara h 6 only
accounts for ~6% of the total peanut protein; therefore the estimated protein
concentration of peanut in serum is expected to be greater (6 ng peanut protein/mL)
(JanssenDuijghuijsen et al., 2017b; Koppelman et al., 2016). Given the unknown
concentrations of peanut proteins in serum, the level of detection required by MS
methods is largely unknown. We developed the targeted methods in the following order,
PRM, MRM, and MRM3, with each method ideally providing improvements to
sensitivity.

MATERIALS AND METHODS

Reagents
All reagents used were of analytical grade for all experiments. All reagents used
for LC-MS/MS sample preparations and analyses were of MS grade.

Discovery Identification of Peanut Peptide Targets
For initial data-dependent acquisitions, samples were prepared on an equal protein
basis. All samples prepared will have the same amount protein present in the sera-peanut
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matrix sample as is present in their individual component samples (peanut or serum
alone); non-depleted samples were prepared as described in Chapter 2 (page 79).

Sample Preparation and In-Solution Reduction, Alkylation, and Trypsin
Digestion for Discovery LC-MS/MS
Initial identifications of unique peanut peptides were determined experimentally
by discovery LC-MS/MS of (1) non-depleted serum, (2) raw peanut extract, and (3) an
incurred matrix of non-depleted serum and raw peanut extract (10:1 (w/w)), as described
previously in Chapter 2 (page 79).
However, for model matrices prepared in this chapter, we used commercially
available human serum (human serum sterile, ImmunO, MP Biomedicals) and raw peanut
extract (0.01 M PBS), combined at a 10:1 w/w ratio, with a maximum of 30 µg protein
for trypsin digestion. This incurred serum-peanut matrix will serve as our model system
for all subsequent stages of MS method development, unless otherwise noted. Control
samples were prepared using equivalently.
Samples were evaluated by discovery LC-MS/MS using a standard in-solution
reduction, alkylation, and trypsin digestion protocol modified from Thermo™ InSolution Trypsin Digestion and Guanidination, as previously described (page 80).

Discovery LC-MS/MS Acquisition Method
We used the optimized discovery acquisition developed in Chapter 2, using the
same instrument platform and equipment (page 84). All instrument parameters remained
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the same, except, the UPLC column was equipped with a Javelin™ Direct-Connection
Column Filter, 2.1 mm (Thermo Scientific™), a Hypersil Gold aQ C18 1.9 μm, 20 × 2.1
mm pre-column (Thermo Scientific™) and a Hypersil Gold C18 1.9 μm, 100 × 1 mm
analytical reversed phase column (Thermo Scientific™).

Data Analysis
Acquired discovery data were evaluated using a peanut database (Arachis
hypogaea, taxon identifier 3818) downloaded from UniProt (8/31/2016) and PEAKS
version 8.5 software (Bioinformatics Solutions; Cheriton et al., 2019) for identification of
unique proteotypic peanut peptides, as previously described (page 82), however the
parent mass tolerance was set to 5 ppm. Label-free quantification was performed to
quantify peptide abundance and data were normalized to TIC.

Peptide Selection
Peptides identified using discovery MS were selected for evaluation as candidate
PRM targets. The following criteria were used to evaluate peptides: (1) selected peptide
sequences must be unique and attributable to peanut protein(s); (2) selected peptides must
be absent from sera only data; (3) candidate peptides must originate from a multiply
charged precursor ion (2+, 3+, or 4+); (4) contain 5 – 20 amino acid residues; (6) have
tryptic cleavage sites; (7) no miscleavage events; and (8) absent of any post-translational
modifications (PTMs) other than carbamidomethylation, a product of alkylation (Korte et
al., 2016; Rauniyar, 2015). Peptides must be present in relatively high abundances in
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both the peanut and serum-peanut matrices. If peptides were detected at multiple charge
states both charge states were included in preliminary target selection. Once all candidate
peptides were identified by the above listed criteria, the inclusion list was further refined.
Of the peptides identified, only those detected within the top 10% of all identified
candidate peptides by signal abundance were included for further evaluation in PRM
method development.

PRM Method Development
The PRM method was developed by evaluating peptides selected by discovery
LC-MS/MS. Due to the large number of peptides included, we divided the peptides into
two inclusion lists based on retention times; target list A and target list B. Peptides were
ranked according to retention times, and split between the two lists, by selecting every
other peptide based on retention time.

MS Method Settings for PRM Evaluation
Once peptides were designated to the appropriate inclusion list, we evaluated
peptide performance against the same set of samples, sera-peanut matrix, peanut, and
serum. Samples were prepared identically as those previously described using the same
instrument platform and chromatography in the discovery LC-MS/MS experiment. In
total, 52 peptides from the four major allergenic peanut proteins (Ara h 1, Ara h 2, Ara h
3, Ara h 6) were identified (described in detail in results section, page 171). These
peptides divided into two inclusion lists, with a maximum of 27 and 26 peptides in each

152
list, respectively. Peptides in the initial inclusion list(s) were not scheduled. Scheduling
reduces background interferences by only scanning for specific m/z events during a
defined time window (e.g. peptide retention time). LC method run time was 113 minutes,
with PRM scan time of 73 minutes (2 – 75 minutes). MS acquisition settings were set as
follows: MS2 resolution was set to 140,000; AGC target 1e6; maximum IT 500 ms; loop
count 30; isolation window 1.6 m/z with an isolation offset set to 0.0 m/z; NCE set to 27.
Instrument gas and source settings for PRM acquisitions were identical to those
previously described (page 81).

PRM Optimization and Evaluation of Selected Target Peptides
The PRM peptide list was refined by adjusting the chromatographic gradient to 5
– 50% mobile phase B (0.1% formic acid in acetonitrile). All instrument and gas settings
were kept the same as previously described (page 151).
The same set of prepared matrix samples was injected using PRM acquisition.
The target list was reduced to 19 target peptides after the last series of peptide
evaluations. Peptides were then combined into a single inclusion list, with the loop count
set to 20. We included peptide retention times with +/- 1.5 minutes of the mean
calculated peptide retention time.
The method sensitivity (limit of detection) was evaluated by preparing serum
incurred with serially diluted peanut protein. The volume of serum used in each model
sample remained constant while the peanut extract was serially diluted. The
concentrations of each peanut extract are described in Table 3-1. An equivalent volume
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from each peanut extract was added to sera, to maintain equal sample volume(s).
Samples were prepared for LC-MS/MS by digestion, de-salting (C18), and re-suspension,
as previously described for model samples (page 79). Samples were injected in
duplicate. We evaluated both (1) sera-peanut matrices and (2) peanut, without the matrix
background, at decreasing concentrations of peanut protein.
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ratio of sera:peanut

10:1
100:1
500:1
1,000:1
2,000:1
5,000:1
10,000:1

ng peanut
protein injected
80
8
1.6
1.1
0.40
0.16
0.08

ppm peanut
protein in
original sample
110
11.0
2.20
1.10
0.56
0.22
0.11

Table 3-1. Dilution series of peanut in serum for evaluation
of PRM method sensitivity.

Data Analysis of PRM Methodology
i.

Peptide Selection

PRM data were analyzed using Skyline v20 software (Maclean et al., 2010).
Parent ions were selected by the PRM method and fragmented, therefore we evaluated
the transitions of each parent (MS1) ions. Peptides with six or more detectable
transitions were retained for further evaluation as target peptides. We evaluated y- or bions only and removed other ion products from analyses.
The settings used to analyze PRM data in Skyline were set to match the
acquisitions method parameters with an ion match tolerance set to 0.7 m/z, and a method
match tolerance set to 0.055 m/z
Transitions, y1, y2, b1, and b2, were removed, as were, transitions which were not
detected. Transitions which were positive in sera (alone) were removed. The transition
ratio pattern in sera-peanut samples must be identical to peanut (alone), with similar
recorded retention times. Peptides were ranked by summed peptide peak area. The top 5
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peptides, for each major allergenic peanut protein, which meet the above described
criteria were included further evaluation.

ii.

Peptide Selection and Refinement

Peptides were evaluated using Skyline, as previously described in the previous
section (page 154). The retention time stability was evaluated and the scanning windows
were adjusted for their mean observed retention time, if vastly different from previous
analyses. Peptides must have three robust transitions, which meet the above criteria in
order to remain included as target candidate peptide. The dilution series was evaluated
for robust peptide detection at each level. The LOD was assessed in a qualitative manner
by observing lack of transition detection, shifts in retention time, and poor peak shape.
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MRM

Instrument Settings and Method Optimization
Since we anticipated needing high levels of sensitivity and low-level peptide
detection, we developed an MRM method using the optimized targets and
chromatographic settings determined during PRM method development.
MRM analysis was performed on a SCIEX QTRAP 6500+, a triple quadrupole
mass spectrometer coupled with a Shimadzu Nexera II UHPLC (binary pump) with a
Hypersil Gold uHPLC column (100 x 2.1 mm, 1.9 µm) equipped with a filter (Javelin™
Direct-Connection Column Filter, 2.1 mm (Thermo Scientific™). The PRM
chromatographic method was directly transferred. Peptide scheduling was re-evaluated
on the QTRAP instrument platform. Mobile phases were as follows: A was 0.1% formic
acid in water, B was 0.1% formic acid in acetonitrile. To accommodate the larger
column, the flow rate was increased to 300 µL/min and column oven temperature was set
to 40°C. Low mass (<1000 m/z) acquisition setting was used.
The following instrument settings were optimized for MRM peptide detection in
order they are listed: vertical probe position set to 8, horizontal probe position set to 6,
curtain gas (CUR) set to 30, ion spray voltage (IS) of 5500, temperature (TEM) 300°C,
ion source gas 1 (GS1) at 40, ion source gas (GS2) at 50, and collision gas (CAD) set to
high.
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For optimization, we infused mobile phase A (0.1% formic acid in water) buffer
and observed the responses for each gas setting. Once all acquisition settings were
optimized, a peanut sample was injected for validation.

MRM Peptide Target Selection and Evaluation
To evaluate selected peptide targets, we injected (2 µL) the model samples, sera,
peanut, and sera-peanut, (0.5 µg/µL) as performed in previous experiments. Initial
peptide targets determined by PRM were included for evaluation as MRM targets. We
included the top six transitions for each selected peptide for evaluation by MRM.
The peptide dependent instrument settings, collision energy (CE), dwell time, and
declustering potential (DP) were optimized to maximize sensitivity for the MRM method.
Peptide dependent settings are generally determined by direct infusion of synthesized
isotopically labeled peptide(s). However, the instrument settings were optimized by a
direct infusion of tryptically digested raw peanut extract, prepared in the same manner as
previously described to a final peptide concentration of (0.5 µg/µL), similarly to von
Bargen et al., 2013.
Peptide retention times were determined on the QTRAP platform using an
Enhanced MS scan. Replicate injections (2 µL) of digested peanut extract (0.5 µg/µL)
were performed to determine mean retention time. The mean retention time ± 45 seconds
were included.
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MRM Method Sensitivity Determination
We similarly analyzed the same two prepared dilution series, (1) sera-peanut and
(2) peanut, to determine MRM method LOD (Table 3-2). MRM data were analyzed
using Skyline software following the same criteria described for PRM analyses (Maclean
et al., 2010).
The settings used to analyze MRM data in Skyline were set to match the
acquisition method parameters with an ion match tolerance set to 0.5 m/z, and a method
match tolerance set to 0.6 m/z. The LOD was assessed in a qualitative manner by
observing lack of transition detection, shifts in retention time, and poor peak shape.
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ratio of sera:peanut

10:1
50:1
250:1
750:1
1,250:1
3,750:1
6,250:1
31,250:1

ng peanut
protein injected
93.3
18.7
3.7
1.2
0.75
0.25
0.15
0.03

ppm peanut
protein in
original sample
115
22.9
4.58
1.53
0.92
0.31
0.18
0.04

Table 3-2. Dilution series of peanut in serum for evaluation
of MRM and MRM3 method sensitivity.

MRM3

Instrument Setting Optimizations
MRM3/MS3 ions were determined using direct infusion of a tryptically digested
peanut extract prepared as described previously (page 80). A total amount of 30 µg
peanut protein were digested, and re-suspended to a concentration of 0.5 µg/µL prior to
infusion. The digested peanut sample was infused at a rate of 20 µL/min. This flow rate
provided suitable detection of all MRM transitions.
Selection of MRM3 product ions, or tertiary fragment ions, was determined by
evaluating parent ions (MS1) used in MRM experiments. The determination of MRM3
transitions is an iterative process and must be determined experimentally using the
MRM3 Optimization Script within the instrument software, Analyst.
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For each individual peptide, the parent (MS1) ion m/z was input into the MS3
Optimization Script. MS1 ion selection settings were set with an ion mass tolerance of
±2 Da, a scan rate of 1,000 Da/sec, and the MS1 must not be below 10% of the total ion
current, using an Enhanced Resolution (ER) scan. DP is determined during the Q1
Multiple Ion scan using a ramp from 0 – 100 V, with increment measurements of 5 V.
The Enhanced Product Ion (EPI) scans for MS2 selection recorded the top-5 MS2
product ions, at a scan rate of 1,000 Da/sec, mass range of 225 – 1,000 m/z, CE set at 40,
with a collisional energy spread (CES) set to 25. MS/MS/MS (MS3) scan rate was set to
1,000 Da/sec, with Q0 trapping, a fixed fill time of 100 ms, and a mass range of 100 to
1000 m/z. The optimized MS2 excitation energy (AF2) are determined within the MS3
Script. All stages of ion selection are performed iteratively with continuous infusion of
the peanut sample (20 µL/min).
Identification of secondary product ions (MS3) was difficult for many peptides.
In order to have multiple peptide targets for MRM3, we investigated using nonfragmented MS2 peptide ions as MS3 targets. To do so, the MS2 m/z value was input for
both the MS2 and MS3 m/z’s.

MRM3 Cycle Time Optimization
During an MRM3 method, scheduling is not possible within the software. To
circumvent this problem, we divided our experiment into eight periods, wherein scans for
each respective target occurred within a defined period. Without scheduling, the method
has high cycle times, greatly impacting sensitivity.
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MRM3 Peptide Target Selection
MS3 fragmentation spectra of tertiary product ions will be recorded and assessed
manually. For inclusion as an MRM3 target, the ions must have good signal intensity, yor b-ion(s) originating from MS2 fragment ion sequence, and absent from non-specific
MS3 fragmentation events (e.g. loss of NH3 or H2O ions) (Korte and Brockmeyer, 2016).
The LOD was assessed in a qualitative manner by observing lack of transition detection,
shifts in retention time, and poor peak shape.

MRM3 Method Evaluation
The selected tertiary product ions were evaluated for uniqueness against our
model analytical samples, sera, peanut, and sera-peanut. The LOD for MRM3 was
performed as previously described using two dilution series of (a) peanut and (b) serapeanut, according to Table 3-2. The chromatographic separation of peptides is unaffected
by the implementation of a second stage MS fragmentation, and no changes were made to
the chromatographic settings. Peptide scheduling will be added for MRM3 acquisitions
to achieve decreased cycle times. MRM3 data were analyzed by Analyst software.
Skyline software is incompatible for analysis of MRM3 data files, due to the addition of
an ion trap scan for MRM3 detection.
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Evaluation of Subject Serum Samples by MRM and MRM3
We evaluated subject samples previously determined positive by Ara h 6 specific
sandwich ELISA (JanssenDuijghuijsen et al., 2017b) using our developed MRM and
MRM3 methods. We evaluated two subject sera at baseline (0 hour) and their highest
measured two selected time points, 60 and 120 minutes. Complete ELISA results and
subject characteristics are described in the original publication. A positive control (blank
subject sera-peanut 100:1 (w/w)), was prepared. Following each analytical sample, a
blank sample consisting of re-suspension solution was injected. We performed this
experiment twice, on two separate occasions. The subject serum was collected from
healthy individuals who regularly consume peanuts and are not allergic to peanuts
(JanssenDuijghuijsen et al., 2017b).

Optimization of High-Resolution PRM Acquisitions
Following investigations of multiple targeted methods, PRM, MRM, and MRM3,
we re-investigated the use of high-resolution PRM methods. Due to the specificity
required for detection of low abundance serum-proteins, we anticipate the need for highresolution acquisitions. Confirmation using MRM and MRM3 methods was
unconvincing, even though peanut specific transitions were monitored. Likely, the
potential number of interfering serum ions factored into this lack of detection. We have
approached this section in the same manner as previously described targeted methods.
Our aim was to analyze the maximum level of protein for detection of peanut proteins in
sera using the previously developed PRM method. We calculated the amount of serum
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necessary to achieve detection, based on the calibration curves from initial PRM studies
and estimated concentrations of peanut in serum from JanssenDuijghuijsen et al., 2017b.
Serum used in this set of experiments was collected and analyzed using ELISA by
JanssenDuijghuijsen et al., 2017b. Blood was collected from patients into serum
separator tubes at the define time points following ingestion (30, 60, 120, 240, 360
minutes). Collected blood was allowed to clot (room temperature, 20 minutes, in the
dark), followed by centrifugation (2000 x g, 10 minutes, room temperature), ultimately
producing serum. Serum was stored at -80°C (JanssenDuijghuijsen et al., 2017b).

Evaluation of Large Scale Digestion Methodology
We prepared a larger volume (45 µL) of our model matrix, non-depleted
commercial serum (MP Biomedicals) with peanut extract (50:1 (w/w)) for LC-MS/MS
analysis. Commercial serum was initially used to evaluate the optimal amount of
digested protein to be injected and separated on the liquid chromatography column.
To accommodate the increased amount of digested protein, we modified the
previously developed in-solution trypsin digestion procedures from Chapter 2 (page 80).
Commercial and subject (baseline) serum (80 µg/µL) were diluted (45 µL) to 10 µg/µL
with acetonitrile and water to achieve a final concentration of 5% acetonitrile at the end
of digestion. Samples were mixed with ammonium bicarbonate (50 mM) and reduced by
adding dithiothreitol (100 mM), followed by heating at 95°C for either, (A) 5 minutes or
(B) 20 minutes. Alkylation was performed with iodoacetamide (100 mM) at room
temperature in the dark for 20 minutes. Trypsin (Pierce™ Trypsin Protease, MS Grade,

164
90057) was added at two enzyme:protein ratios, either 1:50 or 1:100 (w/w)
enzyme:protein. Trypsin (1 µg/µL in 5 mM acetic acid) was added to reduced and
alkylated protein samples, and allowed to digest for 3 hours at 37°C. A second addition
of trypsin was added, resulting in a final enzyme:protein ratio of 1:50 or 1:100 (w/w),
respectively, and incubated overnight at 30°C. The digestion was stopped by freezing
samples. The remaining tryptic digests were de-salted using Strata-X 33 µm polymeric
reversed phase 10 mg/1 mL columns (Phenomenex, Aschaffenburg, Germany). Columns
were conditioned with 100 % methanol and equilibrated with 5% acetonitrile, 0.1%
formic acid. Digested peptides were loaded into equilibrated columns and washed twice
with 5% acetonitrile and 0.1% formic acid. Peptides were eluted from columns by 70%
methanol, 0.1% formic acid (500 µL). The elution step was repeated once. De-salted
peptides were dried under vacuum by centrifugal evaporation Jouan RC-10.10; RCT-90;
Winchester, VA, USA. Peptides were re-suspended to 80 µg/µL in 5% acetonitrile, 0.1%
formic acid. Modified digestion and reduction procedures were evaluated by SDSPAGE.

SDS-PAGE Evaluation of Digestion Methodology
Samples for SDS-PAGE were taken at various time points, 0, 3, 18, and 24 hours,
and after de-salting and re-suspension procedures. SDS-PAGE was conducted under
reducing conditions using NuPAGE Bis-Tris Mini Gels 4-12% (1.0 mm, 12 wells) and
constant voltage (200V) for 40 minutes in an XCell SureLock Mini Cell Electrophoresis
System (Invitrogen Life Technologies). Non-digested serum (e.g. control) was diluted
22-fold prior to SDS-PAGE sample preparation, to a concentration of 3.6 µg/µL.
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Aliquots taken during digestion, diluted control serum (10 µL), and re-suspended peptide
digests after de-salting (12 µL) were combined with 4 x concentrated Laemmli buffer and
1% β-mercapto-ethanol (BME). Due to peptide re-suspension following de-salting and
solvent evaporation, different volumes were required to maintain equal protein loading of
each sample. Reduction occurred by heating all samples for 5 minutes at 95°C. Samples
(10 µL) were loaded into each gel well. Precision Plus Protein Dual Xtra Standards (BioRad) were used as the molecular weight (MW) standard. Gels were stained, overnight, in
Coomassie Brilliant Blue R-250 (Bio-Rad) stain. Gels were then de-stained (Coomassie
Brilliant Blue R-250 Destaining solution, Bio-Rad), rehydrated, and imaged.

Evaluation of Protein Loading by PRM
The following section describes the optimized in-solution trypsin digestion
procedure from our previous evaluations. Commercial serum (80 µg/µL) was combined
with raw peanut extract (50:1 (w/w)). The matrix samples, sera-peanut (45 µL), were
diluted to 10 µg/µL with acetonitrile:water achieving a final concentration of 5%
acetonitrile at the end of digestion. Samples were digested and de-salted as previously
described (page 163) using a longer incubation time for reduction (95°C for 20 minutes)
and a 1:100 (w/w) enzyme:protein ratio. A third aliquot of trypsin, at equal volume to
previous trypsin aliquots, was added following overnight digestion to insure complete
protein digestion, resulting in a final 1:67 final enzyme:protein ratio. Samples were
incubated at 30°C for 3 hours following the third addition of trypsin. Following desalting, peptides were re-suspended into two separate volumes of 5% acetonitrile, 0.1%
formic acid to a final concentration of either (A) 11.5 µg/µL or (B) 52.4 µg/µL, ranging
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from 11 – 1100 µg protein, chromatographically separated, and evaluated by PRM. PRM
method is described in detail below. Injections were performed in increasing order of
protein, and a blank sample (5% acetonitrile, 0.1% formic acid) was injected between
analytical samples.
We optimized the amount of protein loading primarily at two protein load levels,
first, at 600 µg with Sigma sera and subject serum collected by JanssenDuijghuijsen et
al., 2017b. We secondly evaluated a higher protein load up to 3000 µg with baseline
subject serum.
Then, we evaluated active subject serum at baseline and selected time points
(baseline (0), 30 60, 120, 240, 360 minutes) were evaluated using the same sample
preparation parameters, the retention times and loop count were adjusted according to the
amount of protein loaded.
At each of these protein levels, we evaluated serum collected at all time points
(baseline, 30, 60, 120, 240, and 360 minutes) collected by JanssenDuijghuijsen et al.,
2017b. At the higher amounts of protein injected, we monitored column pressures during
chromatography and blank injection cleaning methods.

LC-MS/MS Analysis of Increased Protein Loading by PRM
Peptide digests were chromatographically separated using an UltiMate 3000RSL®
liquid chromatography (UPLC) system (Thermo ScientificTM) equipped with a Hypersil
Gold C18 1.9 μm, 100 x 2.1 mm, 1.9 µm reversed phase column (Thermo ScientificTM)
attached with an in-line filter cartridge (1 mm ID, 0.2 μm) (Thermo Scientific™), and a
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column oven temperature maintained at 35°C. Mobile phases were as follows, (A) 0.1%
(v/v) formic acid in water, (B) 0.1% (v/v) formic acid in acetonitrile, (C) 1:1:1:1
acetonitrile, isopropanol, methanol, water, and (D) was 100% methanol.
The separation column was equilibrated at 7.5% mobile phase B for 7.5 minutes.
Peptides were separated using a linear gradient of 7.5 – 25% mobile phase B over 20
minutes at a flow rate of 300 µL/min. Following the gradient elution, the column was
washed using the same flow rate for 3 minutes at 98% mobile phase B, followed by
100% mobile phase D for 3 minutes. The separation column was re-equilibrated for 4
minutes.
The total protein load was evaluated using the optimized PRM method as
previously described, using the same equipment and instrumentation. However, in these
experiments, the javelin and pre-column were replaced with an inline filter cartridge. In
summary, peptides were separated using a Hypersil GOLD Vanquish (100 x 2.1 mm, 1.9
μm particle) (Thermo Scientific™) separation column with an inline filter cartridge (1
mm ID, 0.2 μm) (Thermo Scientific™). Peptide retention times were input to the
inclusion list, and monitored for stability after each protein level injection. If peptide
retention times demonstrated shifts, the retention time windows were adjusted iteratively.
The column pressures were monitored during both chromatographic separation,
blank injections, and cleaning methods in all higher protein injections.
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Data Analysis of Optimized PRM Methodology
Peanut peptide detection was evaluated for intensity and retention time stability.
Shifts in retention time due to protein load were recorded and evaluated in Skyline
(Maclean et al., 2010).

Evaluation of Subject Serum Samples with Higher Protein Loads
We evaluated subject samples previously determined positive by Ara h 6 specific
sandwich ELISA (JanssenDuijghuijsen et al., 2017b) using our developed MRM and
MRM3 methods. Subject serum numbers 2 and 7, as identified in the original manuscript,
were selected for PRM evaluation, but hereafter, the sera samples are referred to as
subject sera 1 and 2, respectively. The evaluated sera included the baseline (0 minutes)
and their highest measured absorption time points, 60 and 120 minutes. ELISA results
and subject characteristics are described in the original publication (JanssenDuijghuijsen
et al., 2017b).
Subject sera (40 µL) were enzymatically digested and de-salted as previously
described (page 163). Peptides were re-suspended to 30 µg/µL in 7.5% acetonitrile,
0.1% formic acid in water. Each digest was injected (20 µL) in duplicate and analyzed
using the optimized PRM method as previously described (page 162) and analyzed by
Skyline using the same analysis parameters (page 154)
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Optimization of Chromatography Methodology for Higher Protein Loads
Due to the increased protein requiring chromatographic separation, more robust
cleaning procedures were required. Two column wash methods were injected after each
analytical sample. The first column wash method consisted of an isocratic flow of 100%
mobile phase C (1:1:1:1: methanol:acetonitrile:isopropanol:water) (300 µL/min) for 20
minutes.
The second wash phase utilized the same mobile phases as previously described
(page 81). The column was equilibrated (300 µL/min) for 7.5 minutes at 7.5% mobile
phase B, followed by a linear gradient from 7.5 to 98% mobile phase B. Mobile phase B
was maintained at 98% for 8 minutes. The column was washed (300 µL/min) with 100%
mobile phase C for 5 minutes, followed by 100% mobile phase D (300 µl/min) for 5
minutes. The column was re-equilibrated (300 µl/min) at 7.5% mobile phase B for 12
minutes.

Multiple Injections
In order to load higher amounts of protein on the liquid chromatography column,
we needed to maintain a consistent concentration of re-suspended peptides prior to
analysis by LC-MS/MS. To do so, the peptide concentration was maintained at < 20
µg/µL, and, we injected each sample multiple times to achieve the desired amount or
protein load. Baseline subject serum was combined with peanut extract (50:1 (w/w)) to
monitor protein loading. Other key parameters monitored included chromatographic
pressures during samples and blank injections, protein recovery, transition ratios, and
peptide retention time stability.
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Multiple, repeated injections of a single peptide sample were injected for
chromatographic separation. The column flow was maintained at the equilibration
settings until all protein was successfully injected onto the column. Once all injections
were performed, the chromatographic gradient began. Individual injection methods were
written in order to load protein on column before beginning chromatographic elution.
The same, previously described mobile phases, were used (page 169). The column
loading injection methods included injection parameters and an isocratic solvent flow
(7.5% mobile phase B). The final injection included the parameters for chromatographic
elution and MS acquisition. Optimized loop count and retention times for increased
protein loading were used. After each analytical sample injection (i.e. serum sample), the
column was cleaned by injections of blank samples (mobile phase C) using the optimized
column cleaning methods described above.

Serum Time Course Evaluation using Multiple Injections and Heavy
Labeled Peptides
We ultimately evaluated the subject sera (JanssenDuijghuijsen et al., 2017b)
samples which we determined were positive. The ten selected peanut peptide targets,
with their corresponding heavy peptides, were monitored by PRM LC-MS/MS. AQUA
peptide standards (Thermo Scientific™) were synthesized with a heavy isotope labeled
13

C(6)15N(4) C-terminal arginine or 13C15N(2) C-terminal lysine with

carbamidomethylation (+57.02 Da) of cysteine residues. Peptides were synthesized to
97% purity, as determined by LC-MS/MS.

171
Peptide concentration was determined by calculating the heavy to light ratios of
peptide peak areas.

Subject Serum Injections with Heavy Peptides for Quantification
Subject sera 1 and 2, (JanssenDuijghuijsen et al., 2017b) were analyzed (600 µg)
or (2800 µg) using the multiple injection protocol and PRM acquisition with heavy
peptides. The loop count was modified for inclusion of heavy peptides. We additionally
evaluated multiple injections for recovery of heavy peptides. A mix of heavy labeled
peptides were prepared in an equimolar manner. Heavy peptides were injected (8 µL) to
achieve 100 fmol (12.5 fmol/µL individual heavy peptide) of each heavy peptide for LCMS/MS evaluation. The previously described chromatographic wash methods were
included after each sample injection (page 169).

Data Analysis
All data were analyzed using Skyline v 20 (Maclean et al., 2010) (page 154), as
previoulsy described.

RESULTS AND DISCUSSION

Discovery Identification of Peanut Peptide Targets
The identification of unique peanut peptides from discovery mass spectra allowed
us to generate a list of candidate peptides. This list of candidate peptides was further
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refined in subsequent developmental phases. Peptides identified as candidate peptide
targets met the criteria described in the methods section (page 150). In total, 52
candidate peptides were identified from discovery data, representing each major
allergenic protein family (Figure 3-1). We identified 20 – Ara h 1 peptides, 6 – Ara h 2
peptides, 19 – Ara h 3 peptides, and 7 – Ara h 6 peptides. The variation in number of
peptides per protein detected are as anticipated. The prolamin proteins, Ara h 2 and Ara
h 6, have much shorter protein sequences than the cupins, Ara h 1 and Ara h 3. As such,
we would expect few unique peanut peptides to be detected in the shorter protein
sequences, Ara h 2 and Ara h 6.

Figure 3-1. The relative abundance of the top peanut peptide targets
identified by discovery LC-MS/MS.
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By selecting peptide targets using an experimental workflow, we were able to
confirm the presence of target peptides in a sample matrix, an advantage over in silico
peptide selections. Similar workflows using discovery MS for peptide identification for
monitoring in targeted acquisitions (e.g. PRM, MRM) has been successfully reported by
other investigators (von Bargen et al., 2013; Korte et al., 2016a; Korte et al., 2016b).
Peanuts are typically consumed after roasting, a process known to induce protein
aggregation, particularly for Ara h 1 (Koppelman et al., 1999; Schmitt et al., 2010). The
heating induced aggregation reduces protein solubility and consequently, overall
extractability (Koppelman et al., 1999; Schmitt et al., 2010). As a result of reduced
solubility, these aggregated proteins are not efficiently extracted in saline buffer.
However, these proteins remain present in the food matrix and are exposed to the
immune system after digestion alongside other peanut proteins. To identify all potential
unique peanut allergens, all proteins should therefore be included in peptide selections.
By using a raw peanut extract, we were able to identify unique Ara h 1 peptides alongside
other major allergenic peanut peptides. The incurred matrix (serum-peanut) was prepared
at high concentrations of peanut, concentrations greater than the expected in vivo levels,
to ensure uniqueness of selected peanut peptides in a serum matrix background. It is
critical to evaluate each matrix component individually (peanut, serum) as well as in the
presence of a matrix background, to eliminate any co-eluting peptide events which may
be produced in matrix combination. Secondly, we have chosen to use commercially
available human serum as a representative of healthy human adults, which is ultimately
our final sample population.
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PRM
The peptide targets identified in discovery were verified in a targeted PRM
method, to confirm their detectability. The same samples were analyzed, and the peptide
acceptance criteria were unchanged. After peptide evaluation using PRM acquisition, we
reduced our number of targets to 26 peptides. The chromatographic gradient was
modified to improve peptide separation and detection. We modified the organic:aqueous
solvent gradient by adjusting the total percentage aqueous solvent throughout the course
of the run. The time of the gradient was modified, affecting the overall slope. In cases
where some peptides were not able to be adequately separated, the peptides with the
highest abundance were retained for further evaluations. After chromatographic
optimizations, we ultimately selected 13 peanut peptide targets, 4 – Ara h 1, 1 – Ara h 2,
4 – Ara h 3, and 3 – Ara h 6 peptides were selected. The optimal retention times were
determined and included during PRM acquisitions for the 12 selected peptides (Figure 32).
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Figure 3-2. Relative abundance of the selected twelve
peanut peptides by PRM detection at 0.80 ng peanut
protein in a sera-peanut model matrix.
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A dilution series of peanut peptides in sera background (sera-peanut) were
evaluated by the optimized PRM method and 12 selected peptides (Table 3-3). The best
peptide for each protein (Ara h 1, Ara h 2, Ara h 3, Ara h 6) are described in Figure 3-3.
Each individual dilution curves is located in Supplementary Figures 3-1 to 3-9. Each
sample contained the same amount of serum protein and decreasing amounts of peanut
protein (Table 3-1). The dilution series reported detection of all 12 peptides, with a
minimum of three transitions per peptide. We were able to detect 0.80 ng peanut protein
using the PRM method in a serum matrix (790 ng serum protein) (Figure 3-2). In the
dilution series of peanut, lower limits of detection were observed in the peanut only
matrix, than when in a non-depleted sera matrix.
Table 3-4 lists the individual limit of detection for each peptide. Protein
composition values were determined by Koppelman et al., 2016, and were used here to
convert total peanut protein to specific peanut protein (e.g. Ara h 1). Based on the
published data, we estimated the total protein composition at 18% Ara h 1, 6% Ara h 2,
70% Ara h 3, and 6% Ara h 6 (Koppelman et al., 2016).
In a comparison of the peanut and sera-peanut matrices, the limit of detection was
generally lower in the sera-peanut matrix for most peptides. One Ara h 1 peptide had a
lower detection limit in peanut alone. Only this one peptide had a lower detection limit
in peanut alone.
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Figure 3-3. Relative abundance of the top three summed transitions for the
best performing peptide(s) of (A) Ara h 1, (B) Ara h 2, (C) Ara h 3, (D) Ara h
6 peptides, as detected by PRM, at decreasing quantities of peanut protein in a
constant amount of serum. Blue lines represent sera-peanut, where sera
remains unchanged. Black lines represent peanut only, in the absence of a
sera background.
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Peptide
Protein
Peptide
Reference
Name
Ara h 1 GTGNLELVAVR
GTGN
NNPFYFPSR
NNPF
DLAFPGSGEQVEK DLAF
EGALMLPHFNSK
EGAL
Ara h 2 NLPQQCGLR
NLPQ
Ara h 3 TANDLNLLILR
TAND
SPDIYNPQAGSLK SPDI
QIVQNLR
QIVQ
AHVQVVDSNGNR AHVQ
WLGLSAEYGNLYR WLGL
Ara h 6 CDLDVSGGR
CDLD
ELMNLPQQCNFR ELMN
VNLKPCEQHIMQR VNLK

m/z

RT

564.8222++
571.2749++
688.8383++
448.5641+++
543.2797++
628.3721++
695.3541++
435.7614++
432.5532+++
771.3910++
489.7191++
775.3661++
413.9644++++

23.3
23.5
20.5
15.5
17.2
26.0
20.8
17.6
13.9
24.9
16.6
23.2
18.7

Table 3-3. Peanut peptides evaluated by PRM.

Table 3-4. Detection limit of individual peanut peptides by
PRM.
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In the sera-peanut matrix, Ara h 3 was consistently detectable at 280 pg Ara h 3
(400 pg peanut protein). In the sera-peanut matrix, Ara h 2 had a lower detection limit of
24 pg Ara h 2 (400 pg peanut protein). Ara h 6 had a lower detection limit in the serapeanut matrix of 47.4 pg Ara h 6 (790 pg total peanut protein).
The overall limit of detection for all peptides was concluded to be 790 pg peanut
protein, which is equivalent to 1.0 ppm peanut protein (4.0 ppm total peanut) for the
PRM method.

MRM
The MRM settings were optimized for peptide detection and are described in the
materials and methods section. The top six transitions reported in the PRM evaluations
in both peanut and sera-peanut were evaluated for initial detection by MRM. Transitions
were not scheduled during this initial evaluation. We determined the four best transitions
for each peptide for the MRM method.
The CE for each peptide, a key fragmentation setting, was first determined by
evaluating the relative abundance reported by the selected top four peptide transitions by
MRM. This is typically performed using heavy peptides and direct infusion, however
due to the uncertainty of our peptide status following gastric digestion, we evaluated the
CE using our model samples (peanut, sera-peanut).
Following transition selection and retention time determinations, we evaluated the
detection limit for MRM. Figure 3-6 and Table 3-5 demonstrate the peptide LODs for
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MRM. Not all peptides included in the PRM method were suitable for MRM analysis,
therefore fewer peptides were evaluated by MRM. In our final method, we were able to
detect 4 – Ara h 1, 1 – Ara h 2, 4 – Ara h 3, and 1 – Ara h 6 peptides. The peptides
QIVQ, VNLK, CDLD were not detectable by the MRM method. The peptides, (QIVQ,
CDLD), exhibited poor linearity and relative abundance during PRM method
development.
Peptides, and their transitions, included in the MRM LOD evaluations are
described in Table 3-6. We monitored a minimum of two transitions per peptide in this
evaluation. In general, the detection limits were relatively similar to the PRM detection
limits. Similarly, in the sera-peanut matrix, generally equal or lower limits of detection
were observed for nearly all peptides. The best performing peptides were Ara h 2
(NLPQ) and Ara h 6 (ELMN) with detection at 15 pg Ara h 2 or 74.4 pg Ara h 6.
One Ara h 3 peptide (WLGL) had a noticeably higher (13100 pg Ara h 3)
detection limit in the peanut only matrix for two of its five identified transitions (Table 37). Since there are five identified transitions for this peptide, these transitions can be
removed from the method. Interestingly, when in the sera-peanut matrix, this peptide
(WLGL) exhibits detection at 2600 pg Ara h 3, demonstrating an increased solubility in a
serum matrix, observed in both PRM and MRM acquisitions. Since serum is ultimately
the anticipated background matrix, we chose to include this peptide for evaluations.
Figure 3-4 describes the relative abundance of serially diluted peanut in the
presence and absence of a sera matrix, as detected by MRM. Overall, each transition was
detected similarly in both matrices and exhibited linearity over the course of the dilution
series.
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Protein

pg peanut protein LOD

Ara h 1
Ara h 2
Ara h 3
Ara h 6

1240
1240
3730
1240

ppm peanut protein
LOD
1.53
1.53
4.58
1.53

ppm peanut
LOD
6.11
6.11
18.3
6.11

Table 3-5. MRM detection limit table determined by the dilution series.

Table 3-6. MRM peptide transitions, parent and fragment ion m/z.
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Figure 3-4. Relative abundance of (A) Ara h 1, (B) Ara h 2, (C) Ara h 3, (D) Ara h 6
peptides, as detected by MRM, at decreasing quantities of peanut protein in a constant
amount of serum. Each colored line represents individual transitions for a given peanut
protein. Solid lines represent sera-peanut matrix, dashed lines represent peanut matrix,
in the absence of sera background.

Table 3-7. Detection limit of individual peanut peptides by MRM.
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MRM3
Many of the MS2 peptide fragments had non-specific mass losses, largely
attributed to –NH3 or –H2O losses. To provide the most sensitive detection method, we
enabled Q0 trapping. Interestingly, a peptide that produces a good MS2 fragment is not
always able to fragment again, producing secondary fragment ions, MS3 ions. Product
ions were manually evaluated against a predicted fragment masses derived from each
MS2 peptide. MRM3 transitions were determined using an automated script available in
Analyst. The top five resulting product ions were evaluated for fragmentation patterns.
We were able to identify six true MS3 fragment ions from Ara h 1, Ara h 2, and Ara h 3.
No MS3 ions were identified from Ara h 6. These ion fragments are considered ‘true
MS3’ targets, as they did not have any non-specific mass losses (e.g. –NH3, –H2O).
Due to the challenge of identifying ‘true MS3’ fragments, we assessed ion
detection without the additional fragmentation step, but rather, used the non-fragmented
m/z again for detection by MRM3 in the linear ion trap of the third quadrupole. Using
this approach, we were able to detect all peptides included in the MRM method. With the
combination of both non-fragmented peptides and MS3 fragmented (‘true’) peptides, we
were able to generate an MRM3 method for all major allergenic peanut proteins (Table 38). We included 18 non-fragmented peptide transitions in the MRM3 methodology
(Table 3-8). In total, 24 peptide transitions were included in the final MRM3
methodology (Table 3-8). In order to keep cycle times low, we divided the MRM3
acquisition method into eight periods. Without dividing the method into eight periods,
the cycle time for all the MRM3 transitions would have been very long and reducing
overall ion detection.
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Table 3-8. MS3 peanut peptide targets for monitoring.

We evaluated the dilution series of the MRM3 method using the same dilutions as
described in the MRM method. As depicted in Figure 3-5, peptides were more readily
detected in the sera-peanut matrix, than in peanut alone. These results are consistent with
previous dilution series’ results (PRM, MRM). The dilution series was performed using
all 24 identified targets.
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For certain peptides, there was a distinct difference in the reported abundances
among transitions. The limit of detection results were highly variable using the MRM3
method, with some peptides performing much better than others. Figure 3-5
demonstrates detection of serially diluted peanut in the presence and absence of serum.
The prolamin peptides, Ara h 2 (NLPQ) and Ara h 6 (ELMN) exhibited low levels of
detection at 1.8 – 74 pg Ara h 2 and 45 pg Ara h 6 (Figure 3-5 B and D, respectively).
The best performing Ara h 3 peptide (SPDI) ranged from 21 – 525 pg Ara h 3 (Figure 3-5
C). We observed a lack of linearity in some MRM3 analyzed peanut peptides, indicating
these peptides may not be suitable as MRM3 targets. The Ara h 3 peptide, SPDI,
demonstrates high linearity and suitably sensitive detection. Contrastingly, a different
Ara h 3 peptide, TAND exhibited poor linearity, and was less sensitive than SPDI (Figure
3-5 C).
Determination of true MS3 fragments was challenging due to the lack of tertiary
product ions. Some MS2 peptide targets fragmented more readily than other peptides.
As such, peptides which make excellent MS2 targets, are not always suitable MS3
targets.
In summary, we observed no consistent LOD measurements between peptides of
the same protein family. However, the Ara h 3 peptide, SPDI, exhibited sufficient
sensitivity and linearity with its true MS3 peptide fragment ions. We were able to detect
30 pg peanut protein by this peptide, equivalent to 0.04 ppm peanut protein (0.15 ppm
peanut). It is critical to note this observed sensitivity was in a prepared model matrix. If
this peptide exists in serum following gastric digestion, it would be a suitable target for
low detection monitoring. Furthermore, peanut peptides which have previous in vivo
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peanut protein detections have been accomplished by ELISA’s targeting the prolamins,
Ara h 2 and Ara h 6, which are known to remain partially intact following digestion.

189

Figure 3-5. Relative abundance of (A) Ara h 1, (B) Ara h 2, (C) Ara h 3,
(D) Ara h 6 peptides, as detected by MRM3, at decreasing quantities of
peanut protein in a constant amount of serum. Each colored line represents
individual transitions for a given peanut protein. Solid lines represent serapeanut matrix, dashed lines represent peanut matrix, in the absence of sera
background.
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To assess any potential differences between MRM3 peptide transitions, we
evaluated the ‘true MS3’ fragments only using our optimized methodology (Figure 3-6).
The results do not show any improvements in overall detection compared to the MRM
method. The Ara h 2 peptide, NLPQ, and the Ara h 3 peptide, SPDI, both demonstrate
good linearity and similar detection in both peanut and sera-peanut matrices. In
comparison to the acquisition method which included both ‘true MS3’ fragment ions and
the non-fragmented MS2 ions, this analysis using only the ‘true MS3’ ions showed no
improvements in peptide detection.
However, the limit of detection does not show any improvements, therefore using
the ‘true’ secondary peptide fragments may not be a suitable method for low detection of
peanut proteins in serum.
Overall, for the MRM3 acquisitions, detection of non-fragmented MS2 transitions
was more successful than detection of secondary fragment ions (MS3) in the model serapeanut matrices.
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Figure 3-6. Relative abundance of the dilution series while monitoring
true secondary fragment ions (MS3 ions).

Evaluation of Subject Sera Samples by MRM and MRM3
Subject sera samples (serum 1, serum 2) at baseline (0 minutes) and selected time
points (60, 120 minutes) were evaluated using MRM and MRM3 methods. We evaluated
two individual subjects (JanssenDuijghuijsen et al., 2017b), determined previously
positive by an Ara h 6 ELISA. In this experiment, we injected 600 µg total protein for
evaluation. However, no positive peanut detections were made in subject serum by either
MRM or MRM3.
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One key problem with these evaluations was the use of commercially prepared
serum. Commercial serum is prepared from a pool of subject serum which has been
passed through a 0.1 micron filter and sterilized. Commercially prepared serum is likely
slightly less concentrated than a single subject serum, and as a result, the subject serum
samples exhibit a lower signal-to-noise ratio due to poor peak isolation.
Another key issue impacting these experimental results was the individual
dilution of serum and raw peanut extract prior to enzymatic digestion for LC-MS/MS
analysis. By diluting the analytical matrix components, this may ultimately be less
representative of serum following the consumption of peanut. Although we observed
LODs for the MRM and some MRM3 peptides to previously published ELISA results
(JanssenDuijghuijsen et al., 2017b), we were unable to replicate these results using our
current methodology.

Optimization of High-Resolution PRM
In order to load more protein for LC-MS/MS analysis, we optimized the reduction
and trypsin (digestive enzyme) concentrations. We increased the reduction incubation
time to 20 minutes. We simultaneously evaluated the trypsin concentration at
enzyme:substrate ratios of 1:50 and 1:100 (w/w).
In our final method, we were able to detect ten peptides robustly including, 4 –
Ara h 1, 1 – Ara h 2, 4 – Ara h 3, 2 – Ara h 6 peptides. The peptides QIVQ, CDLD were
poorly detected in the previous PRM study, and not detectable by MRM, therefore we
chose to remove them from our methodology.
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The experiments described within this section were conducted using a sera-peanut
matrix prepared with subject serum as it is the most representative preparation material
for evaluating experimental conditions since it has not been filter sterilized. For all serapeanut model matrices prepared for evaluations in the following sections, we used
baseline subject serum.
SDS-PAGE indicated the current digestion protocol is sufficient for digestion of
serum proteins (Figure 3-7). Secondly, the SDS-PAGE demonstrates, the modified
digestions were also suitable for digestion procedures. Numerous peptides were
visualized <10 kDa, and a majority of these peptides gradually decreased in intensity
after 24 hours of digestion. To conserve trypsin, we opted to use the 1:100 w/w ratio,
since no differences in overall digestion patterns were observed by SDS-PAGE.

Figure 3-7. SDS-PAGE evaluation of modified protein reduction and trypsin digestion procedures. Each
panel represents different experiment conditions (A) 1:50 (w/w) enzyme:substrate ratio with 5 minute
reduction at 95°C; (B) 1:50 (w/w) enzyme:substrate ratio with 20 minutes reduction at 95°C; (C) 1:100
(w/w) enzyme:substrate ratio with 20 minutes reduction at 95°C. Lanes 3, 4, and 5 represent digestion
aliquots taken at 3, 8, and 24 hours.
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Evaluation of Protein Loading for analysis by PRM
In this series of experiments, we reduced the number of PRM targets to the 10
best performing peptides, which are readily detectable and able to be separated
chromatographically into distinct peaks (Table 3-9).
Protein
Ara h 1
Ara h 1
Ara h 1
Ara h 1
Ara h 2
Ara h 3
Ara h 3
Ara h 3
Ara h 6
Ara h 6

Peptide
DLAFPGSGEQVEK
GTGNLELVAVR
NNPFYFPSR
EGALMLPHFNSK
NLPQQCGLR
SPDIYNPQAGSLK
WLGLSAEYGNLYR
TANDLNLLILR
VNLKPCEQHIMQR
ELMNLPQQCNFR

m/z
688.8383++
564.8222++
571.2749++
448.5641+++
543.2737++
695.3541++
771.3910++
628.3721++
413.9644++++
775.3661++

Table 3-9. PRM peptide targets monitored with increased
protein loading.

In our optimized PRM methodology and acquisition settings, we changed the
chromatographic column to a larger column (100 x 2.1 mm, 1.9 um) to facilitate
increased protein loading.
We first evaluated a protein load of 600 µg for detection of peanut peptides in
serum. In our preliminary studies, we determined 600 µg of protein was suitable for
loading due to stable peptide retention times and peak area recovery. Beyond a 600 µg
protein load, we observed greater shifts in retention times. Figure 3-8 demonstrates
peanut peak area of the top 3 abundant peptide transitions per each increasing amount of
protein injected.
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Figure 3-8. Peak area of top 3 transitions per peptide for each amount of
protein evaluated; each major allergenic peanut proteins are represented.
(A) Ara h 1, DLAF; (B) Ara h 2, NLPQ; (C) Ara h 3 SPDI; (D) Ara h 6,
ELMN.
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Evaluation of Subject Samples with an Increased Protein Load
Two subject sera (serum 1, serum 2), at baseline, 60, and 120 minutes, were
evaluated at a 600 µg load for PRM analysis. The experiment was performed twice, on
two separate occasions. A positive control, (blank subject sera-peanut 100:1 (w/w)), was
additionally evaluated.
We observed detection of peanut proteins in subject 1 at 60 minutes postconsumption, in both individual analytical injections by PRM with a 600 µg total protein
load. We detected four peanut peptides (SPDI, VNLK, WLGL, TAND), with four
detectable transitions for SPDI, VNLK, WLGL and four detectable transitions for TAND
(Figure 3-9; Supplementary Table 3-1). The peptide elution times and fragment ion
tolerance values were within the acceptance criteria.
We also observed detection of peanut proteins in subject 2 at 120 minutes in both
individual analytical injections. The same peptides (SPDI, VNLK, WLGL, TAND)
detected in subject serum 1 (60 minutes) were also detected in subject serum 2 (120
minutes). For all detected peptides, five transitions were observed, except for VNLK,
which had four detectable transitions. The peptide elution times and fragment ion
tolerance values were within the acceptance criteria.
The peptide transition ratios are illustrated in Figure 3-9. The same peptide
transitions were detected in each individual subject serum at two time points. We
detected between 5-8 points across the peaks. Although, it is preferred to have
approximately 10-15 points across the peak for quantification, this was convincing
evidence of peanut peptide detection in serum. Since we did not evaluate these samples
with a peptide standard, we are unable to accurately quantify the amount of peanut
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protein detected. Further, we were able to detect multiple peptides from different
proteins, strengthening the evidence that these proteins remain detectable in vivo.
One additional key factor which must be taken into consideration is the serum
was collected from healthy subjects. The rate of uptake of allergenic food proteins is
suggested to differ between sensitized and non-sensitized individuals (Reitsma et al.,
2014; Samadi et al., 2018).
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The QExactive+ offers high mass accuracy detection of fragment ions, which is
beneficial in detection of low abundant peptides (Domon and Aebersold, 2010; Gallien et
al., 2013).
We then evaluated the entire time course (0, 30, 60, 120, 240, and 360 minutes) of
the positive subject serum 1 and 2, to determine the overall absorption. Evaluation of
individual absorption curves indicated no positive detection of peanut peptides. This is
unexpected since we previously reported positive detection for these same subject sera
using the same experimental conditions and PRM acquisition methodology. Upon further
evaluation of the collected data, we observed gradual increases in pressure over the
course of sequence injections. The increased pressure suggests a slight column blockage
due to an accumulation of protein on the column that are not removed by the current
cleaning protocols following chromatographic separation, and prior to injection of the
subsequent sample. Consequently, we developed improved cleaning methods of the
separation column to facilitate higher protein loading.
Upon re-evaluation, we again observed no positive detection of peanut in the
same set of subject sera. However, the pressure of the column was largely stabilized and
no cumulative increases in pressure were observed (data not shown).

Multiple Injections
Following the evaluation of an entire serum time course and improvements to
cleaning procedures, we wanted to again evaluate increased loading since detection in the
serum time course samples was unsuccessful. The event of duplicate detection in
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separate subject samples with a robust transition pattern was convincing evidence that
peanut peptides were detectable in serum. However, detection was not robust or
reproducible, which led us to the assumption that by loading more protein, while
maintaining a clean column after each injection, we would be able to robustly detect
peanut peptides.
The concentration of all serum samples was maintained the same (<20 µg/µL). In
preliminary studies, at peptide concentrations >20 µg/µL we observed precipitation in resuspended sample digests, after being frozen and thawed. One freeze-thaw cycle resulted
in opaque particles, which were extremely challenging to re-solubilize prior to injection.
There was a significant reduction in detection of peanut peptides prepared at
concentrations >20 µg/µL. For all sample digests < 20 µg/µL, the detectable area for
peanut peptides were comparable. Given our experimental limitations, we developed an
alternative injection method, wherein the same sample, from the same vial, was injected
repeatedly onto the separation column. Once the desired amount of protein was injected
onto the column, gradient elution began. The theoretical binding capacity of the
separation column was calculated by determining the volume of cylinder (V=π•r2•h),
resulting in cm3 unit or mL. Knowing that the separation column has an 11% carbon
load, we assumed the percentage carbon load is equivalent to peptide binding capacity.
We then multiplied the carbon load (11%) by the total calculated column volume,
resulting in a total binding capacity of 38.09 mg protein. We reduced the calculated
value by a factor of 10 as a margin of safety, resulting in a total estimated binding
capacity of 3.809 mg protein.
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In our experiments we tested up to 3 mg of protein injected (sera-peanut), using
our multiple injection protocol. Using the cleaning protocols described previously, we
observed no drastic shifts in pressure over the method run and no subtle increases in
pressure throughout the sequence run.

Multiple Injections with Isotopically Heavy Labeled Peptides and Subject
Serum Samples
Isotopically heavy labeled peptides were added to subject serum samples prior to
PRM evaluations. We injected 2800 µg (2.8 mg) of protein for evaluation.
We were able to observe detection of heavy peptides in all samples, which eluted
at the predicted retention times of the light peptides. We observed no positive detection
of peanut peptides in the increased loaded samples, even with stable pressures within the
expected ranges and peptide retention times, observed.
Due to the lack of detection at the increased load of protein on column, we
suspect high loading is not beneficial to achieving peanut protein detection. It is more
likely, peanut peptides are detectable between 600 – 2800 µg protein, with the inclusion
of optimized cleaning methods and heavy peptides.
One key difference between the two protein loading amounts, 600 and 2800 µg,
were the number of injections. Detection observed at 600 µg protein load was performed
in one injection, whereas in the higher protein load (2800 µg), multiple injections were
performed. Although according to our preliminary investigations, we determined the
multiple injections were sufficient and did not show significant decreases in peak area.
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CONCLUSIONS
Throughout Chapter 2 and Chapter 3, we evaluated two sera collections. In sera
collected by Baumert et al., 2009, the proteins were encapsulated, and digestion
assumingly began once the capsules reached the stomach. The serum samples collected
in this manner, are useful in a research and proof of concept studies, but, are less
representative of our final sample matrix, serum collected following consumption.
The second set of subject serum evaluated was collected from individuals who
consumed roasted peanuts (100 g light roasted peanuts within 10 minutes). In these
serum samples, the peanut material was exposed to the entire gastrointestinal tract and
collected after consumption, making these sera samples more representative of the
ultimate anticipated matrix.
Regardless of the form or the administration method, we were unable to robustly
detect peanut proteins in serum. We were able to detect four peanut peptides, from
multiple peanut proteins (Ara h 1, Ara h 3, and Ara h 6) in two subjects, at two serum
time points collection using a targeted method at a significantly larger protein injection
than typical proteomic methods. These subject sera also reported positive detection for
Ara h 6 by JanssenDuijghuijsen et al., 2017b. We were unable to reproduce these results
by injecting more protein for analysis. This is suggestive there is a median range where
these proteins are detectable, likely between 600 – 2000 µg protein. Utilization of
thorough and validated cleaning procedures following each sample injection, will likely
improve robust detection
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The utilization of targeted methods was highly advantageous in comparison to
depletion methods and discovery LC-MS/MS. We evaluated three different targeted
methods, however, we were only able to achieve detection once we increased our
analytical protein injections to 600 µg. PRM methods with their high-resolution are the
ideal instrument platform to use for in vivo detection of peanut proteins. PRM methods
allow for comparison of peptide transition ratios, which is an additional confirmatory step
for detection at extremely low peptide concentrations. By increasing our injections 2 and
3-fold by the use of multiple injections we were still unable to detect peanut peptides,
suggesting a direct increase in protein load is not equivalent to recording an identical
increase in peptide detection. The additional use of heavy peptides during these multiple
injection experiments also demonstrated we were able to detect the heavy peptides at
consistent ratios, indicating the multiple injections were adequate and did not suffer from
significant signal losses. It is probable that the S/N ratio was acceptable for detection of
peptides at 600 µg, however, this must be further evaluated in order to develop a routine
analytical method.
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CHAPTER 4: INTERMOLECULAR ASSOCIATION OF PEANUT ALLERGENS
AND THE IMPACT OF THERMAL PROCESSING

ABSTRACT
The expression patterns and sequences of peanut proteins are well studied,
however, the intermolecular arrangements of seed storage proteins in plants are largely
unstudied. These protein arrangements may have implications to food allergy
sensitization, elicitation, and protein behavior during gastrointestinal digestion.
To study peanut protein intermolecular arrangements, we used size-exclusion
chromatography (SEC) with offline mass spectrometry (MS) to detect and quantify
peptides. Raw and roasted peanuts (Arachis hypogaea) were extracted in conditions
designed to maintain native (TBS) or denatured protein conformations (GuHCl). Native
MW of proteins were determined using Gaussian modelling allowing for the analysis of
isoforms and complexes. Bottom-up analysis of SEC fractions, and Gaussian modelling
for native MW determination, proved an effective offline separation technique. Most
proteins elute as expected, however we noted several exceptions. Ara h 3 exists as an
oligomer, but at an equilibrium between trimers or hexamers. Some of the prolamins
(Ara h 2 and 6) eluted at higher MWs than expected, alongside the cupins (Ara h 1 and
3). We additionally characterized post-translationally processed Ara h 1 into two, distinct
and unassociated forms
The analytical workflow presented, and automated assignment of MW using
Gaussian fitting, allows for the study of protein conformation in complex protein
mixtures.
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INTRODUCTION
The sequences and expression patterns of individual allergenic peanut proteins
have been well-studied (Burks et al., 1998; Chruszcz et al., 2011; Koppelman et al., 2005,
2016). However, the intermolecular associations between peanut seed storage proteins,
which are deposited in seed storage vacuoles, a high-density and low water environment,
are not well-understood (Müntz, 1998). These molecular arrangements of peanut
allergens may have implications for food allergen sensitization and behavior during
gastric digestion. Furthermore, the impact of food processing on these molecular
arrangements is unknown.
Peanut allergens have been extensively studied, due to their severe potency and
high prevalence rates of sensitization (van Boxtel et al., 2008; Koppelman et al., 2004;
Gupta et al., 2019; Maleki et al., 2000a). The major peanut allergens (Ara h 1, 2, 3, and
6) are seed storage proteins, which provide a reservoir of amino acids for use during plant
germination and growth (Shewry et al., 1995). During seed storage protein translation
the proteins are ultimately deposited in the storage vacuoles where they form protein
bodies, however, the arrangements of seed storage proteins within these protein bodies is
unknown (Shewry et al., 1995). Therefore, the aim of our study was to assess
arrangements of these peanut seed storage proteins.
Ara h 1 and 3 are globulin proteins belonging to the cupin superfamily (Burks et
al., 1995b; Kleber-Janke et al., 1999; Rabjohn et al., 1999;). Ara h 1 is classified as a 7S
vicilin with a monomeric molecular weight of 63.5 kDa that associates into a 180 kDa
trimer (Maleki et al., 2000b; van Boxtel et al., 2006). The 7S vicilin (Ara h 1) is
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translated as a pre-pro-protein, which undergoes two post-translational proteolytic
cleavage events to produce mature Ara h 1. In this process, the signal peptide (~25
amino acids) is cleaved first, followed by a secondary cleavage of the subsequent 53 – 59
amino acids of the N-terminal sequence (de Jong et al., 1998; Wichers et al., 2004). As a
result, mature Ara h 1 exists as a truncated sequence compared to the full length sequence
(Burks et al., 1995b). Ara h 3, the 11S legumin, is a 60 kDa monomer that associates as a
hexamer (360 kDa) composed of two homo-trimers (Koppelman et al., 2003; Jin et al.,
2009). Recent elucidation of the peanut genome has allowed characterization of the
many Ara h 3 isoforms in peanuts (Bertioli et al., 2019). Ara h 3 contains acidic and
basic subunits which remain associated until they undergo gastrointestinal digestion
(Marsh et al., 2008). It appears the acidic subunit is more allergenic than the basic
subunit (Marsh et al., 2008).
The 2S albumins, Ara h 2 and 6, belong to the prolamin superfamily and are
highly homologous proteins sharing 59% sequence identity and a common conserved
disulfide stabilized alpha helical protein core structure (Koppelman et al., 2005; Moreno
and Clemente, 2008). These structural characteristics confer thermal stability and
resistance towards gastric digestion, contributing to the severe allergenic potency of Ara
h 2 and 6 (Blanc et al., 2009; Flinterman et al., 2007; Klemans et al., 2013).
Raw peanuts typically undergo thermal processing (e.g. roasting, boiling, frying,
blanching) prior to consumption, likely influencing structural arrangement(s) and
conformation (Beyer et al., 2001; Guillon et al., 2016; Zhang et al., 2016). Roasting, in
particular, induces protein denaturation and aggregation causing reduced protein
solubility in aqueous buffer systems (e.g. TBS, PBS etc.) (Kopper et al., 2005; Schmitt et
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al., 2010). Reports of increased allergenicity have been attributed to thermal processing
due to increased epitope and IgE binding sites (Beyer et al., 2001; Mondoulet et al.,
2005). Furthermore, the formation of oligomeric structures due to thermal processing,
may also contribute to reported increases in allergenicity (Maleki et al., 2000a).
Peanut allergy is one of the most prevalent food allergies, with current estimates
at 2% of children and 0.6% of adults diagnosed with peanut allergy, and, nearly all
individuals are sensitized to multiple peanut proteins (Ara h 1, 2, 3, or 6) (Gupta et al.,
2011; Sicherer et al., 2010). The cumulative dose of allergenic protein dictates individual
sensitization and overall reaction severity (Ballmer-Weber et al., 2015; Turner et al.,
2016). Individuals who are only sensitized to Ara h 2 and 6, reported more severe
reactions than those sensitized to Ara h 1 and 3, and as such, the prolamins (Ara h 2, 6)
are predictors of reaction severity (Koppelman et al., 2004; Kukkonen et al., 2015). The
molecular arrangement(s) and initial presentation of these allergenic proteins to the
immune system are suspected to influence sensitization and reaction severity, therefore
understanding the molecular arrangements of these peanut proteins is important.
Our aim was to study the intermolecular associations between peanut proteins
using size-exclusion chromatography (SEC) coupled with offline discovery liquid
chromatography tandem mass spectrometry (LC-MS/MS) to detect and quantify peptides
in individual size fractions. SEC is an established technique used for separation of
proteins and protein complexes based on their molecular radii in which large proteins
elute rapidly and smaller proteins elute more slowly (Fekete et al., 2014). We analyzed
raw and roasted peanuts in the presence or absence of chaotropic reagents to solubilize
heavily aggregated material, which is absent from most studies. The mass spectrometry
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(MS) data were analyzed against our peanut database derived from the peanut genome
(Bertioli et al., 2019), allowing us to distinguish between peanut protein isoforms. The
combination of SEC with offline LC-MS/MS offers a data-rich method allowing us to
describe detailed intermolecular associations of seed storage proteins.

MATERIALS AND METHODS
Reagents
All reagents for protein preparation (defatting, extraction) and size exclusion
chromatography were of analytical reagent grade. All reagents for MS sample
preparation and analyses were of MS grade.
The following reagents were used during gel filtration protein preparations:
hexane, deionized distilled water, tris-buffered saline (Tris-HCl, NaCl), GuHCl (GuHCl,
Tris-HCl, EDTA), acetone.
The following reagents were used during LC-MS/MS sample preparation and data
acquisition: water, acetonitrile (ACN), ammonium bicarbonate (ABC), dithiothreitol
(DTT), iodoacetamide (IAA), trypsin, formic acid (FA), methanol (MeOH), and acetic
acid.

Sample Preparation
Raw peanuts (var. Runner) were obtained from the Golden Peanut Company
(Alpharetta, GA). Peanuts (25 g) were roasted in a conventional oven (Groen
Combination oven, Model No. CC10-E) at 160°C for 13.5 minutes. All peanuts (raw,
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roasted) were ground into a powder under liquid nitrogen in a freezer mill (Spex 6850
CentriPrep Freezer/Mill (Metuchen, NJ) followed by manual grinding with a mortar and
pestle until a fine powder was achieved. Ground peanut powder was defatted twice in
hexane (1:20 w/v) and allowed to dry overnight at room temperature.

Protein Extraction
Peanut proteins were extracted (1:25 w/v) by mixing 0.5 g defatted peanut powder
with 12.5 mL of extraction buffer either (a) tris buffered saline (TBS, 50 mM Tris-HCl,
150 mM NaCl, pH 7.4) or (b) guanidine hydrochloride (GuHCl, 5 M GuHCl, 50 mM
Tris, 5 mM EDTA) in a sonicating water bath for 20 minutes at room temperature (20°C).
Extracts were clarified by centrifugation (3500 x g, 10°C, 10 minutes). The
supernatant(s) were removed and dialyzed overnight using 3.5 kDa molecular weight cut
off (MWCO) dialysis tubing (Snakeskin dialysis tubing, 3.5K MWCO, 16 mm ID; Prod.
No. 88424, ThermoScientific™, Rockford, IL, USA) against the appropriate extraction
buffer at room temperature. The dialysates were filter sterilized using 0.2 µm syringe
filters (Fisherbrand, Cat. No. 09-719C). Protein concentrations were determined by 2D
Quant protein assay (GE Healthcare, 80648356). The protein fractions extracted in TBS
represent soluble proteins, whereas proteins extracted in GuHCl, a chaotropic buffer,
represent the total peanut protein composition.
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Size Exclusion Chromatography (SEC)
Peanut protein solutions (1.5 mg/mL TBS extracts, 5 mg/mL GuHCl extracts)
were applied to a Superdex 200 column (16 x 600 mm) (HiLoad 16/600 Superdex 200
prep grade) attached to the AKTA Avant 25 chromatography system (GE Healthcare Life
Sciences NJ, USA) and monitored at 214 and 280 nm. For all extracts, the column was
equilibrated and eluted with TBS at a 1 mL/min flow rate. All SEC extracts were
analyzed in duplicate. Fractions were collected by volume (4 mL). The SEC column
was calibrated by using the molecular weight markers: cytochrome c (12.4 kDa),
carbonic anhydrase (29 kDa), albumin (66 kDa), alcohol dehydrogenase (150 kDa), betaamylase (200 kDa), and blue dextran (2000 kDa) (Gel Filtration Molecular Weight
Markers Kit for Molecular Weights 12,000–200,000 Da; MWGF200, Sigma-Aldrich, St.
Louis, MO, USA). Blue dextran was used to determine column void volume.

Sample Preparation for LC-MS/MS
Following gel filtration separation, and protein quantification (by 2D quant assay
(GE Healthcare, ID)), aliquots (200 µL – determined to be less than 30 µg), the fractions
obtained from TBS extracts (raw and roasted peanut) were precipitated with acetone.
Aliquots of fractions obtained from GuHCl extracts were also precipitated with acetone,
but the aliquot volume was limited by the maximum fraction concentration found, such
that the maximum total protein precipitated was 30 µg. As such, 45 µL – raw peanut and
30 µL – roasted peanut were used. Precipitation was conducted by adding four volumes
of -20°C acetone to each aliquoted fraction(s) and incubated for 2 hours at -80°C. After
incubation, samples were centrifuged (16,000 x g, 10 minutes, 5°C) and the supernatant
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was removed. The precipitated pellet was washed twice, with 7.5 volumes of chilled (20°C) 4:1 acetone:water, followed by centrifugation at (16,000 x g, 10 minutes, 5°C) and
dried.
Acetone precipitated protein fractions were prepared for enzymatic digestion
using a modified in-solution trypsin digestion protocol (In-Solution Tryptic Digestion and
Guanidination Kit, ThermoScientific, Rockford, IL, USA). Protein pellets were resolubilized in 31.5 µL of 15% (v/v) acetonitrile followed by an addition of 45 µL of 50
mM ammonium bicarbonate. Samples were then reduced by the addition of 4.5 µL of
100 mM dithiothreitol and heated at 95°C for 5 minutes. Following reduction, 9 µL of
100 mM iodoacetamide was added to and incubated in the dark at room temperature for
20 minutes. Proteins were digested with 300 ng trypsin (100 ng/µL in 5 mM acetic acid)
at 37°C for 3 hours followed by a second addition of 300 ng trypsin with overnight
incubation at 30°C. Peptide digests were desalted using C-18 spin columns (Pierce C-18
spin columns, ThermoScientific, Rockford, IL, USA) according to manufacturers’
instructions, eluted in 50% (v/v) acetonitrile, and dried under a vacuum by centrifugal
evaporation (Jouan RC-10.10; RCT-90; Winchester, VA, USA). Peptides were resolubilized in 50 µL of 5% (v/v) acetonitrile, 0.1% (v/v) formic acid prior to injection on
LC-MS/MS.

LC-MS/MS Separation and Acquisition
Tryptic digests (2 µL injection) were chromatographically separated using an
UltiMate 3000RSL® liquid chromatography (UPLC) system (Thermo ScientificTM)
equipped with a Hypersil Gold C18 1.9 μm, 100 x 1 mm reversed phase column (Thermo
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ScientificTM) with a pre-column (20 x 2.1 mm reversed phase, 1.9 µm, Thermo
ScientificTM) set at 35°C. Mobile phase A contained 0.1% (v/v) formic acid in water and
mobile phase B contained 0.1% (v/v) formic acid in acetonitrile. Peptides were separated
using a linear gradient of 2 – 40% mobile phase B over 70 minutes at a flow rate of 60
µL/min. Data dependent acquisitions (DDA) were performed on a Thermo Q Exactive
PlusTM Hybrid Quadrupole-OrbitrapTM mass spectrometer (Thermo ScientificTM)
operating in positive ion mode using a top-20 method.
Survey scan mass spectra (400 – 1400 m/z) were acquired at a nominal resolution
of 70,000 FWHM (200 m/z) and an AGC target of 3e6. Fragmentation spectra were
acquired at a nominal resolution of 70,000 FWHM with normalized collisional energy
(NCE) set at 27 and dynamic exclusion of 20 seconds, AGC target of 1e5, and a
maximum inject time of 240 ms. The electrospray ionization settings were as follows:
sheath gas 15 AU, auxiliary gas flow 4.2 AU, spray voltage 3500 kV, capillary
temperature 320°C, S-lens RF level 60.

Data Analysis
Acquired mass spectral data were analyzed using PEAKS version 8.5
(Bioinformatics Solutions Inc., Waterloo, Ontario, Canada). Identification and label-free
quantification of proteins were performed using a custom database derived from the
peanut genome (Bertioli et al., 2019; Marsh et al., 2020). Peptides were selected to
represent allergen protein families as described in Marsh et al., (2020). Data were
analyzed using the following criteria: 5 ppm parent ion mass tolerance, FDR 1%, parent
ion charge states 2, 3, 4+, and normalized to original extract volume. For each allergen
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protein family, three selected peanut peptides were chosen due to their presence in
multiple isoforms. Peptides unique to allergen isoforms were also chosen for individual
isoform quantification. Data were normalized to original SEC sample volume. Data
presented in this manuscript were analyzed using allergen protein families, unless
otherwise noted. In order to determine the observed peptide MW, we applied Gaussian
curve fitting (nonlinear regression) to determine the mean elution time. We then
calculated the MW based upon the determined elution time using the standard curve
generated from the MW markers.

RESULTS
Determination of Mean Protein Elution with Gaussian Distribution
Fitting
In order to determine the observed (e.g. calculated) protein MW, we applied a
Gaussian curve fit to the elution profile of identified peptides corresponding to specific
peanut proteins using PRISM. Generally, chromatographic peaks exhibit symmetrical
Gaussian shapes (Le Vent 1995; Uversky 1993). This distribution is a theoretical curve
fit to the SEC chromatographic data, which determines the mean elution time, standard
deviation, and amplitude for individual peptides along the Gaussian fitted curve. We
were further able to determine the molecular weight of the identified peptides with
excellent precision between observed MWs for each protein. However, since we do not
know the true value of our protein MWs, we are unable to determine the accuracy of our
observed MWs. Using the mean protein elution time, we are able to determine the
observed (e.g. calculated) protein MWs by inference from our standard curve.
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Peanut Protein Elution
By pairing offline SEC with LC-MS/MS, we identified a majority of the peanut
peptides present within our genomically derived peanut database. The observed elution
time(s) for these peanut specific peptides (Table 4-1), determined by a Gaussian fitted
curve, were used to calculate the protein MWs and hereafter referred to as observed MW.
The results presented describe the elution profile of raw peanuts extracted in TBS (saline
extractions), unless otherwise noted. In the GuHCl extractions, nearly all the protein
eluted in the aggregate fraction(s) with a large MW unit.
The major allergenic peanut proteins, Ara h 1, 2, 3, and 6, eluted predominantly
as expected and were present as either monomers or large oligomers (Figure 4-1). The
cupins, Ara h 1 and 3, were predominantly present as oligomers whereas Ara h 2 and 6,
the majorly allergenic prolamins, were present as monomers. The minor peanut
allergens, Ara h 7 and 8 eluted as monomers whereas as Ara h 9, 10, and 11 eluted as
octamers and most likely associated with the cupins (Figure 4-1). Peanut peptides
derived from the same parent protein (e.g. Ara h 2) should elute identically resulting in
the same calculated MW. However, in several instances, we observed unexpected elution
profiles due to differences in individual protein isoforms (e.g. Ara h 3), post-translational
cleavage of proteins (e.g. Ara h 1), and intermolecular associations between proteins,
each of which are described in further detail in the following sections.
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Figure 4-1. Observed MWs of TBS extracted peanut
proteins with each point representing a single peptide
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Table 4-1. Elution of raw peanut proteins extracted in TBS detected by shared
peptides. Calculated MWs were determined by Expasy. Observed MWs
determined by Gaussian modeling.
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Differences in Elution of Ara h 3 Isoforms
We identified 21 individual Ara h 3 isoforms in our genomically derived peanut
protein database, and grouped isoforms into families based on shared identical peptide
sequences (Bertioli et al., 2019; Marsh et al., publication in progress). A table of shared
peptides among Ara h 3 isoforms are listed in Table 4-1. As shown in Figure 4-2, we
demonstrate Ara h 3 exists largely as an oligomer (178 – 280 kDa) in aqueously extracted
raw peanuts (Figure 4-3 and Table 4-2). We observed Ara h 3 exists as a mixture of
trimer and hexamer. Additionally, Ara h 3 isoforms appeared to distribute between trimer
and hexamer differently, as evidenced by calculated MWs that could not be explained by
primary sequence alone (Figure 4-3).
The expected monomeric MW of each Ara h 3 isoform was determined using the
known isoform sequence, removing known signal peptides if present, and molecular
weight determination using Expasy, compute pI/MW tool which calculated the MW
based on entered peptide sequence(s) (https://web.expasy.org/compute_pi/) (ExPASy:
SIB Bioinformatics Resource Portal). The number of subunits was calculated using the
ratio of observed MW versus expected MW determined by SEC elution and LC-MS/MS.
As an example, the expected monomeric MW of Ara h 3.01/11 is 71 kDa, and was
observed to aggregate into a trimer (246 kDa) (Figure 4-2). Contrastingly, Ara h 3.09/14,
with an expected monomeric MW of 45 kDa, was determined to be existing as a hexamer
(280 kDa). The determined number of subunits was between 3 and 6 subunits with many
of the Ara h 3 isoforms calculated to exist between four or five subunits, assuming the
aggregates are composed of identical monomers. We suspect these aggregates may exist
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as a mixture of peanut proteins, such as Ara h 3 associating with Ara h 6. This is
suggestive of a mixed ratio of oligomeric states, between the trimeric and hexameric
arrangements, and could exist in an equimolar state between the oligomeric states. No
differences in MW were determined for isoforms of Ara h 1, 2, and 6.

Determined mW (Da)

3×10 5

2×10 5

1×10 5

0 1 12 06 05 0 7 15 0 9 1 0 1 1 1 3 1 4 1 6 20 1 8 1 9
3. 02/ 03/ 04/ 3. 08/ 3. 3. 3. 3. 3. 3. 17/ 3. 3.
3. 3. 3.
3.
3.

Ara h 3 isoform
Figure 4-2. Observed MWs of TBS extracted Ara h 3 proteins detected by
unique peptides.
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Protein

Peptide

m/z

Arah3_1_02 R.ISSANSLTFPILR.W
709.90
Arah3_2_02 K.GVMEIVVTGC(+57.02)R.A
610.81
Arah3_2_02 K.AGSDAFDWVAIK.T
640.32
Arah3_2_02 K.TSDNPIINTLAGELSLVR.A
957.02
Arah3_3_06 R.GLSILVPAER.R
527.82
Arah3_4_06 K.FFVPPSQQSLR.A
653.35
Arah3_5_06 K.SQSDNFEYVAFK.T
717.83
Arah3_5_06 R.GENESEEEGAIVTVK.G
795.88
Arah3_7_06 R.GEEQENEGNNIFSGFAQEFLQHAFQVDR.E
1080.83
Arah3_7_06 R.QGGEENEC(+57.02)QFQR.L
741.31
Arah3_7_06 R.ILNPDEEDESSR.S
702.32
Arah3_9_06 R.LTAEEAINLK.K
551.31
Arah3_9_06 K.LVALEPSK.R
428.76
Arah3_9_06 K.TVAESLGIDMGIAGK.V
731.38
Arah3_10_06 K.FFVPPSQQSPR.A
645.34
Arah3_10_06 R.GENESEEEGAIVTVR.G
809.88
Arah3_10_06 K.TDSRPSIANLAGENSVIDNLPEEVVANSYGLPR.E 1166.59
Arah3_13_16 K.SPDEEEEYDEDEYAEEER.Q
1131.92
Arah3_13_16 K.FFVPPFQQSPR.A
675.35
Arah3_13_16 R.AGQEQENEGGNIFSGFTSEFLAQAFQVDDR.Q 1097.83
Arah3_14_16 K.LVALEPTK.R
435.77
Arah3_14_16 R.LTAEEAISLK.K
537.81
Arah3_14_16 K.TVAESLDIDMGIAGK.V
760.39
Arah3_15_16 R.FYIAGNTEDEHGEGGR.E
876.59
Arah3_15_16 K.NIVMVEGGLDVVRPEPGSR.A
56.77
Arah3_15_16 K.LPILADLQLSAER.G
480.28
Arah3_16_16 R.FYLAGNQEQEFLR.Y
807.9
Arah3_16_16 R.FQVGQDDPSQQQQDSHQK.V
700.65
Arah3_16_16 R.ILSPDEEDESSR.S
688.81
Arah3_17_16 R.QILQNLR.G
442.77
Arah3_17_16 R.GENESDEQGAIVTVR.G
802.38
Arah3_18_16 R.IDSEGGFIETWNPK.S
796.88
Arah3_19_16 K.GGLSILVPPEWR.Q
662.37
Arah3_20_16 R.VFDEELQEGHVLVVPQNFAVAGK.S
1263.16

charge
2
2
2
2
2
2
2
2
3
2
2
2
2
2
2
2
3
2
2
3
2
2
2
2
4
3
2
3
2
2
2
2
2
2

monomeric Gaussian Calculated
MW
determined number of
(Expasy) MW (kDa) subunits
71
250
3.5
49
230
4.7
49
230
4.7
49
230
4.7
49
180
3.7
58
240
4.1
58
230
4.0
58
240
4.1
57
270
4.7
57
270
4.7
57
270
4.7
44
230
5.2
44
230
5.2
44
230
5.2
58
230
4.0
58
250
4.3
58
270
4.7
58
210
3.6
58
240
4.1
58
270
4.7
44
230
5.2
44
230
5.2
44
280
6.4
48
220
4.6
48
230
4.8
48
230
4.8
57
260
4.6
57
270
4.7
57
270
4.7
58
240
4.1
58
250
4.3
50
220
4.4
49
230
4.7
58
260
4.5

Table 4-2. Unique Ara h 3 peptides for Gaussian MW determinations
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Post Translational Cleavage of Ara h 1 N-Terminal Sequence
The Ara h 1 gene product is processed into two forms, the N-terminal region (prepro) protein and the mature Ara h 1 product (Hurlburt et al., 2014; Wichers et al., 2004).
We observed evidence of post-translational processing of Ara h 1 by identifying Nterminal peptides present as distinct monomeric molecular entities from our raw peanut
extracts (Figure 4-3). Peptides (Table 4-3; Figure 4-4) associated with the N-terminal
region were identified at 12 kDa, independent from the mature Ara h 1 peptides as a
distinct molecule (Figure 4-3). This type of processing has been observed in certain tree
nuts and other legumes (Downs et al., 2014; Marcus et al., 1999).
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Figure 4-3. Determined MW of Ara h 1 peptides plotted by
beginning residue of amino acids.

227

Accession

Peptide sequence(s)

m/z z

564.82 2
Ara h 1.01/02 GTGNLELVAVR
(unique
NTLEAAFNAEFNEIR
869.92 2
peptides)
SFNLDEGHALR
629.81 2
552.27 2
Ara h 1.01/02 K.TENPC(+57.02)AQR.C
(N-terminal R.C(+57.02)LQSC(+57.02)QQEPDDLK.Q 812.85 2
peptides)
R.C(+57.02)VYDPR.G
405.18 2

Calculated
MW (kDa)

Observed
MW
(kDa)

62

210

9.2

11

Table 4-3. Shared and N-terminal peptides used for Ara h 1
protein elution from TBS extractions.

>Arah1_2_19
MRGRVSPLMLLLGILVLASVSATHAKSSPYQKKTENPCAQRCLQSCQQEPD
DLKQKACESRCTKLEYDPRCVYDPRGHTGTTNQRSPPGERTRGRQPGDY
DDDRRQPRREEGGRWGPAGPREREREEDWRQPREDWRRPSHQQPRKI
RPEGREGEQEWGTPGSHVREETSRNNPFYFPSRRFSTRYGNQNGRIRVLQ
RFDQRSRQFQNLQNHRIVQIEAKPNTLVLPKHADADNILVIQQGQATVTV
ANGNNRKSFNLDEGHALRIPSGFISYILNRHDNQNLRVAKISMPVNTPGQ
FEDFFPASSRDQSSYLQGFSRNTLEAAFNAEFNEIRRVLLEENAGGEQEER
GQRRWSTRSSENNEGVIVKVSKEHVEELTKHAKSVSKKGSEEEGDITNPIN
LREGEPDLSNNFGKLFEVKPDKKNPQLQDLDMMLTCVEIKEGALMLPHF
NSKAMVIVVVNKGTGNLELVAVRKEQQQRGRREEEEDEDEEEEGSNREV
RRYTARLKEGDVFIMPAAHPVAINASSELHLLGFGINAENNHRIFLAGDKD
NVIDQIEKQAKDLAFPGSGEQVEKLIKNQKESHFVSARPQSQSQSPSSPEK
ESPEKEDQEEENQGGKGPLLSILKAFN
Figure 4-4. Ara h 1 protein sequence. Italicized letters represent signal
peptide; underlined letters represent N-terminal (‘prepro’) peptide.
Calculated MWs were determined by Expasy. Observed MWs determined by
Gaussian modeling.
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Intermolecular Associations between Peanut Proteins
The prolamins, Ara h 2, 6, and 7 exist predominantly as monomers, but we
observed the elution of the prolamins in higher MW containing fractions (Figure 4-5).
The elution profiles of each individual prolamin peptide demonstrate a small proportion
(1.5%) of the prolamin peptides were present in the cupin containing fractions (170 - 320
kDa), suggesting an association between prolamin (Ara h 2, 6, 7) and cupin peanut
proteins (Ara h 1, 3). Nearly all of the identified prolamin peptides eluting in higher MW
fractions were predominantly cysteine-containing peptides. This is interesting because
work with purified proteins has suggested Ara h 2 and 3 are cross-reactive, however in
light of our observations, this may not be the case (Bublin et al., 2013; Smit et al., 2015).
This elution behavior was also observed in roasted peanut extracts as well; suggesting the
co-elution of prolamins with cupins is not solely attributed to thermal processing.
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Figure 4-5. Elution profiles of prolamin peptides
extracted in TBS (Ara h 2, Ara h 6). Individual points
represent a single peptide. Panel (A) shows the entire
elution profile. Panel (B) shows the elution profile during
a 50-70 minute window, highlighted in Panel (A).
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Effect of Thermal Processing
We additionally analyzed a set of roasted peanuts to evaluate any changes in
molecular arrangements due to thermal treatment. Roasted peanut were prepared from
the same raw peanut starting material and roasted as described in Methods section. We
observed a clear increase in calculated MWs for roasted peanuts (Figure 4-6). Thermal
processing likely induces aggregation causing changes in the conformation of the peanut
proteins. Some proteins, particularly Ara h 1, underwent significant aggregation and
were poorly extracted under aqueous conditions. However, when we extracted roasted
peanut proteins under chaotropic conditions (e.g. GuHCl), we were able to recover Ara h
1 (data not shown), supporting thermally induced protein aggregation of Ara h 1. As
expected, Ara h 2 and 6 were largely present as monomers in roasted peanuts.
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Figure 4-6. Observed peptide MWs in raw and roasted peanut
proteins extracted in TBS.
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DISCUSSION
Proteins in the foods we eat are often poorly characterized, and the overall protein
contents unknown. In many cases, limited sequence information is available for
individual foods. Protein conformation in foods is important for understanding overall
digestibility and allergy, for some foods, and is nearly entirely unstudied. The
combination of SEC with offline, bottom-up proteomics based-LC-MS/MS and semiautomated MW calculation is a powerful and surprisingly precise technique. Our
described methodology is able to identify multiple isoforms with exceptional protein
coverage. The use of the recently derived genomic peanut database, describing all
potential peanut isoforms, further enhanced protein characterization. By extracting raw
peanuts in TBS, we were able to assess the arrangements of the soluble major seed
storage proteins. The majority of the peanut proteins behave as expected, however we
observed several interesting anomalies, providing insight into previously suspected
peanut protein behavior(s).
Ara h 3 is known to exist in many isoforms, but not all isoforms have been fully
elucidated in publically available databases. Using our methodology, we detected 80%
(17/21) individual isoforms with exceptional peptide coverage. Purification of each Ara
h 3 isoform would be a massive undertaking, but using our methodology, we were able to
demonstrate the presence of multiple, individual Ara h 3 isoforms, and their observed
MWs. We determined Ara h 3 to exist as an oligomer, but specifically as a mixture of
monomers based on the number of calculated subunits present for each isoform (Table 42). Since a majority of the Ara h 3 conformations were composed of four or five
subunits, it is likely that Ara h 3 exists in a state of equilibrium between the trimeric and
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hexameric arrangements. These mixed aggregates may be composed of one individual
Ara h 3 isoform, or more likely, various Ara h 3 isoforms. The individual isoform
potency is unknown; however, it is likely all isoforms contribute to an individual’s
overall reaction severity. Furthermore, the potential mixed aggregates, composed of
several Ara h 3 isoforms will additionally influence reaction severity.
Similar to other studies of allergenic protein post-translational processing, the Nterminal region of Ara h 1 exists as a distinct protein molecule due to post-translational
processing (Aalberse et al., 2019; Downs et al., 2014). This N-terminal cleavage pattern
has been previously described, but lack of association with the mature protein is novel
(Wichers et al., 2004). The cleaved N-terminus has distinct physicochemical properties
distinct to the mature Ara h 1 protein, and could potentially act as an independent
sensitization molecule (Aalberse et al., 2019). Similar to our findings, Aalberse et al.,
(2019) determined the pro-peptide to be present as an individual molecule. According to
the IUIS repository, the N-terminal region, or Ara h 1 propeptide, demonstrates allergenic
activity without the mature Ara h 1 present, and is therefore recognized as an allergen
(IUIS designation: Ara h 1.0101 (26-84)). (Aalberse et al., 2019; Burks et al., 1995a).
A minor proportion of the prolamins (Ara h 2, Ara h 6), which are small,
monomeric proteins, eluted uncharacteristically in cupin containing fractions. Previous
studies of purified proteins have suggested Ara h 2 and Ara h 3 are cross-reactive,
however in light of our observations this may not be the case (Bublin et al., 2013; Smit et
al., 2015). Due to their structural arrangements, individuals may be co-sensitized to both
prolamins and cupins simultaneously. In both peanut preparations, raw and roasted, we
observed identical elution patterns of the prolamins first, predominantly as monomers and
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secondly, as a subset co-eluting as oligomers with the cupins. Prolamin peptides coeluting in the same fraction as the cupins were predominantly cysteine-containing
peptides, which may be indicative of interactions between the proteins. These protein
arrangement characteristics between prolamins and cupins may be indicative of
sensitization patterns among peanut allergic individuals.
Prior to consumption, peanuts generally undergo some type of thermal processing
(e.g. boiling, roasting, add one more), inducing protein aggregation by disrupting
intramolecular forces causing structural and conformational shifts (Schmitt et al., 2010;
Koppelman et al., 1999). These structural shifts lead to aggregation by exposing the
hydrophobic groups to the solvent phase where they interact with other matrix
components or proteins (Hebling et al., 2012). Other chemical interactions occur
between peanut proteins and/or peanut proteins and a food matrix. We observed a 20fold decrease in Ara h 1 protein recovery after roasting, which is unsurprising as Ara h 1
is highly susceptible to heating (> 80°C) readily forming higher molecular arrangements
(MW 500 - 600) (van Boxtel et al., 2006; Chruszcz et al., 2011; Koppelman et al., 1999).
Several studies have suggested roasting causes protein aggregation and co-elution of
peanut proteins (e.g. prolamins and cupins) however, based on our results, it is apparent
these associations exist as a product of plant protein synthesis.
Most often, peanuts are consumed after roasting and possess a different
intermolecular protein arrangement than native raw peanuts. Regardless of processing
steps, an individual’s immune system is exposed to all peanut proteins present in the
seed. This has been suspected to be a cause of poly-sensitization as most individuals are
sensitized to multiple peanut proteins. However, diagnostic materials may not be
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representative of the entire peanut seed. In preparation of diagnostic materials, such as
skin prick tests (SPT), it is important to consider protein arrangements, type (raw,
roasted), and extraction conditions. Generally, individuals who undergo SPT’s are only
exposed to the soluble proteins present in the prepared test extract. Understanding these
intermolecular arrangements in different peanut preparations, will better inform clinicians
and researchers.
Improving our knowledge of the intermolecular associations of complex proteins
is important in understanding sensitization patterns and overall protein behavior. Most
allergic individuals are sensitized to multiple peanut proteins presenting varying degrees
of reaction severity, which is often attributed to roasting (or other thermal treatments).

CONCLUSIONS
To study intermolecular arrangements of peanut proteins, pairing SEC with
offline LC-MS/MS, and automated MW calculation generated thousands of identified
peptides detected across the SEC column. The combination of these techniques in one
comprehensive methodology, allowed for the remarkably precise derivation of native
protein MWs and multiple determinations of individual peptides. The use of automated
MW determinations by Gaussian modeling further enhances the study of protein
conformations, isoforms, and complexes. This methodology can be readily applied to
basic protein research for studying interactions, and would be particularly helpful in
characterizing allergenic foods as well as biopharmaceuticals.
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SUPPLEMENTARY

CHAPTER 2
SPT
(AU)

ICAP IgE
(kUa/L)

IgE (ISU)

Patient ID

Dilution

Other
atopy

Peanut

Ara h 1

Ara h 3

Ara h 2

Ara h 6

Peanut

Peanut

PN2060

1:20

yes

9.0

51.7

27.1

64.5

76.0

224

53.0

PN2073

1:50

yes

35

60.4

15.1

31.3

64.5

141

575

PN2075

1:20

yes

20

50.2

14.5

24.0

50.2

378

DD

1:20

no

15

57.7

5.71

18.4

21.3

PN2079

1:50

no

12

96.7

58.2

98.5

124.3

173

Pool

1:50

n.a.

n.a.

53.4

15.2

39.3

76.5

251

72.5

n.d.
85.5
787

Supplementary Table 2-1. Peanut allergic subject characteristics and
serology. Dilution value represents serum dilution prior to serologic
measurements. SPT indicates the value for skin prick test, IgE (ISU)
represents, ICAP represents the Immunocap measured responses.

n.d.
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CHAPTER 3

Supplementary Figure 3-1. Relative abundance of individual Ara h 1
peptides (A-D) at decreasing quantities of peanut protein in a constant
amount of serum in PRM. Blue lines represent sera-peanut matrices;
black lines represent peanut only in the absence of a sera background.
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Supplementary Figure 3-2. Relative abundance of individual (A) Ara h 2 and
(B-D) Ara h 6 peptides at decreasing quantities of peanut protein in a constant
amount of serum in PRM. Blue lines represent sera-peanut matrices; black lines
represent peanut only in the absence of a sera background.
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Supplementary Figure 3-3. Relative abundance of individual Ara h 3 peptides
(A-D) at decreasing quantities of peanut protein in a constant amount of serum in
PRM. Blue lines represent sera-peanut matrices; black lines represent peanut
only in the absence of a sera background.
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Supplementary Figure 3-4. Relative abundance of individual Ara h 1 peptides (A-D)
at decreasing quantities of peanut protein in a constant amount of serum in MRM.
Transitions are represented by different colored lines. Solid lines represent sera-peanut
matrices; dashed lines represent peanut only in the absence of a sera background.
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Supplementary Figure 3-5. Relative abundance of individual (A) Ara h 2 (B) Ara
h 6 peptides at decreasing quantities of peanut protein in a constant amount of serum
in MRM. Transitions are represented by different colored lines. Solid lines represent
sera-peanut matrices; dashed lines represent peanut only in the absence of a sera
background.
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Supplementary Figure 3-6. Relative abundance of individual Ara h 3 peptides (AC) at decreasing quantities of peanut protein in a constant amount of serum in
MRM. Transitions are represented by different colored lines. Solid lines represent
sera-peanut matrices; dashed lines represent peanut only in the absence of a sera
background.
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Supplementary Figure 3-7. Relative abundance of individual Ara h 1 peptides (A-D) at
decreasing quantities of peanut protein in a constant amount of serum in MRM3.
Transitions are represented by different colored lines. Solid lines represent sera-peanut
matrices; dashed lines represent peanut only in the absence of a sera background.
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Supplementary Figure 3-8. Relative abundance of individual (A) Ara h 2 (B) Ara h 6
peptides at decreasing quantities of peanut protein in a constant amount of serum in
MRM3. Transitions are represented by different colored lines. Solid lines represent serapeanut matrices; dashed lines represent peanut only in the absence of a sera background.
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Supplementary Figure 3-9. Relative abundance of individual Ara h 3 peptides (AC) at decreasing quantities of peanut protein in a constant amount of serum in
MRM3. Transitions are represented by different colored lines. Solid lines represent
sera-peanut matrices; dashed lines represent peanut only in the absence of a sera
background.
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Supplementary Table 3-1. List of peptide transitions detection in
positive subject sera samples (subject 1, 2).

